[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 116
1. Afify AM, Stern R, Michael CW: Differentiation of mesothelioma from adenocarcinoma in serous effusions: the role of hyaluronic acid and CD44 localization. Diagn Cytopathol; 2005 Mar;32(3):145-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differentiation of mesothelioma from adenocarcinoma in serous effusions: the role of hyaluronic acid and CD44 localization.
  • Archival paraffin-embedded cell blocks of serous fluids from 28 cases of reactive mesothelial cells, 14 cases of MM, 20 cases of metastatic ovarian carcinomas, 17 cases of metastatic breast carcinomas, 12 cases of metastatic lung ACA, and 12 cases of metastatic gastrointestinal ACA were stained with HA using a biotinylated HABP and CD44S.
  • All MMs and 93% (26/28) of the benign mesothelial cells were positive for intracytoplasmic HA vs. none of ACAs.
  • CD44S was expressed in 100% (28/28) of mesothelial hyperplesia, 86% (12/14) of MMs, 70% (14/20) of ovarian carcinomas, 29% (5/17) of breast carcinomas, 25% (3/12) of gastrointestinal ACAs, and 8% (1/12) of lung ACAs.
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Neoplasm Metastasis. Staining and Labeling

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HYALURONIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 15690337.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Biomarkers, Tumor; 0 / CD44S antigen; 9004-61-9 / Hyaluronic Acid
  •  go-up   go-down


2. Diamantopoulou S, Sikiotis K, Panayiotides J, Kassanos D: Serous cystadenoma with massive ovarian edema. A case report and review of the literature. Clin Exp Obstet Gynecol; 2009;36(1):58-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serous cystadenoma with massive ovarian edema. A case report and review of the literature.
  • BACKGROUND: Massive ovarian edema is an usual tumour-like condition.
  • It may be confused with an ovarian neoplasm.
  • The pathology examination revealed serous cystadenoma with massive ovarian edema.
  • CONCLUSIONS: Conservative treatment and ovarian suspension may be more appropriate, when histology on frozen section suggests a benign lesion.
  • [MeSH-major] Cystadenoma, Serous / pathology. Ovarian Neoplasms / pathology

  • Genetic Alliance. consumer health - Edema.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19400422.001).
  • [ISSN] 0390-6663
  • [Journal-full-title] Clinical and experimental obstetrics & gynecology
  • [ISO-abbreviation] Clin Exp Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 27
  •  go-up   go-down


3. Li Q, Liu S, Lin B, Yan L, Wang Y, Wang C, Zhang S: Expression and correlation of Lewis y antigen and integrins α5 and β1 in ovarian serous and mucinous carcinoma. Int J Gynecol Cancer; 2010 Dec;20(9):1482-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and correlation of Lewis y antigen and integrins α5 and β1 in ovarian serous and mucinous carcinoma.
  • INTRODUCTION: This study investigates the expression and the clinical significance of Lewis y and integrins α5 and β1 in serous and mucinous ovarian tumors and then evaluates the association between them.
  • METHODS: Lewis y and integrin α5 and β1 expression are detected on tissues from malignant, borderline, and benign ovarian serous and mucinous tumors and normal tissues.
  • RESULTS: Lewis y was mainly expressed in ovarian serous and mucinous cancers (88.33%); its positive rate was obviously higher than rates in the borderline (60.00%, P < 0.05) and benign ovarian tumors (35.00%, P < 0.01) and normal ovarian tissues (0, P < 0.01) and was not associated with clinicopathological characteristics.
  • Integrins α5 (85.00%) and β1 (81.67%) were also mainly expressed in ovarian serous and mucinous cancers; their positive rates were all obviously higher than those in benign ovarian tumors (60.00% and 55.00%, respectively; all P < 0.05) and normal tissues (40.00% and 30.00%, respectively; all P < 0.01).
  • The expression intensity of Lewis y and integrins α5 and β1 was significant with clinical stage and differentiation degree (all P < 0.05) in ovarian cancer; positive significant correlation between Lewis y antigen and integrins α5 and β1 was observed in serous and mucinous ovarian cancer tissues.
  • CONCLUSIONS: A close correlation between Lewis y, integrins α5 and β1, and ovarian cancer was observed.
  • Lewis y can influence the biological behavior of a tumor cell as an important composition of integrins α5 and β1 by some signal pathway, such as promoting cell adhesion and migration, and this study provides theoretical evidence of ovarian cancer biological treatment.
  • [MeSH-major] Adenocarcinoma, Mucinous / metabolism. Antigens, CD29 / metabolism. Cystadenocarcinoma, Serous / metabolism. Integrin alpha5 / metabolism. Lewis Blood-Group System / metabolism. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / analysis. Biomarkers, Tumor / metabolism. Case-Control Studies. Female. Humans. Integrin alpha5beta1 / metabolism. Middle Aged. Neoplasm Staging / methods. Prognosis. Young Adult

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21119363.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD29; 0 / Biomarkers, Tumor; 0 / Integrin alpha5; 0 / Integrin alpha5beta1; 0 / Lewis Blood-Group System; 0 / Lewis Y antigen
  •  go-up   go-down


Advertisement
4. Esheba GE, Pate LL, Longacre TA: Oncofetal protein glypican-3 distinguishes yolk sac tumor from clear cell carcinoma of the ovary. Am J Surg Pathol; 2008 Apr;32(4):600-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncofetal protein glypican-3 distinguishes yolk sac tumor from clear cell carcinoma of the ovary.
  • Clear cell carcinoma (CCC) of the ovary is the surface epithelial neoplasm most often confused with primitive germ cell tumors, particularly yolk sac tumor (YST) and dysgerminoma.
  • To investigate whether GPC3 is useful in distinguishing YST from ovarian CCC, we studied the expression of GPC3 in a large series of ovarian neoplasms and compared it to the expression profiles of CK7 and alpha-fetoprotein.
  • Tissue microarrays containing over 400 benign and malignant ovarian neoplasms, including 34 CCCs were stained with monoclonal GPC3 (clone 1G12, Biomosaics, Burlington, VT).
  • These arrays contained a wide assortment of ovarian surface epithelial neoplasms and sex cord stromal neoplasms, as well as germ cell tumors.
  • All but one YST (97%), including those associated with mixed germ cell tumor were positive for GPC3, whereas all teratomas and embryonal carcinomas were negative.
  • Most CCCs (83%) were completely negative for GPC3, as were 99% serous, 94% endometrioid, and 100% mucinous tumors.
  • GPC3 seems to be a promising diagnostic marker for differentiating YST from ovarian CCC (P < 0.0001).
  • [MeSH-major] Antigens, Neoplasm / analysis. Biomarkers, Tumor / analysis. Carcinoma / chemistry. Endodermal Sinus Tumor / chemistry. Glypicans / analysis. Ovarian Neoplasms / chemistry

  • Genetic Alliance. consumer health - Yolk sac tumor.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18277882.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / GPC3 protein, human; 0 / Glypicans; 0 / KRT7 protein, human; 0 / Keratin-7; 0 / alpha-Fetoproteins; 0 / oncofetal antigens
  •  go-up   go-down


5. Trifonov I: [Registry of patients with advanced ovary carcinoma in the province of Stara Zagora]. Akush Ginekol (Sofiia); 2007;46(7):35-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A representative inquiry has been conducted including the most important parameters from the medical files of 61 out-patients with ovarian carcinoma in III or IV stage in the province of Stara Zagora for the period 1997, 1998 and 1999.
  • In 9.83% of the patients benign tumours were found, in 6.55% malignant as concomitant diseases.
  • Histological screening of ovarian tumours showed predominance of the serous carcinoma in the papilliferum--/40.98%/.
  • [MeSH-major] Ovarian Neoplasms / epidemiology. Registries. Surveys and Questionnaires
  • [MeSH-minor] Bulgaria / epidemiology. Female. Humans. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18333420.001).
  • [ISSN] 0324-0959
  • [Journal-full-title] Akusherstvo i ginekologii︠a︡
  • [ISO-abbreviation] Akush Ginekol (Sofiia)
  • [Language] bul
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Bulgaria
  •  go-up   go-down


6. Ye B, Skates S, Mok SC, Horick NK, Rosenberg HF, Vitonis A, Edwards D, Sluss P, Han WK, Berkowitz RS, Cramer DW: Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine. Clin Cancer Res; 2006 Jan 15;12(2):432-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine.
  • PURPOSE: The objective was to identify and characterize low molecular weight proteins/peptides in urine and their posttranslational modifications that might be used as a screening tool for ovarian cancer.
  • EXPERIMENTAL DESIGN: Urine samples collected preoperatively from postmenopausal women with ovarian cancer and benign conditions and from nonsurgical controls were analyzed by surface-enhanced laser desorption/ionization mass spectrometry and two-dimensional gel electrophoresis.
  • Quantitative and semiquantitative ELISAs were developed for preliminary validation in patients of 128 ovarian cancer, 52 benign conditions, 44 other cancers, and 188 healthy controls.
  • RESULTS: A protein (m/z approximately 17,400) with higher peak intensities in cancer patients than in benign conditions and controls was identified and subsequently defined as eosinophil-derived neurotoxin (EDN).
  • A glycosylated form of EDN was specifically elevated in ovarian cancer patients.
  • Modified forms EDN and osteopontin fragments were elevated in early-stage ovarian cancers and a combination of both resulted to 93% specificity and 72% sensitivity.
  • CONCLUSIONS: Specific elevated posttranslationally modified urinary EDN and osteopontin COOH-terminal fragments in ovarian cancer might lead to potential noninvasive screening tests for early diagnosis.
  • [MeSH-major] Biomarkers, Tumor / urine. Eosinophil-Derived Neurotoxin / urine. Neoplasms, Glandular and Epithelial / urine. Ovarian Neoplasms / urine. Sialoglycoproteins / urine
  • [MeSH-minor] Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Clear Cell / surgery. Adenocarcinoma, Clear Cell / urine. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Adenocarcinoma, Mucinous / urine. Amino Acid Sequence. Carcinoma, Endometrioid / pathology. Carcinoma, Endometrioid / surgery. Carcinoma, Endometrioid / urine. Case-Control Studies. Cystadenocarcinoma, Serous / pathology. Cystadenocarcinoma, Serous / surgery. Cystadenocarcinoma, Serous / urine. Electrophoresis, Gel, Two-Dimensional. Enzyme-Linked Immunosorbent Assay. Female. Glycosylation. Humans. Molecular Sequence Data. Neoplasm Invasiveness. Osteopontin. Prognosis. Proteome. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Cancer Res. 2006 Jan 15;12(2):323-7 [16428467.001]
  • (PMID = 16428483.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1P50 CA 105009; United States / NCI NIH HHS / CA / R21 CA 111949-01; United States / NCI NIH HHS / CA / U01 CA 86381
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proteome; 0 / SPP1 protein, human; 0 / Sialoglycoproteins; 106441-73-0 / Osteopontin; EC 3.1.- / Eosinophil-Derived Neurotoxin
  •  go-up   go-down


7. Lancaster JM, Sayer RA, Blanchette C, Calingaert B, Konidari I, Gray J, Schildkraut J, Schomberg DW, Marks JR, Berchuck A: High expression of insulin-like growth factor binding protein-2 messenger RNA in epithelial ovarian cancers produces elevated preoperative serum levels. Int J Gynecol Cancer; 2006 Jul-Aug;16(4):1529-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High expression of insulin-like growth factor binding protein-2 messenger RNA in epithelial ovarian cancers produces elevated preoperative serum levels.
  • The molecular etiology of epithelial ovarian cancer remains unclear.
  • Using microarray expression analysis, we recently reported that expression of the insulin-like growth factor binding protein-2 (IGFBP-2) gene is elevated in advanced epithelial ovarian cancers.
  • The aim of this study was to further delineate the role of IGFBP-2 in the pathoetiology of epithelial ovarian cancer and determine if elevated ovarian cancer IGFBP-2 gene expression is reflected in serum.
  • Relative IGFBP-2 expression was measured using quantitative real-time polymerase chain reaction in 113 epithelial ovarian cancers and 6 normal ovarian surface epithelial samples.
  • Preoperative serum IGFBP-2 levels were measured by radioimmunoassay in 84 women (42 ovarian cancers, 26 benign gynecological conditions, and 10 healthy female controls).
  • Ovarian cancers demonstrated 38-fold higher mean IGFBP-2 expression than normal ovarian epithelium (P < 0.01).
  • Serum IGFBP-2 levels were elevated in women with early- and advanced-stage ovarian cancer compared to controls and patients with benign gynecological conditions (P = 0.05 and P < 0.01, respectively).
  • Epithelial ovarian cancers express high levels of IGFBP-2 relative to normal ovarian epithelium, and this is associated with elevated serum IGFBP-2 levels compared to both normal controls and patients with benign gynecological disease.
  • Our findings provide further support that the insulin-like growth factor pathway plays a significant role in epithelial ovarian cancer pathogenesis.
  • Further, IGFBP-2 may represent an additional serum biomarker with utility in detection and monitoring of epithelial ovarian cancer.
  • [MeSH-major] Biomarkers, Tumor / blood. Gene Expression Regulation, Neoplastic / genetics. Insulin-Like Growth Factor Binding Protein 2 / blood. Neoplasms, Glandular and Epithelial / blood. Ovarian Neoplasms / blood. RNA, Messenger / blood
  • [MeSH-minor] Adenocarcinoma, Clear Cell / blood. Adenocarcinoma, Clear Cell / genetics. Adenocarcinoma, Clear Cell / surgery. Adenocarcinoma, Mucinous / blood. Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / surgery. CA-125 Antigen / blood. Case-Control Studies. Cystadenocarcinoma, Serous / blood. Cystadenocarcinoma, Serous / genetics. Cystadenocarcinoma, Serous / surgery. Endometrial Neoplasms / blood. Endometrial Neoplasms / genetics. Endometrial Neoplasms / surgery. Female. Humans. Immunoenzyme Techniques. Neoplasm Staging. Ovarian Cysts / blood. Ovarian Cysts / genetics. Ovary / pathology. Precancerous Conditions / blood. Precancerous Conditions / genetics. Precancerous Conditions / surgery. Preoperative Care. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16884361.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / Insulin-Like Growth Factor Binding Protein 2; 0 / RNA, Messenger
  •  go-up   go-down


8. Kalyanasundaram K, Ganesan R, Perunovic B, McCluggage WG: Diffusely infiltrating endometrial carcinomas with no stromal response: report of a series, including cases with cervical and ovarian involvement and emphasis on the potential for misdiagnosis. Int J Surg Pathol; 2010 Apr;18(2):138-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffusely infiltrating endometrial carcinomas with no stromal response: report of a series, including cases with cervical and ovarian involvement and emphasis on the potential for misdiagnosis.
  • The neoplasms consisted of 12 endometrioid carcinomas, 1 mixed endometrioid and clear cell carcinoma, and 1 serous carcinoma.
  • Several of the cases were seen in consultation and the pattern of infiltration raised a number of differential diagnoses, both benign and malignant, depending on the site of tumor involvement, including adenomyosis, adenomyoma, primary endocervical glandular lesions, cervical mesonephric remnants, endometriosis or tuboendometrioid metaplasia, and ovarian cortical inclusion cysts.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. Ovarian Neoplasms / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnostic Errors / prevention & control. Female. Humans. Middle Aged. Myometrium / pathology. Neoplasm Invasiveness. Stromal Cells / pathology


9. Zhong M, Li J, Ding YQ, Song LL: [ZNF217 gene was detected in ovarian serous cystadenocarcinoma by fluorescence in situ hybridization]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2006 Dec;23(6):665-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [ZNF217 gene was detected in ovarian serous cystadenocarcinoma by fluorescence in situ hybridization].
  • OBJECTIVE: To investigate amplification of zinc finger protein 217 (ZNF217) gene in ovarian serous cystadenocarcinoma and its clinical significance.
  • METHODS: Twenty three specimens of ovarian carcinoma, 10 specimens of ovarian benign tumors and 7 specimens of normal ovaries and two ovarian cancer cell lines, SKOV3 and HO-8910 were examined by fluorescence in situ hybridization (FISH).
  • RESULTS: The amplification of ZNF217 was gained in 12 case of ovarian cancers, there was only 1 case in ovarian benign tumor and not amplication in normal ovary.
  • CONCLUSION: The amplification of ZNF217 is associated with ovarian cancer.
  • Oncogenes ZNF217 maybe play a role in cell differentiation and indicate poorer survival in patients with ovarian cancer.
  • [MeSH-major] Cystadenocarcinoma, Serous / genetics. Ovarian Neoplasms / genetics. Trans-Activators / genetics
  • [MeSH-minor] Adult. Aged. Cell Differentiation. Cell Line, Tumor. Cystadenoma, Serous / genetics. Cystadenoma, Serous / pathology. Female. Gene Amplification. Humans. In Situ Hybridization, Fluorescence. Middle Aged. Neoplasm Staging. Survival Analysis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17160949.001).
  • [ISSN] 1003-9406
  • [Journal-full-title] Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
  • [ISO-abbreviation] Zhonghua Yi Xue Yi Chuan Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Trans-Activators; 0 / ZNF217 protein, human
  •  go-up   go-down


10. Rodabaugh KJ, Mhawech-Fauceglia P, Groth J, Lele S, Sood AK: Prostate-derived Ets factor is overexpressed in serous epithelial ovarian tumors. Int J Gynecol Pathol; 2007 Jan;26(1):10-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostate-derived Ets factor is overexpressed in serous epithelial ovarian tumors.
  • The frequent overexpression of prostate-derived Ets factor (PDEF) mRNA in ovarian cancer has been previously reported.
  • The aim of this study was to evaluate PDEF protein expression in ovarian cancer and how this expression might vary at different stages of epithelial ovarian tumors in comparison to normal ovary.
  • A new rabbit polyclonal antibody to PDEF was prepared, and immunohistochemistry was performed on tissue sections from 12 normal ovaries, 10 cases of benign serous cystadenoma, 17 cases of low malignant potential tumor, 19 cases of stage 1, and 15 cases of advanced stage primary epithelial (serous) ovarian carcinomas and their peritoneal metastases.
  • All 12 normal ovary and 10 benign serous cystadenoma cases were negative for PDEF expression.
  • In contrast, 6 of 17 (35%) low malignant potential tumors, 5 of 19 (27%) stage 1, and 5 of 15 (33%) advanced stage ovarian tumors stained positive for PDEF expression.
  • Together, these results show frequent overexpression of PDEF protein in epithelial ovarian tumors and its lack of expression in normal ovary and cystadenomas, and this supports a role for PDEF in ovarian tumorigenesis.
  • Furthermore, these results suggest that PDEF is a potential marker and target in ovarian cancer.
  • [MeSH-major] Cystadenocarcinoma, Serous / metabolism. Neoplasms, Glandular and Epithelial / metabolism. Ovarian Neoplasms / metabolism. Proto-Oncogene Proteins c-ets / metabolism
  • [MeSH-minor] Amino Acids / immunology. Animals. Antibodies / immunology. Biomarkers, Tumor / metabolism. Cell Line, Tumor. Female. Humans. Neoplasm Staging. Ovary / metabolism. Peptide Fragments / immunology. Rabbits

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Int J Gynecol Pathol. 2007 Apr;26(2):205
  • (PMID = 17197890.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30CA16056; United States / NCI NIH HHS / CA / R 41 CA84167
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Amino Acids; 0 / Antibodies; 0 / Biomarkers, Tumor; 0 / Peptide Fragments; 0 / Proto-Oncogene Proteins c-ets; 0 / SPDEF protein, human
  •  go-up   go-down


11. Bi SN, Dai SZ, Yao Q, Che YC, Wang N: [Expression of mesothelin mRNA and protein in ovarian carcinomas]. Zhonghua Zhong Liu Za Zhi; 2008 Apr;30(4):288-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of mesothelin mRNA and protein in ovarian carcinomas].
  • OBJECTIVE: To investigate the expression of mesothelin (MESO) mRNA and protein and its significance in ovarian carcinomas.
  • METHODS: Semi-quantitative reverse transcription polymerase chain reaction (RT-PCR) and immunohistochemistry were used to detect the expression level of MESO mRNA and protein, respectively, in 124 samples of ovarian tumor and normal tissues, including 84 epithelial ovarian carcinomas, 12 borderline ovarian tumors, 16 benign ovarian tumors and 12 normal ovarian tissues.
  • RESULTS: The expression of MESO mRNA and protein in epithelial ovarian carcinomas (1.4005 +/- 0.4646, 2.7857 +/- 2.2712) and borderline ovarian tumors (1.0650 +/- 0.3100, 2.9167 +/- 2.391) were significantly higher than that in benign ovarian tumors (0.6463 +/- 0.2419, 1.2500 +/- 1.6125) and normal ovarian tissues (0.6439 +/- 0.2729, 0.9167 +/- 1.2401) (P < 0.05), and also significantly higher in serous cystadenocarcinoma (1.5255 +/- 0.4151, 3.3036 +/- 2.6141) and endometrioid carcinoma (1.5250 +/- 0.5419, 3.0000 +/- 2.3094) than that in mucinous cystadenocarcinoma (1.0675 +/- 0.3149, 1.0556 +/- 1.9242) (P < 0.05).
  • CONCLUSION: The results of this study demonstrated that the expression of MESO mRNA and protein is increased in ovarian carcinomas and borderline ovarian tumors, and MESO may play a role in the adhesion and dissemination of ovarian carcinomas.
  • [MeSH-major] Carcinoma, Endometrioid / metabolism. Cystadenocarcinoma, Mucinous / metabolism. Cystadenocarcinoma, Serous / metabolism. Membrane Glycoproteins / metabolism. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Case-Control Studies. Female. GPI-Linked Proteins. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Ovary / metabolism. Ovary / pathology. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18788634.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / RNA, Messenger; 0 / mesothelin
  •  go-up   go-down


12. Nosov V, Su F, Amneus M, Birrer M, Robins T, Kotlerman J, Reddy S, Farias-Eisner R: Validation of serum biomarkers for detection of early-stage ovarian cancer. Am J Obstet Gynecol; 2009 Jun;200(6):639.e1-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Validation of serum biomarkers for detection of early-stage ovarian cancer.
  • OBJECTIVE: Ovarian cancer has the highest mortality of all the gynecologic malignancies with most patients diagnosed at late stages.
  • We identified 3 serum proteins (apolipoprotein A-1, transthyretin, and transferrin) for the detection of ovarian cancer and reported them combined with CA-125 to effectively detect early-stage mucinous tumors.
  • The objectives of this study were to assess the effectiveness of the panel in detection of early-stage serous and endometrioid ovarian cancers.
  • STUDY DESIGN: In all, 358 serum samples (control, benign adnexal masses, and early-stage and late-stage ovarian cancer) were obtained from the National Cancer Institute.
  • CONCLUSION: A panel of 4 serum biomarkers effectively detected early-stage ovarian cancers with the highest reported overall sensitivity of 96%.
  • Prospective clinical analysis of the panel is needed to validate it as an effective screening tool for early-stage ovarian cancer.
  • [MeSH-major] Apolipoprotein A-I / blood. CA-125 Antigen / blood. Early Detection of Cancer. Ovarian Neoplasms / blood. Ovarian Neoplasms / diagnosis. Prealbumin / analysis. Transferrin / analysis
  • [MeSH-minor] Adult. Biomarkers / blood. Female. Humans. Middle Aged. Neoplasm Staging. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Obstet Gynecol. 2009 Jun;200(6):e1-3 [19482110.001]
  • (PMID = 19285648.001).
  • [ISSN] 1097-6868
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apolipoprotein A-I; 0 / Biomarkers; 0 / CA-125 Antigen; 0 / Prealbumin; 0 / Transferrin
  •  go-up   go-down


13. Longacre TA, McKenney JK, Tazelaar HD, Kempson RL, Hendrickson MR: Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (&gt; or =5-year) follow-up. Am J Surg Pathol; 2005 Jun;29(6):707-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (> or =5-year) follow-up.
  • The natural history, classification, and nomenclature of ovarian serous tumors of low malignant potential (S-LMP) (serous tumors of borderline malignancy, atypical proliferating tumors) are controversial.
  • To determine long-term outcome for patients with S-LMP and further evaluate whether S-LMP can be stratified into clinically benign and malignant groups, the clinicopathologic features of 276 patients with S-LMP and > or =5 year follow-up were studied.
  • The histology of the ovarian primary, extraovarian implants, and recurrent tumor(s) were characterized using World Health Organization criteria and correlated with FIGO stage and clinical follow-up.
  • Stromal microinvasion in the primary tumor was also correlated with adverse outcome, independent of stage of disease, micropapillary architecture, and implant type (P = 0.03).
  • Transformation to low-grade serous carcinoma occurred in 6.8% of patients at intervals of 7 to 288 months (58% > or = 60 months) and was strongly associated with increased tempo of disease and decreased survival (P < 0.001).
  • S-LMP forms a heterogeneous group, morphologically and clinically distinct from benign serous tumors and serous carcinoma.
  • The majority of S-LMP are clinically benign, but recurrences are not uncommon, and persistent disease as well as deaths occur.
  • Progression to low-grade serous carcinoma is highly predictive of more aggressive disease.
  • Other features associated with recurrent and/or progressive disease include FIGO stage, invasive implants, microinvasion in the primary tumor, and micropapillary architecture.
  • The small, but significant risk of progression over time to low-grade serous carcinoma emphasizes the need for prolonged follow-up in patients with S-LMP.
  • [MeSH-major] Cystadenocarcinoma, Serous / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cell Transformation, Neoplastic. Child. Disease Progression. Female. Humans. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Retrospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15897738.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


14. Vereczkey I, Tóth E, Orosz Z: [Diagnostic problems of ovarian mucinous borderline tumors]. Magy Onkol; 2009 Jun;53(2):127-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnostic problems of ovarian mucinous borderline tumors].
  • About 15-20% of all ovarian epithelial neoplasms are of borderline type (or atypical proliferative or carcinoma of low malignant potential) and about 5-7% are mucinous type, which are the second most common type behind the serous borderline tumors.
  • The borderline tumor is a serious diagnostic and treatment problem both for the pathologists and for clinicians.
  • These tumors appeared to be intermediate in their histologic and prognostic features between the benign cystadenomas and clearly malignant carcinomas.
  • To diagnose the intraepithelial carcinoma, to detect the microinvasion and the expansive invasion in a mucinous borderline tumor, to differentiate from the metastasis of colorectal tumors may be very problematic in the majority of the cases.
  • Eleven cases diagnosed as mucinous borderline ovarian tumor in our institute from 2000 to 2008 were reviewed.
  • We discuss all of these problems according to the latest literature and our experience, mentioning the problems of the peritoneal and ovarian pseudomyxomas.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Biomarkers, Tumor / analysis. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. CA-125 Antigen / analysis. Diagnosis, Differential. Female. GPI-Linked Proteins. Homeodomain Proteins / analysis. Humans. Keratin-20 / analysis. Keratin-7 / analysis. Membrane Glycoproteins / analysis. Middle Aged. Neoplasm Invasiveness. Prognosis. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19581178.001).
  • [ISSN] 0025-0244
  • [Journal-full-title] Magyar onkologia
  • [ISO-abbreviation] Magy Onkol
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / CDX2 protein, human; 0 / GPI-Linked Proteins; 0 / Homeodomain Proteins; 0 / Keratin-20; 0 / Keratin-7; 0 / Membrane Glycoproteins; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0 / mesothelin
  •  go-up   go-down


15. Daponte A, Ioannou M, Mylonis I, Simos G, Minas M, Messinis IE, Koukoulis G: Prognostic significance of Hypoxia-Inducible Factor 1 alpha(HIF-1 alpha) expression in serous ovarian cancer: an immunohistochemical study. BMC Cancer; 2008;8:335
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of Hypoxia-Inducible Factor 1 alpha(HIF-1 alpha) expression in serous ovarian cancer: an immunohistochemical study.
  • The few publications addressing the prognostic significance of Hypoxia-Inducible Factor 1 alpha (HIF-1 alpha) cellular expression in ovarian cancer produced contradictory findings which are not permissible to widely acceptable conclusions and clinical applications.
  • METHODS: One hundred (n = 100) neoplastic and 20 benign (controls) pathological samples from paraffin-embedded tissue were included.
  • Also 22 borderline serous adenocarcinoma patients and 20 benign controls were stained.
  • Only patients with the diagnosis of serous carcinoma of stage III, G3 who received 6 cycles of postoperative TC (175-180 mg/m2 paclitaxel and carboplatin after calculating the area under the concentration curve) with complete medical records (n = 55) were selected for survival analysis.
  • RESULTS: The frequency of the nuclear expression of HIF-1 alpha in benign tumours was significantly lower (median: no expression) than in borderline and ovarian cancer tumours combined (p < 0.001).
  • HIF-1 alpha expression in serous ovarian carcinoma was not stage dependent.
  • CONCLUSION: Our report confirms the prognostic value of HIF-1 alpha when restricted to poorly differentiated serous ovarian carcinoma.
  • [MeSH-major] Gene Expression. Hypoxia-Inducible Factor 1, alpha Subunit / metabolism. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Female. Humans. Immunohistochemistry. Neoplasm Staging. Prognosis. Survival

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Annu Rev Cell Dev Biol. 1999;15:551-78 [10611972.001]
  • [Cites] Cancer Res. 1999 Nov 15;59(22):5830-5 [10582706.001]
  • [Cites] Am J Pathol. 2000 Aug;157(2):411-21 [10934146.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):1830-2 [11280732.001]
  • [Cites] Clin Cancer Res. 2001 Jun;7(6):1661-8 [11410504.001]
  • [Cites] Cancer Lett. 2002 Feb 25;176(2):215-23 [11804750.001]
  • [Cites] Biochem J. 2002 Feb 15;362(Pt 1):71-9 [11829741.001]
  • [Cites] Cancer Res. 2002 May 1;62(9):2493-7 [11980639.001]
  • [Cites] Cancer Cell. 2003 Apr;3(4):363-75 [12726862.001]
  • [Cites] Cancer Treat Rev. 2003 Aug;29(4):297-307 [12927570.001]
  • [Cites] Nat Rev Cancer. 2003 Oct;3(10):721-32 [13130303.001]
  • [Cites] Gynecol Oncol. 2003 Dec;91(3):513-7 [14675669.001]
  • [Cites] Cell Cycle. 2004 Feb;3(2):172-5 [14712084.001]
  • [Cites] EMBO J. 1998 Nov 16;17(22):6573-86 [9822602.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8665-73 [15623651.001]
  • [Cites] Cancer Res. 2005 Oct 1;65(19):9021-8 [16204076.001]
  • [Cites] Sci STKE. 2005 Oct 18;2005(306):re12 [16234508.001]
  • [Cites] Med Hypotheses. 2006;66(2):380-3 [16229963.001]
  • [Cites] J Clin Oncol. 2006 Feb 10;24(5):727-35 [16418497.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:405-12 [16515634.001]
  • [Cites] Handb Exp Pharmacol. 2006;(172):259-77 [16610363.001]
  • [Cites] Curr Top Med Chem. 2006;6(11):1163-71 [16842153.001]
  • [Cites] Gynecol Oncol. 2006 Aug;102(2):292-9 [16443261.001]
  • [Cites] Clin Cancer Res. 2006 Aug 1;12(15):4562-8 [16899602.001]
  • [Cites] Mol Cancer Res. 2006 Sep;4(9):601-5 [16940159.001]
  • [Cites] J Biol Chem. 2006 Nov 3;281(44):33095-106 [16954218.001]
  • [Cites] Cancer Res. 2007 Mar 15;67(6):2408-13 [17363557.001]
  • [Cites] Cancer Lett. 2007 Jun 18;251(1):164-7 [17215078.001]
  • [Cites] Hum Pathol. 2007 Sep;38(9):1310-20 [17555795.001]
  • [Cites] Cell Physiol Biochem. 2007;20(6):995-1006 [17982282.001]
  • [Cites] Cancer. 2000 Jun 1;88(11):2606-18 [10861440.001]
  • (PMID = 19014607.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit
  • [Other-IDs] NLM/ PMC2651893
  •  go-up   go-down


16. Shao SL, Cai Y, Wang QH, Yan LJ, Zhao XY, Wang LX: [Expression of GLUT-1, p63 and DNA-Pkcs in serous ovarian tumors and their significance]. Zhonghua Zhong Liu Za Zhi; 2007 Sep;29(9):697-700
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of GLUT-1, p63 and DNA-Pkcs in serous ovarian tumors and their significance].
  • OBJECTIVE: To investigate the expression of GLUT1, p63 and DNA-Pkcs in serous ovarian tumors and their significance.
  • METHODS: GTUL1, p63 and DNA-Pkcs expression at protein level was detected by immunohistochemistry in patients with serous ovarian tumors.
  • RESULTS: Cells in the normal ovarian tissues were not stained with GTUL1 and p63 antiserum, but DNA-Pkcs was positively stained.
  • The intensity of GTUT1 and p63 expression was stronger in malignant ovarian serous tumors compared with other subtypes (P < 0.01).
  • There were significant differences of DNA-PKcs among normal ovaries (100.0%), benign (95.0%), borderline (90.0%) and malignant (60.0%) serious ovarian neoplasms (P < 0.01).
  • CONCLUSION: The results suggest that the abnormal expression of GTUT1, p63 and DNA-Pkcs may perhaps participate in serous ovarian tumor occurrence and development and may be considered as a marker reflecting tumor malignant behavior.
  • [MeSH-major] Cystadenocarcinoma, Serous / metabolism. DNA-Activated Protein Kinase / metabolism. Glucose Transporter Type 1 / metabolism. Nuclear Proteins / metabolism. Ovarian Neoplasms / metabolism. Trans-Activators / metabolism. Tumor Suppressor Proteins / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Cystadenoma, Serous / metabolism. Cystadenoma, Serous / pathology. Epithelium / metabolism. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Ovary / cytology. Transcription Factors. Young Adult

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18246802.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Glucose Transporter Type 1; 0 / Nuclear Proteins; 0 / SLC2A1 protein, human; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; EC 2.7.11.1 / DNA-Activated Protein Kinase; EC 2.7.11.1 / PRKDC protein, human
  •  go-up   go-down


17. Alberti N, Serrano-Egea A, García-García E, Ballestín C, Pérez-Barrios A, López-Ríos F, de Agustín P: Primary papillary serous carcinoma of the peritoneum: report of a case with diagnosis by fine needle aspiration and immunocytochemistry. Acta Cytol; 2007 Mar-Apr;51(2):203-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary papillary serous carcinoma of the peritoneum: report of a case with diagnosis by fine needle aspiration and immunocytochemistry.
  • BACKGROUND: Primary papillary serous carcinoma (PPSC) of the peritoneum is a rare neoplasm, histologically indistinguishable from papillary serous carcinoma of the ovary, which diffusely involves the peritoneum but spares or minimally invades the ovaries.
  • CASE: A woman developed an extensive peritoneal neoplasm 4 years after hysterectomy and bilateral salpingo-oophorectomy for benign disease.
  • Fine needle aspiration of the tumor was performed, and the cytologic and immunocytochemical findings were consistent with papillary serous carcinoma.
  • CONCLUSION: Fine needle aspiration cytology coupled with immunocytochemical and clinical data allows an unequivocal preoperative diagnosis of papillary serous carcinoma (primary peritoneal or with an ovarian origin).
  • [MeSH-major] Cystadenocarcinoma, Papillary / diagnosis. Cystadenocarcinoma, Serous / diagnosis. Ovarian Neoplasms / diagnosis. Peritoneal Neoplasms / diagnosis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ascites / etiology. Biomarkers, Tumor / analysis. Biomarkers, Tumor / biosynthesis. Biopsy, Fine-Needle / methods. Diagnosis, Differential. Female. Humans. Hysterectomy. Immunohistochemistry / methods. Middle Aged. Pleural Effusion, Malignant / etiology. Pleural Effusion, Malignant / pathology. Predictive Value of Tests. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17425204.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


18. Artini PG, Ruggiero M, Monteleone P, Carpi A, Cristello F, Cela V, Genazzani AR: Vascular endothelial growth factor and its soluble receptor in benign and malignant ovarian tumors. Biomed Pharmacother; 2008 Jul-Aug;62(6):373-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vascular endothelial growth factor and its soluble receptor in benign and malignant ovarian tumors.
  • An imbalance between pro-angiogenic and anti-angiogenic factors is hypothesized in the pathogenesis of ovarian cystic disease.
  • The aim of the following study was to explore the possible role of free vascular endothelial growth factor receptor 1 (sVEGFR-1), a soluble regulator of vascular endothelial growth factor (VEGF) action, in ovarian cystoadenoma, endometriomata and cystoadenocarcinoma.
  • Forty-eight women, of whom fourteen had ovarian serous cysts, twenty-eight had stage III-IV ovarian endometriomata, and six had stage IIIB-IIIC ovarian carcinoma, were included.
  • Sampling of serum, peritoneal and ovarian cystic fluids and of tumor tissue was performed before, during and following surgery, respectively.
  • VEGF and sVEGFR-1 expression was evaluated in tumor tissue.
  • Western blot evidenced a marked expression of VEGF and soluble VEGFR-1 in endometriosis tissue with respect to benign cyst tissue but a lower expression of both molecules, contrary to that expected, in cancer tissue.
  • In conclusion, all in all, our data indicate that an excess of local VEGF with respect to its soluble receptor VEGFR-1 may be a key factor in the onset and maintenance of pathological neo-angiogenesis in ovarian cyst formation.
  • [MeSH-major] Ovarian Diseases / metabolism. Ovarian Neoplasms / metabolism. Vascular Endothelial Growth Factor A / metabolism. Vascular Endothelial Growth Factor Receptor-1 / metabolism
  • [MeSH-minor] Adult. Aged. Ascitic Fluid / chemistry. Cyst Fluid / chemistry. Cystadenocarcinoma / metabolism. Cystadenoma / metabolism. Endometriosis / metabolism. Female. Gene Expression. Humans. Middle Aged. Neoplasm Staging. Neovascularization, Pathologic / physiopathology. Ovarian Cysts / metabolism. Ovarian Cysts / physiopathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Disorders.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18037256.001).
  • [ISSN] 0753-3322
  • [Journal-full-title] Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie
  • [ISO-abbreviation] Biomed. Pharmacother.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-1
  •  go-up   go-down


19. Jain D, Akhila L, Kawatra V, Aggarwal P, Khurana N: Psammocarcinoma of ovary with serous cystadenofibroma of contralateral ovary: a case report. J Med Case Rep; 2009;3:9330
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Psammocarcinoma of ovary with serous cystadenofibroma of contralateral ovary: a case report.
  • INTRODUCTION: Psammocarcinoma of ovary is a rare serous neoplasm characterized by extensive formation of psammoma bodies, invasion of ovarian stroma, peritoneum or intraperitoneal viscera, and moderate cytological atypia.
  • CASE PRESENTATION: We herein report a case of psammocarcinoma of ovary with serous cystadenofibroma of contralateral ovary in a 55 year old Asian Indian female.
  • CONCLUSION: To the best of author's knowledge, ours is the rare case describing coexistence of this very rare malignant serous epithelial tumor with a benign serous cystadenofibroma of contralateral ovary.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Comput Assist Tomogr. 2007 May-Jun;31(3):490-2 [17538302.001]
  • [Cites] Gynecol Oncol. 2007 Apr;105(1):248-51 [17222893.001]
  • [Cites] Arch Gynecol Obstet. 2009 Jun;279(6):931-6 [18982336.001]
  • [Cites] Gynecol Oncol. 2009 Jun;113(3):402-4 [19345402.001]
  • [Cites] Arch Gynecol Obstet. 2009 Aug;280(2):283-6 [19096859.001]
  • [Cites] Int J Gynecol Cancer. 2009 Jul;19(5):844-6 [19574771.001]
  • [Cites] J Pathol. 2004 Mar;202(3):336-40 [14991899.001]
  • [Cites] Int J Gynecol Pathol. 1990;9(2):110-21 [2332269.001]
  • [Cites] Gynecol Oncol. 1995 Nov;59(2):309-11 [7590493.001]
  • [Cites] Pathologe. 1997 Nov;18(6):463-6 [9451736.001]
  • [Cites] South Med J. 1998 May;91(5):477-80 [9598860.001]
  • [Cites] Obstet Gynecol. 1998 Oct;92(4 Pt 2):659-61 [9764653.001]
  • [Cites] Gynecol Oncol. 2005 Jan;96(1):259-62 [15589614.001]
  • [Cites] Clin Nucl Med. 2005 Jun;30(6):395-9 [15891291.001]
  • [Cites] Gynecol Oncol. 2005 Nov;99(2):510-1 [16051342.001]
  • [Cites] Cytojournal. 2008;5:7 [18416848.001]
  • (PMID = 20072673.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2806332
  •  go-up   go-down


20. Pan Y, Jiao J, Zhou C, Cheng Q, Hu Y, Chen H: Nanog is highly expressed in ovarian serous cystadenocarcinoma and correlated with clinical stage and pathological grade. Pathobiology; 2010;77(6):283-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nanog is highly expressed in ovarian serous cystadenocarcinoma and correlated with clinical stage and pathological grade.
  • We investigated whether the Nanog expression is associated with the occurrence and development of ovarian cancer.
  • METHODS: Immunohistochemistry was used to examine the expression of Nanog in 43 normal ovarian epithelia, 110 serous cystadenomas, 80 borderline serous cystadenomas, and 107 serous cystadenocarcinomas.
  • RESULTS: The expression intensity of Nanog in normal ovarian tissue, benign, borderline, and malignant tumors showed a gradual rising trend.
  • Among the serous cystadenocarcinomas, 42.86% were detected to be positive for stage I, 70.97% for stage II, 95.31% for stage III, and 100% for stage IV.
  • CONCLUSIONS: Nanog was highly expressed in ovarian serous cystadenocarcinoma, and showed a positive correlation with clinical stage and grade.
  • Nanog may play an important role in the development of dedifferentiation and progression of serous ovarian carcinoma.
  • [MeSH-major] Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / pathology. Homeodomain Proteins / metabolism. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Cell Dedifferentiation. Cystadenoma, Serous / metabolism. Cystadenoma, Serous / pathology. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Ovary / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2011 S. Karger AG, Basel.
  • (PMID = 21266826.001).
  • [ISSN] 1423-0291
  • [Journal-full-title] Pathobiology : journal of immunopathology, molecular and cellular biology
  • [ISO-abbreviation] Pathobiology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / NANOG protein, human
  •  go-up   go-down


21. Odunsi K, Wollman RM, Ambrosone CB, Hutson A, McCann SE, Tammela J, Geisler JP, Miller G, Sellers T, Cliby W, Qian F, Keitz B, Intengan M, Lele S, Alderfer JL: Detection of epithelial ovarian cancer using 1H-NMR-based metabonomics. Int J Cancer; 2005 Feb 20;113(5):782-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of epithelial ovarian cancer using 1H-NMR-based metabonomics.
  • Currently available serum biomarkers are insufficiently reliable to distinguish patients with epithelial ovarian cancer (EOC) from healthy individuals.
  • In an effort to examine the utility of the metabonomic approach for discriminating sera from women with EOC from healthy controls, we performed (1)H-NMR spectroscopic analysis on preoperative serum specimens obtained from 38 patients with EOC, 12 patients with benign ovarian cysts and 53 healthy women.
  • PCA analysis allowed correct separation of all serum specimens from 38 patients with EOC (100%) from all of the 21 premenopausal normal samples (100%) and from all the sera from patients with benign ovarian disease (100%).
  • SIMCA analysis using the Cooman's plot demonstrated that sera classes from patients with EOC, benign ovarian cysts and the postmenopausal healthy controls did not share multivariate space, providing validation for the class separation.
  • The metabonomic approach deserves further evaluation as a potential novel strategy for the early detection of epithelial ovarian cancer.
  • [MeSH-major] Magnetic Resonance Spectroscopy / methods. Neoplasms, Glandular and Epithelial / diagnosis. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma, Clear Cell / blood. Adenocarcinoma, Clear Cell / diagnosis. Adenocarcinoma, Clear Cell / surgery. Adult. Aged. Aged, 80 and over. Carcinoma, Endometrioid / blood. Carcinoma, Endometrioid / diagnosis. Carcinoma, Endometrioid / surgery. Case-Control Studies. Cystadenocarcinoma, Mucinous / blood. Cystadenocarcinoma, Mucinous / diagnosis. Cystadenocarcinoma, Mucinous / surgery. Cystadenocarcinoma, Serous / blood. Cystadenocarcinoma, Serous / diagnosis. Cystadenocarcinoma, Serous / surgery. Female. Humans. Middle Aged. Neoplasm Staging. Ovarian Cysts / metabolism. Postmenopause. Premenopause. Prognosis. ROC Curve. Sensitivity and Specificity


22. Coronado Martín PJ, Fasero Laiz M, García Santos J, Ramírez Mena M, Vidart Aragón JA: [Overexpression and prognostic value of p53 and HER2/neu proteins in benign ovarian tissue and in ovarian cancer]. Med Clin (Barc); 2007 Jan 13;128(1):1-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Overexpression and prognostic value of p53 and HER2/neu proteins in benign ovarian tissue and in ovarian cancer].
  • BACKGROUND AND OBJECTIVE: To investigate the prognostic value of p53 and HER2/neu overexpression in epithelial ovarian cancer (EOC).
  • PATIENTS AND METHOD: p53 and HER2/neu immunostaining were performed in 198 tissue samples, 124 EOC, 44 benign ovarian tumors and 30 normal ovaries.
  • RESULTS: Neither p53 nor HER2/neu overexpression was seen in the benign ovarian tumors.
  • [MeSH-major] Cystadenoma, Mucinous / genetics. Cystadenoma, Serous / genetics. Ovarian Neoplasms / genetics. Receptor, ErbB-2 / genetics. Teratoma / genetics. Tumor Suppressor Protein p53 / genetics
  • [MeSH-minor] Aged. Biomarkers, Tumor. Confidence Intervals. Endometriosis / genetics. Endometriosis / pathology. Endometriosis / surgery. Female. Follow-Up Studies. Genes, p53. Humans. Immunohistochemistry. Middle Aged. Multivariate Analysis. Neoplasm Recurrence, Local. Neoplasm Staging. Ovarian Diseases / genetics. Ovarian Diseases / pathology. Ovarian Diseases / surgery. Prognosis. Proportional Hazards Models. Risk. Survival Analysis. Time Factors


23. Chase DM, Crade M, Basu T, Saffari B, Berman ML: Preoperative diagnosis of ovarian malignancy: preliminary results of the use of 3-dimensional vascular ultrasound. Int J Gynecol Cancer; 2009 Apr;19(3):354-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative diagnosis of ovarian malignancy: preliminary results of the use of 3-dimensional vascular ultrasound.
  • Each mass was preoperatively judged to be benign or malignant based upon a study of vascularity within an ovarian mass using 3D ultrasound.
  • Masses with orderly vascular architecture were categorized as probably benign, and masses with chaotic vascular patterns were categorized as malignant.
  • Suspicious 3D vascular ultrasound findings predicted malignant neoplasm in 10 patients.
  • There was 1 case of a low-malignant potential tumor without a suspicious ultrasound finding.
  • CONCLUSIONS: In this preliminary and observational study, 3D ultrasound examination of vascular architecture was discriminatory in distinguishing benign ovarian masses from malignancy.
  • [MeSH-major] Adenocarcinoma, Clear Cell / ultrasonography. Carcinoma, Papillary / ultrasonography. Cystadenocarcinoma, Serous / ultrasonography. Endometrial Neoplasms / ultrasonography. Ovarian Neoplasms / ultrasonography

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19407559.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Shibata K, Kajiyama H, Mizokami Y, Ino K, Nomura S, Mizutani S, Terauchi M, Kikkawa F: Placental leucine aminopeptidase (P-LAP) and glucose transporter 4 (GLUT4) expression in benign, borderline, and malignant ovarian epithelia. Gynecol Oncol; 2005 Jul;98(1):11-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Placental leucine aminopeptidase (P-LAP) and glucose transporter 4 (GLUT4) expression in benign, borderline, and malignant ovarian epithelia.
  • The authors evaluated P-LAP and GLUT4 expression in benign, borderline, and malignant ovarian epithelia.
  • METHODS: Histologic sections of formalin-fixed, paraffin-embedded specimens from 11 patients with benign serous or mucinous cystadenomas, 14 patients with serous or mucinous borderline tumors, and 80 patients with epithelial-ovarian adenocarcinomas (29 serous, 17 endometrioid, 14 mucinous, and 20 clear cell adenocarcinomas) were stained for P-LAP and GLUT4 using each polyclonal antibody.
  • Expressions of P-LAP and GLUT-4 in ovarian cancer cells were detected by Western blotting.
  • RESULTS: P-LAP immunoreactivity was detected in 2 of 11 benign cystadenomas.
  • None of the 11 benign ovarian tumors showed any immunoreactivity for GLUT4.
  • P-LAP was expressed in 23 of 29 in serous, 15 of 17 endometrioid, 13 of 14 mucinous, and all clear-cell adenocarcinomas.
  • The tendency toward increased P-LAP expression with advancing grade was observed in serous adenocarcinomas.
  • GLUT4 was expressed in 13 of 29 serous, 13 of 17 endometrioid, 13 of 14 mucinous, and 18 of 20 clear-cell adenocarcinomas.
  • CONCLUSIONS: P-LAP and GLUT4 are available not only for the evaluation of ovarian epithelial malignancy, but also as targets for molecular therapy.
  • Further study to investigate the roles of P-LAP and GLUT4 in ovarian carcinoma is needed.
  • [MeSH-major] Cystinyl Aminopeptidase / biosynthesis. Monosaccharide Transport Proteins / biosynthesis. Muscle Proteins / biosynthesis. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Growth Processes / physiology. Cell Line, Tumor. Epithelium / enzymology. Epithelium / metabolism. Female. Glucose Transporter Type 4. Humans. Middle Aged. Neoplasm Invasiveness. Ovarian Diseases / enzymology. Ovarian Diseases / metabolism. Ovarian Diseases / pathology. Transfection

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15907336.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glucose Transporter Type 4; 0 / Monosaccharide Transport Proteins; 0 / Muscle Proteins; 0 / SLC2A4 protein, human; EC 3.4.11.3 / Cystinyl Aminopeptidase; EC 3.4.11.3 / leucyl-cystinyl aminopeptidase
  •  go-up   go-down


25. Elgaaen BV, Haug KB, Wang J, Olstad OK, Fortunati D, Onsrud M, Staff AC, Sauer T, Gautvik KM: POLD2 and KSP37 (FGFBP2) correlate strongly with histology, stage and outcome in ovarian carcinomas. PLoS One; 2010;5(11):e13837
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] POLD2 and KSP37 (FGFBP2) correlate strongly with histology, stage and outcome in ovarian carcinomas.
  • BACKGROUND: Epithelial ovarian cancer (EOC) constitutes more than 90% of ovarian cancers and is associated with high mortality.
  • Previously, we reported a limited number of mRNAs strongly upregulated in human osteosarcomas and other malignancies, and six were selected to be tested for a possible association with three subgroups of ovarian carcinomas and clinical parameters.
  • METHODOLOGY/PRINCIPAL FINDINGS: The six selected mRNAs were quantified by RT-qPCR in biopsies from eleven poorly differentiated serous carcinomas (PDSC, stage III-IV), twelve moderately differentiated serous carcinomas (MDSC, stage III-IV) and eight clear cell carcinomas (CCC, stage I-IV) of the ovary.
  • Superficial scrapings from six normal ovaries (SNO), as well as biopsies from three normal ovaries (BNO) and three benign ovarian cysts (BBOC) were analyzed for comparison.
  • The gene expression level was related to the histological and clinical parameters of human ovarian carcinoma samples.
  • Except for POLD2, the serous carcinomas showed a similar transcription profile, being clearly different from CCC.
  • CONCLUSIONS/SIGNIFICANCE: We have identified two biomarkers which are markedly upregulated in two subgroups of ovarian carcinomas and are also associated with stage and outcome.
  • [MeSH-major] Blood Proteins / genetics. DNA Polymerase III / genetics. Ovarian Neoplasms / genetics. RNA, Messenger / metabolism
  • [MeSH-minor] Aged. Cystadenocarcinoma, Serous / diagnosis. Cystadenocarcinoma, Serous / genetics. Female. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Humans. Neoplasm Staging. Neoplasms, Glandular and Epithelial / diagnosis. Neoplasms, Glandular and Epithelial / genetics. Outcome Assessment (Health Care). Ovarian Cysts / diagnosis. Ovarian Cysts / genetics. Prognosis. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 2000 Feb;156(2):409-17 [10666369.001]
  • [Cites] JAMA. 2009 Jul 15;302(3):261-75 [19602686.001]
  • [Cites] Mol Cell Biol. 2000 Dec;20(23):9028-40 [11074001.001]
  • [Cites] Endocr Rev. 2001 Apr;22(2):255-88 [11294827.001]
  • [Cites] Cancer Res. 2001 May 1;61(9):3741-9 [11325847.001]
  • [Cites] J Immunol. 2001 May 15;166(10):6404-12 [11342666.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Cancer Cell. 2002 Feb;1(1):53-62 [12086888.001]
  • [Cites] Cancer Res. 2002 Aug 15;62(16):4722-9 [12183431.001]
  • [Cites] Anticancer Res. 2003 May-Jun;23(3B):2201-16 [12894494.001]
  • [Cites] Clin Cancer Res. 2003 Oct 15;9(13):4811-8 [14581352.001]
  • [Cites] BMC Bioinformatics. 2002 Nov 24;3:36 [12445336.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1511-8 [15111296.001]
  • [Cites] J Biol Chem. 1987 Mar 25;262(9):4355-9 [3031073.001]
  • [Cites] Cancer. 1999 Feb 1;85(3):669-77 [10091740.001]
  • [Cites] Int Rev Cytol. 2005;242:1-54 [15598466.001]
  • [Cites] FEBS Lett. 2004 Dec 17;578(3):239-44 [15637807.001]
  • [Cites] Oncogene. 2005 Feb 3;24(6):1053-65 [15558012.001]
  • [Cites] Mod Pathol. 2005 Feb;18 Suppl 2:S19-32 [15761464.001]
  • [Cites] J Immunol. 2006 Aug 1;177(3):1772-9 [16849487.001]
  • [Cites] Oncogene. 2006 Sep 28;25(44):5994-6002 [16652150.001]
  • [Cites] Expert Rev Mol Med. 2007;9(13):1-12 [17477890.001]
  • [Cites] J Biomed Inform. 2007 Dec;40(6):707-25 [17418646.001]
  • [Cites] J Clin Oncol. 2008 Feb 20;26(6):995-1005 [18195328.001]
  • [Cites] Cell Res. 2008 May;18(5):538-48 [18427574.001]
  • [Cites] Carcinogenesis. 2009 Mar;30(3):423-31 [19126650.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] Biochim Biophys Acta. 2000 Sep 7;1493(1-2):231-6 [10978529.001]
  • (PMID = 21079801.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Blood Proteins; 0 / KSP37 protein, human; 0 / RNA, Messenger; EC 2.7.7.- / DNA Polymerase III; Ovarian epithelial cancer
  • [Other-IDs] NLM/ PMC2973954
  •  go-up   go-down


26. Exacoustos C, Romanini ME, Rinaldo D, Amoroso C, Szabolcs B, Zupi E, Arduini D: Preoperative sonographic features of borderline ovarian tumors. Ultrasound Obstet Gynecol; 2005 Jan;25(1):50-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative sonographic features of borderline ovarian tumors.
  • OBJECTIVE: To determine the sonographic findings that distinguish borderline ovarian tumors (BOT) from both benign and invasive malignant tumors, thus allowing conservative treatment and laparoscopic management of these tumors.
  • We compared these findings with those of 337 patients with benign ovarian tumors and those of 82 patients with invasive malignant ovarian tumors.
  • RESULTS: Of the 33 BOT, 15 were mucinous and 18 were serous cystadenomas.
  • The presence of papillae, defined as a small number of solid tissue projections, 1-15 mm in height and 1-10 mm in width (base) and length (base), into the cyst cavity from the cyst wall, was significantly more frequent in BOT (48%) than it was in benign (4%) and invasive (4%) malignant tumors.
  • Intracystic solid tissue (> 15 mm in height or > 10 mm in width or length) was observed in 48% of invasive malignant masses but in only 18% of BOT and in 7% of benign tumors (P < 0.001).
  • No sonographically unilocular, hypoechoic, smooth-walled adnexal cysts were invasively malignant but three unilocular cysts with a diameter of > 6 cm were serous BOT.
  • [MeSH-major] Ovarian Neoplasms / surgery. Ovarian Neoplasms / ultrasonography. Preoperative Care / methods
  • [MeSH-minor] Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Adenocarcinoma, Mucinous / ultrasonography. Adolescent. Adult. Aged. Aged, 80 and over. Child. Cystadenoma, Serous / pathology. Cystadenoma, Serous / surgery. Cystadenoma, Serous / ultrasonography. Diagnosis, Differential. Female. Humans. Middle Aged. Neoplasm Invasiveness. Postmenopause. Premenopause. Retrospective Studies. Sensitivity and Specificity. Ultrasonography, Doppler / methods

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2004 ISUOG.
  • (PMID = 15619309.001).
  • [ISSN] 0960-7692
  • [Journal-full-title] Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology
  • [ISO-abbreviation] Ultrasound Obstet Gynecol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


27. Kalir T, Rahaman J, Hagopian G, Demopoulos R, Cohen C, Burstein DE: Immunohistochemical detection of glucose transporter GLUT1 in benign and malignant fallopian tube epithelia, with comparison to ovarian carcinomas. Arch Pathol Lab Med; 2005 May;129(5):651-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical detection of glucose transporter GLUT1 in benign and malignant fallopian tube epithelia, with comparison to ovarian carcinomas.
  • OBJECTIVE: We present an immunohistochemical survey of GLUT1 expression in benign and malignant fallopian tube epithelia, and compare serous carcinomas of the fallopian tube and ovary.
  • DESIGN: One hundred two routinely fixed and processed archival specimens (36 benign fallopian tubes, 29 primary tubal adenocarcinomas, and 37 primary ovarian adenocarcinomas) were immunostained with rabbit anti-GLUT1 and developed with streptavidin-biotin/diaminobenzidine.
  • RESULTS: Benign tubes (n = 36) were either negatively stained (58.3%) or displayed rare weak staining (0.5+ to 1+, rarely 2+; 41.7%); of the latter, 4 specimens showed chronic salpingitis, and 6 showed hyperplasia (epithelial tufting and stratification).
  • Nineteen tubal carcinoma sections showed residual benign epithelium, which was consistently nonstaining.
  • On average, GLUT1 staining in primary fallopian tube cancers was less extensive than in primary ovarian adenocarcinomas.
  • CONCLUSIONS: GLUT1 immunostaining of fallopian tube adenocarcinomas was substantially stronger and more extensive than staining of benign tubal epithelium, consistent with previously described findings in carcinomas versus benign tissues from many primary sites.
  • The difference in extent of GLUT1 staining between primary tubal and primary ovarian serous adenocarcinomas is discussed.
  • [MeSH-major] Adenocarcinoma / metabolism. Fallopian Tube Neoplasms / metabolism. Fallopian Tubes / metabolism. Immunohistochemistry / methods. Monosaccharide Transport Proteins / metabolism. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Epithelial Cells / metabolism. Epithelial Cells / pathology. Female. Glucose Transporter Type 1. Humans. Hyperplasia / metabolism. Hyperplasia / pathology. Neoplasm Staging. Precancerous Conditions / metabolism. Precancerous Conditions / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15859637.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glucose Transporter Type 1; 0 / Monosaccharide Transport Proteins; 0 / SLC2A1 protein, human
  •  go-up   go-down


28. Osterberg L, Akeson M, Levan K, Partheen K, Zetterqvist BM, Brännström M, Horvath G: Genetic alterations of serous borderline tumors of the ovary compared to stage I serous ovarian carcinomas. Cancer Genet Cytogenet; 2006 Jun;167(2):103-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic alterations of serous borderline tumors of the ovary compared to stage I serous ovarian carcinomas.
  • Borderline tumors of the ovary comprise 10-20% of all epithelial ovarian tumors, and are placed between clearly benign and obviously malignant ovarian tumors.
  • To increase our understanding in relation to this issue, the aim of our study was to analyze both serous borderline and invasive ovarian tumors, and to investigate early carcinogenesis in serous ovarian tumors.
  • Using comparative genomic hybridization, we compared cytogenetic changes in borderline ovarian tumors and stage I invasive tumors.
  • In conclusion, we found four distinct cytogenetic alterations that might be early events in serous ovarian tumors, and that might also characterize a subgroup of borderline ovarian tumors that may have the potential to progress and develop malignancy.
  • [MeSH-major] Aneuploidy. Carcinoma / genetics. Ovarian Neoplasms / genetics. Serous Membrane
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. DNA, Neoplasm / analysis. Female. Humans. Middle Aged. Neoplasm Staging. Nucleic Acid Hybridization

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16737908.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


29. Ye F, Li Y, Hu Y, Zhou C, Hu Y, Chen H: Stage-specific embryonic antigen 4 expression in epithelial ovarian carcinoma. Int J Gynecol Cancer; 2010 Aug;20(6):958-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage-specific embryonic antigen 4 expression in epithelial ovarian carcinoma.
  • METHODS: In this study, we investigated the expression of SSEA-4 in 479 cases of various degrees of ovarian epithelial lesions by immunohistochemistry, consisting of 45 normal ovarian epithelia, 110 benign serous ovarian cystadenomas, 68 borderline serous ovarian cystadenomas, 104 invasive serous ovarian carcinomas, 64 benign serous mucinous cystadenomas, 48 borderline mucinous ovarian cystadenomas, and 40 invasive mucinous carcinomas.
  • RESULTS: The expression of SSEA-4 was found to be increased from normal epithelium to benign cystadenoma and to borderline cystadenoma and adenocarcinoma in both serous and mucinous group.
  • The loss or reduction of the expression of SSEA-4 was significantly correlated with more advanced tumor stage and poorer tumor cell differentiation.
  • CONCLUSIONS: We therefore proposed that SSEA-4 may play a role during the oncogenesis of epithelial ovarian carcinoma and posses a tumor suppressor effect during malignancy promotion.
  • It could be a potential therapy target in patients with epithelial ovarian carcinoma.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma / immunology. Carcinoma / pathology. Ovarian Neoplasms / immunology. Ovarian Neoplasms / pathology. Stage-Specific Embryonic Antigens / metabolism
  • [MeSH-minor] Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Adult. Aged. Biopsy, Needle. Cohort Studies. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / pathology. Cystadenoma, Mucinous / metabolism. Cystadenoma, Mucinous / pathology. Cystadenoma, Serous / metabolism. Cystadenoma, Serous / pathology. Disease Progression. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Prognosis. Reference Values. Sensitivity and Specificity. Statistics, Nonparametric. Tissue Embedding

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20683402.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Stage-Specific Embryonic Antigens; 0 / stage-specific embryonic antigen-4
  •  go-up   go-down


30. Li YL, Ye F, Cheng XD, Hu Y, Zhou CY, Lü WG, Xie X: Identification of glia maturation factor beta as an independent prognostic predictor for serous ovarian cancer. Eur J Cancer; 2010 Jul;46(11):2104-18
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of glia maturation factor beta as an independent prognostic predictor for serous ovarian cancer.
  • Serous ovarian carcinoma (SOC) is the most common subtype of epithelial ovarian cancer which remains the leading cause of death from gynaecologic malignancy.
  • Further knowledge of the proteins involved in serous ovarian cancer may lead to new treatment targets, new markers for early detection or prognosis prediction.
  • In this study, we applied proteomic techniques to analyse the protein expression profiles of SOC and normal ovarian epithelium tissues.
  • Additionally, we analysed glia maturation factor beta (GMFB) protein expression by immunohistochemistry in 246 patients with various degrees of ovarian epithelial lesions.
  • GMFB expression in SOC was found to be significantly enhanced than that in normal epithelium, benign serous adenoma and borderline serous adenoma tissues, and was positively correlated with FIGO stage (P=0.012).
  • [MeSH-major] Biomarkers, Tumor / metabolism. Cystadenocarcinoma, Serous / diagnosis. Glia Maturation Factor / metabolism. Neoplasm Proteins / metabolism. Ovarian Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • The Lens. Cited by Patents in .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20547056.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glia Maturation Factor; 0 / Neoplasm Proteins; 0 / Proteome
  •  go-up   go-down


31. Kato N, Sasou S, Motoyama T: Expression of hepatocyte nuclear factor-1beta (HNF-1beta) in clear cell tumors and endometriosis of the ovary. Mod Pathol; 2006 Jan;19(1):83-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Clear cell tumors of the ovary are frequently associated with ovarian endometriosis.
  • In the present study, we examined 30 clear cell tumors (26 malignant, three borderline, and one benign) and 40 endometriotic cysts to clarify if differentiation into the clear cell lineage already begins in ovarian endometriosis.
  • All of the 30 clear cell tumors, including borderline and benign ones, showed immunohistochemical expression of HNF-1beta in the nucleus, while other types of ovarian epithelial tumors (endometrioid, serous, mucinous, and Brenner tumors) rarely expressed it.
  • In nine of the 12 cases, distinct nuclear immunostaining for HNF-1beta was detected in the endometriotic epithelium, as well as in the clear cell tumor.
  • Furthermore, 16 of 40 (40%) endometriotic cysts without a neoplasm also expressed HNF-1beta, and the expression was almost exclusively observed in the epithelium showing inflammatory atypia.
  • Our results indicate that HNF-1beta is an excellent molecular marker for ovarian clear cell tumors, including benign, borderline and malignant lesions.
  • Early differentiation into the clear cell lineage takes place in ovarian endometriosis, not only in atypical endometriosis, but also in endometriosis with degenerative and regenerative changes, and this is probably responsible for the frequent occurrence of clear cell carcinoma in ovarian endometriosis.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Endometriosis / pathology. Hepatocyte Nuclear Factor 1-beta / biosynthesis. Ovarian Diseases / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Epithelial Cells / chemistry. Epithelial Cells / pathology. Female. Humans. Immunohistochemistry. Middle Aged. Ovarian Cysts / metabolism. Ovarian Cysts / pathology

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16258507.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 138674-15-4 / Hepatocyte Nuclear Factor 1-beta
  •  go-up   go-down


32. Jung SG, Kwon YD, Song JA, Back MJ, Lee SY, Lee C, Hwang YY, An HJ: Prognostic significance of Notch 3 gene expression in ovarian serous carcinoma. Cancer Sci; 2010 Sep;101(9):1977-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of Notch 3 gene expression in ovarian serous carcinoma.
  • The Notch signaling pathway is an important cell signaling system, which regulates cell differentiation, proliferation, and apoptosis, and is aberrantly activated in a wide range of cancer, including ovarian cancers.
  • However, it remains unclear as to whether Notch signaling plays a role in the progression and prognosis of ovarian cancer.
  • We examined the mRNA and protein expression of Notch 3, Jagged 1, and Jagged 2 in 98 ovarian epithelial tumors via real-time PCR and in 175 tumors with immunohistochemical analysis, and then correlated their expression levels with clinicopathological parameters and patient survival.
  • In this study, we detected high levels of Notch3 mRNA and protein expression especially in serous ovarian carcinomas compared to their benign counterparts, accompanied by a positive correlation with the expressions of Jagged 1 and Jagged 2.
  • High levels of Notch 3 mRNA expression (>2-fold than that of benign tumor) were noted in 63% of the serous carcinomas (mean level: 17-fold, P = 0.032).
  • Our results indicate that the Notch 3 signaling pathway is involved in the tumor progression of ovarian serous carcinoma, and higher Notch 3 expression may be an independent poor prognostic factor in this subset of tumors.
  • [MeSH-major] Cystadenocarcinoma, Serous / genetics. Gene Expression Regulation, Neoplastic. Ovarian Neoplasms / genetics. Receptors, Notch / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Calcium-Binding Proteins / genetics. Calcium-Binding Proteins / metabolism. Disease Progression. Female. Humans. Immunohistochemistry / statistics & numerical data. Intercellular Signaling Peptides and Proteins / genetics. Intercellular Signaling Peptides and Proteins / metabolism. Kaplan-Meier Estimate. Membrane Proteins / genetics. Membrane Proteins / metabolism. Middle Aged. Neoplasm Staging. Prognosis. Proportional Hazards Models. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Signal Transduction. Tissue Array Analysis. Young Adult

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Japanese Cancer Association.
  • (PMID = 20624166.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Calcium-Binding Proteins; 0 / Intercellular Signaling Peptides and Proteins; 0 / JAG2 protein, human; 0 / Membrane Proteins; 0 / NOTCH3 protein, human; 0 / RNA, Messenger; 0 / Receptors, Notch; 134324-36-0 / Serrate proteins
  •  go-up   go-down


33. Byrne JA, Balleine RL, Schoenberg Fejzo M, Mercieca J, Chiew YE, Livnat Y, St Heaps L, Peters GB, Byth K, Karlan BY, Slamon DJ, Harnett P, Defazio A: Tumor protein D52 (TPD52) is overexpressed and a gene amplification target in ovarian cancer. Int J Cancer; 2005 Dec 20;117(6):1049-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor protein D52 (TPD52) is overexpressed and a gene amplification target in ovarian cancer.
  • Recurrent chromosome 8q gain in ovarian carcinoma is likely to reflect the existence of multiple target loci, as the separate gain of chromosome bands 8q21 and 8q24 has been reported in independent studies.
  • Since tumor protein D52 (TPD52) has been identified as a chromosome 8q21 amplification target in breast and prostate carcinoma, we compared TPD52 expression in normal ovarian epithelium (n = 9), benign serous adenomas (n = 11), serous borderline tumors (n = 6) and invasive carcinomas of the major histologic subtypes (n = 57) using immunohistochemistry.
  • These analyses revealed that all normal ovarian epithelium samples and benign serous tumors were predominantly TPD52-negative, whereas TPD52 was overexpressed in most (44/57; 77%) ovarian carcinomas regardless of histologic subtype.
  • In an independent cohort of stage III serous carcinomas (n = 18), we also directly compared in situ TPD52 expression using immunohistochemistry and TPD52 copy number using interphase FISH analyses.
  • TPD52 therefore represents a novel molecular marker in ovarian cancer, which is broadly expressed across the different histologic subtypes and whose upregulation frequently reflects increased TPD52 copy number.
  • [MeSH-major] Gene Amplification / genetics. Gene Expression. Neoplasm Proteins / genetics. Ovarian Neoplasms / genetics
  • [MeSH-minor] Biomarkers, Tumor / analysis. CA-125 Antigen / blood. Chromosomes, Human, Pair 8. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Middle Aged. Ovary / chemistry

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc
  • (PMID = 15986428.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / Neoplasm Proteins; 0 / TPD52 protein, human
  •  go-up   go-down


34. Tebben PJ, Kalli KR, Cliby WA, Hartmann LC, Grande JP, Singh RJ, Kumar R: Elevated fibroblast growth factor 23 in women with malignant ovarian tumors. Mayo Clin Proc; 2005 Jun;80(6):745-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevated fibroblast growth factor 23 in women with malignant ovarian tumors.
  • OBJECTIVE: To determine whether fibroblast growth factor 23 (FGF23) concentrations are altered in women with ovarian cancers in which FGF physiology is known to be abnormal.
  • PATIENTS AND METHODS: Between May 2002 and September 2003 at the Mayo Clinic in Rochester, Minn, plasma or serum FGF23 concentrations were measured in 39 healthy women and in 14 with benign ovarian tumors, 14 with early-stage ovarian cancer, and 13 with advanced-stage ovarian cancer.
  • Immunohistochemistry using anti-human FGF23 antibodies was performed on tissue from benign masses and advanced-stage tumors.
  • RESULTS: Serum or plasma FGF23 concentrations were significantly higher in women with advanced-stage ovarian cancer compared with concentrations in women with early-stage ovarian cancer or benign disease or in healthy women.
  • Serum iFGF23 and cFGF23 concentrations were positively correlated with serum phosphorus among women with ovarian cancer.
  • Immunohistochemistry detected FGF23 tissue staining in malignant ovarian cancer cells.
  • CONCLUSION: Serum or plasma FGF23 concentrations are elevated in patients with advanced-stage epithellal ovarian cancer without reductions in serum phosphate concentrations.
  • The presence of elevated FGF23 concentrations in patients with an ovarian mass should suggest advanced-stage disease.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15948297.001).
  • [ISSN] 0025-6196
  • [Journal-full-title] Mayo Clinic proceedings
  • [ISO-abbreviation] Mayo Clin. Proc.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK065830; United States / NIDDK NIH HHS / DK / DK 25409; United States / NIDDK NIH HHS / DK / DK 58546; United States / NIDDK NIH HHS / DK / DK 65830
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / fibroblast growth factor 23; 62031-54-3 / Fibroblast Growth Factors
  •  go-up   go-down


35. Abdel-Azeez HA, Labib HA, Sharaf SM, Refai AN: HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses. Asian Pac J Cancer Prev; 2010;11(1):111-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses.
  • OBJECTIVES: To evaluate the utility of novel serum tumor markers, HE4 and mesothelin either alone or in combination with CA125 in diagnosis and early detection of ovarian carcinoma in patients with pelvic masses.
  • RESULTS: Of 65 patients with pelvic masses; 41 had histologically diagnosed ovarian cancer, and 24 had benign ovarian diseases.
  • The studied tumor markers were significantly increased in malignant compared to benign cases and healthy subjects, and in benign cases compared to healthy subjects (p<0.001).
  • Based upon Receiver operator characteristic (ROC) curves analysis, HE4 had the highest sensitivity as a single marker in detecting ovarian malignancy (82.9%) and early stage malignancy (76.9%), followed by CA125, then mesothelin.
  • The combination of HE4 and CA125 gave the highest sensitivity in detecting ovarian carcinoma and early stage disease (90.2%, 84.6% respectively).
  • CONCLUSIONS: As a single marker, HE4 had the highest sensitivity for detecting ovarian carcinoma specially early stage disease.
  • Combined CA125 and HE4 was a more accurate predictor of ovarian malignancy than either alone.
  • [MeSH-major] Biomarkers, Tumor / blood. Epididymal Secretory Proteins / metabolism. Membrane Glycoproteins / blood. Ovarian Neoplasms / blood. Pelvic Neoplasms / blood
  • [MeSH-minor] Adenocarcinoma, Mucinous / blood. Adenocarcinoma, Mucinous / pathology. CA-125 Antigen / blood. Case-Control Studies. Cystadenocarcinoma, Serous / blood. Cystadenocarcinoma, Serous / pathology. Endometrial Neoplasms / blood. Endometrial Neoplasms / pathology. Female. GPI-Linked Proteins. Humans. Middle Aged. Neoplasm Staging. Prognosis. ROC Curve. Sensitivity and Specificity. beta-Defensins

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20593939.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / DEFB126 protein, human; 0 / Epididymal Secretory Proteins; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / beta-Defensins; 0 / mesothelin
  •  go-up   go-down


36. Ota T, Gilks CB, Longacre T, Leung PC, Auersperg N: HOXA7 in epithelial ovarian cancer: interrelationships between differentiation and clinical features. Reprod Sci; 2007 Sep;14(6):605-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HOXA7 in epithelial ovarian cancer: interrelationships between differentiation and clinical features.
  • Interrelationships between HOXA7 expression and ovarian cancer progression are investigated by cDNA array and by immunohistochemistry of normal ovaries and 538 epithelial ovarian tumor microarrays.
  • HOXA7 mRNA expression was higher in carcinomas than in benign tumors.
  • There were significant associations of strong HOXA7 staining of stroma and tumor nuclei with the clear cell histotype (stroma: P = .0022, nuclei: P = .0003) and of weak/absent staining with serous carcinomas.
  • Tumor E-cadherin expression correlated significantly with HOX7 staining in stroma (P = .0002) but not within tumors.
  • HOXA7 staining of tumor cell nuclei is correlated significantly with improved disease-specific survival (P = .0104), which is suggestive of the biological and potentially clinical importance of subcellular HOXA7 localization.
  • [MeSH-major] Adenocarcinoma, Clear Cell / chemistry. Adenocarcinoma, Mucinous / chemistry. Biomarkers, Tumor / analysis. Carcinoma, Endometrioid / chemistry. Cell Differentiation. Cystadenocarcinoma, Serous / chemistry. Homeodomain Proteins / analysis. Ovarian Neoplasms / chemistry
  • [MeSH-minor] Cadherins / analysis. Cell Nucleus / chemistry. Cluster Analysis. Female. Gene Expression Profiling / methods. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Metaplasia. Neoplasm Staging. Oligonucleotide Array Sequence Analysis. Prognosis. Stromal Cells / chemistry. Stromal Cells / pathology. Tissue Array Analysis


37. Zhen H, Yang S, Wu H, Wang S, Lv J, Ma L, Zhang X: LyGDI is a promising biomarker for ovarian cancer. Int J Gynecol Cancer; 2010 Apr;20(3):316-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] LyGDI is a promising biomarker for ovarian cancer.
  • The aim of this study was to investigate the usefulness of LyGDI as a biomarker for the detection of ovarian cancer, and its specificity and sensitivity were compared with those of cancer antigen 125 (CA125).
  • METHODS: The serum levels of LyGDI were determined by enzyme-linked immunosorbent assay in 42 patients with ovarian disease, including 30 ovarian cancers and 12 benign ovarian lesions, and 76 healthy controls.
  • The expression of LyGDI was also evaluated by immunohistochemical staining in resected ovarian tissues of these patients.
  • RESULTS: The serum LyGDI level of cancers was significantly greater than those of the benign and healthy groups (P = 0.002 and P < 0.0001, respectively), whereas no difference was observed between the benign and control groups (P = 0.889).
  • Based upon receiver operating characteristic curve analysis, LyGDI levels were able to distinguish ovarian cancer from benign ovarian disease (P = 0.0001) and healthy control (P < 0.0001; areas under the receiver operating characteristic curves, 0.876 and 0.833, respectively).
  • For ovarian cancers, 83.3% (25/30) or 80.0% (24/30) was identified by serum LyGDI (> or = 1.5 ng/mL) alone or by CA125 (>35 U/mL) alone.
  • It is of particular importance to note that all cancer patients were identified by use of both markers, and the specificity was 83.3% for the benign group.
  • Immunohistochemical staining confirmed the expression of LyGDI on cancerous epithelial cells other than benign ovarian epithelium.
  • CONCLUSIONS: These results suggest that LyGDI has significant potential as a marker for detection of ovarian cancer in the patients with ovarian enlargement, including detection of early-stage cancers.
  • [MeSH-major] Biomarkers, Tumor / blood. Guanine Nucleotide Dissociation Inhibitors / blood. Ovarian Neoplasms / diagnosis. Tumor Suppressor Proteins / blood
  • [MeSH-minor] Adenocarcinoma, Clear Cell / blood. Adenocarcinoma, Clear Cell / diagnosis. Adenocarcinoma, Mucinous / blood. Adenocarcinoma, Mucinous / diagnosis. Adult. Aged. Aged, 80 and over. CA-125 Antigen / blood. Case-Control Studies. Cystadenocarcinoma, Serous / blood. Cystadenocarcinoma, Serous / diagnosis. Endometrial Neoplasms / blood. Endometrial Neoplasms / diagnosis. Enzyme-Linked Immunosorbent Assay. Female. Humans. Immunoenzyme Techniques. Middle Aged. Neoplasm Staging. Ovary / metabolism. Prognosis. Sensitivity and Specificity. rho Guanine Nucleotide Dissociation Inhibitor beta. rho-Specific Guanine Nucleotide Dissociation Inhibitors

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20375790.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ARHGDIB protein, human; 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / Guanine Nucleotide Dissociation Inhibitors; 0 / Tumor Suppressor Proteins; 0 / rho Guanine Nucleotide Dissociation Inhibitor beta; 0 / rho-Specific Guanine Nucleotide Dissociation Inhibitors
  •  go-up   go-down


38. Athanassiadou P, Grapsa D: Fine needle aspiration of borderline ovarian lesions. Is It useful? Acta Cytol; 2005 May-Jun;49(3):278-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine needle aspiration of borderline ovarian lesions. Is It useful?
  • Borderline ovarian tumors are a low grade form of epithelial ovarian carcinoma with a low rate of growth and a low potential to invade or metastasize.
  • According to the new World Health Organization classification, these tumors are placed between clearly benign and obviously malignant tumors because they exhibit some, but not all, of the morphologic features of malignancy.
  • The pathologic subtype ofperitoneal implants is probably one of the main prognosticfactors in patients with serous tumors of low malignant potential, while the prognostic value of micropapillary serous carcinoma in patients with noninvasive implants remains debatable.
  • [MeSH-major] Biopsy, Fine-Needle. Neoplasms, Glandular and Epithelial / pathology. Ovarian Neoplasms / pathology. Ovary / pathology
  • [MeSH-minor] Female. Humans. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15966290.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Kurman RJ, Shih IeM: The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol; 2010 Mar;34(3):433-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory.
  • Ovarian cancer is the most lethal gynecologic malignancy.
  • Efforts at early detection and new therapeutic approaches to reduce mortality have been largely unsuccessful, because the origin and pathogenesis of epithelial ovarian cancer are poorly understood.
  • This has led to the proposal that ovarian cancer develops de novo.
  • Studies have shown that epithelial ovarian cancer is not a single disease but is composed of a diverse group of tumors that can be classified based on distinctive morphologic and molecular genetic features.
  • One group of tumors, designated type I, is composed of low-grade serous, low-grade endometrioid, clear cell, mucinous and transitional (Brenner) carcinomas.
  • Moreover, the carcinomas exhibit a shared lineage with the corresponding benign cystic neoplasm, often through an intermediate (borderline tumor) step, supporting the morphologic continuum of tumor progression.
  • Type II tumors include conventional high-grade serous carcinoma, undifferentiated carcinoma, and malignant mixed mesodermal tumors (carcinosarcoma).
  • Recent studies have also provided cogent evidence that what have been traditionally thought to be primary ovarian tumors actually originate in other pelvic organs and involve the ovary secondarily.
  • Thus, it has been proposed that serous tumors arise from the implantation of epithelium (benign or malignant) from the fallopian tube.
  • As it is generally accepted that endometriosis develops from endometrial tissue by retrograde menstruation, it is reasonable to assume that the endometrium is the source of these ovarian neoplasms.


40. Jang KY, Kim KS, Hwang SH, Kwon KS, Kim KR, Park HS, Park BH, Chung MJ, Kang MJ, Lee DG, Moon WS: Expression and prognostic significance of SIRT1 in ovarian epithelial tumours. Pathology; 2009;41(4):366-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and prognostic significance of SIRT1 in ovarian epithelial tumours.
  • Therefore, we investigated the prevalence and the prognostic impact of SIRT1 and p53 expression in ovarian epithelial tumours.
  • METHODS: Immunohistochemical expression of SIRT1 and p53 were evaluated using tissue microarray in 40 cases of benign epithelial tumours, 36 cases of borderline tumours, and 90 cases of malignant tumours.
  • RESULTS: Expression of SIRT1 was significantly increased in malignant epithelial tumours compared to benign and borderline epithelial tumours (p < 0.001).
  • In particular, a high proportion of serous carcinoma expressed SIRT1 (86%, 55/64 cases).
  • Despite the frequent expression of SIRT1 in malignant ovarian epithelial tumours, serous carcinomas of high FIGO stage showed less frequent SIRT1 expression compared to that of low stage serous carcinomas (p = 0.029).
  • Moreover, increased expression of SIRT1 in serous carcinoma correlated with increased overall survival by univariate (p = 0.014) and multivariate analyses.
  • CONCLUSIONS: Over-expression of SIRT1 may play an important role in the early stage of ovarian carcinogenesis.
  • [MeSH-major] Biomarkers, Tumor / analysis. Neoplasms, Glandular and Epithelial / metabolism. Neoplasms, Glandular and Epithelial / pathology. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology. Sirtuins / biosynthesis
  • [MeSH-minor] Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Middle Aged. Neoplasm Staging. Prognosis. Sirtuin 1. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19404850.001).
  • [ISSN] 1465-3931
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.5.1.- / SIRT1 protein, human; EC 3.5.1.- / Sirtuin 1; EC 3.5.1.- / Sirtuins
  •  go-up   go-down


41. Nazlioglu HO, Ercan I, Bilgin T, Ozuysal S: Expression of p16 in serous ovarian neoplasms. Eur J Gynaecol Oncol; 2010;31(3):312-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of p16 in serous ovarian neoplasms.
  • PURPOSE: We aimed to examine p16 protein expression in ovarian serous neoplasms along with normal ovarian tissues.
  • MATERIALS AND METHODS: P16 expression was immunhistochemically evaluated in 86 ovarian serous neoplasms (21 cystadenomas, 20 borderline tumors and 45 carcinomas) and 21 non-neoplastic ovarian tissue.
  • The results were also compared with histopathological grade in serous adenocarcinomas.
  • RESULTS: P16 expression rates for benign, borderline ovarian tumors and ovarian cancer were 14.2%, 85% and 86.6%, respectively.
  • No immunoreactivity was found in the non-neoplastic ovarian surface epithelial cells.
  • CONCLUSION: P16 expression is strong and widespread involving most tumor cells in serous papillary ovarian carcinomas, and is probably an early event.
  • [MeSH-major] Cystadenocarcinoma, Serous / chemistry. Neoplasm Proteins / analysis. Ovarian Neoplasms / chemistry

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21077476.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / P16 protein, human
  •  go-up   go-down


42. Krishnamurti U, Sasatomi E, Swalsky PA, Jones MW, Finkelstein SD: Microdissection-based mutational genotyping of serous borderline tumors of the ovary. Int J Gynecol Pathol; 2005 Jan;24(1):56-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microdissection-based mutational genotyping of serous borderline tumors of the ovary.
  • Mutational changes in a number of genetic foci were studied in 12 serous borderline tumors (SBTs) of the ovary including 2 with a micropapillary pattern.
  • Loss of heterozygosity analysis in each tumor was performed with a panel of 12 polymorphic markers on chromosomes 1p, 5q, 9p, 9q, 10q, and 17p.
  • The ovarian tumors displayed allelic losses most frequently on 1p (83.3%), 9q (70%), and 17p (41.7%).
  • In five of six cases, allelic losses were 88% concordant between multiple tumor sites.
  • Only one case of stage III tumor displayed a discordant pattern of allelic loss at different tumor sites.
  • Morphologically heterogenous areas including benign-appearing, typical borderline, and micropapillary areas had a similar pattern of allelic loss.
  • [MeSH-major] Cystadenocarcinoma, Papillary / genetics. Cystadenocarcinoma, Serous / genetics. Mutation / genetics. Ovarian Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Case-Control Studies. Female. Genotype. Humans. Loss of Heterozygosity / genetics. Microdissection. Microsatellite Repeats. Middle Aged. Neoplasm Staging. Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15626917.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Xie D, Yang GF, Chen YQ, Jiang LF, Xiao LZ: [Significance and mechanisms of overexpression of PAK1 gene in epithelial ovarian neoplasms]. Zhonghua Zhong Liu Za Zhi; 2006 Dec;28(12):911-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Significance and mechanisms of overexpression of PAK1 gene in epithelial ovarian neoplasms].
  • OBJECTIVE: To investigate the significance and mechanisms of overexpression of p21-activated kinase 1 gene (PAK1) in epithelial ovarian neoplasms.
  • METHODS: Immunohistochemistry, fluorescence in situ hybridization and terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling methods were used to examine the protein expression and amplification of PAK1 and cell apoptosis in 30 benign ovarian adenomas, 20 borderline tumors and 80 ovarian carcinomas by tissue microarray.
  • RESULTS: In immunohistochemistry study, overexpression of PAK1 protein was observed in 7 (25.9%) informative benign ovarian adenomas, 7 (36.8%) borderline tumors and 53 (68.8%) ovarian carcinomas.
  • A significant inverse correlation of PAK1 overexpression and cell apoptosis was observed in these epithelial ovarian neoplasm cohorts (P = 0.002).
  • In fluorescence in situ hybridization study, only 2 (4.7%) informative ovarian carcinomas showed amplification of PAK1 gene.
  • None of the borderline and benign ovarian tumors showed PAK1 amplification.
  • CONCLUSION: Overexpression of PAK1 protein may be involved in the tumorigenesis of epithelial ovarian neoplasms and it is associated closely with the malignant histological phenotype of ovarian carcinomas.
  • Mechanism other than gene amplification of PAK1 may play a more important role in the regulation of protein expression of PAK1 in ovarian tumors.
  • [MeSH-major] Apoptosis. Cystadenocarcinoma, Serous / metabolism. Ovarian Neoplasms / pathology. p21-Activated Kinases / metabolism
  • [MeSH-minor] Adenoma / genetics. Adenoma / metabolism. Adenoma / pathology. Cystadenocarcinoma, Mucinous / genetics. Cystadenocarcinoma, Mucinous / metabolism. Cystadenocarcinoma, Mucinous / pathology. Female. Gene Amplification. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. In Situ Nick-End Labeling. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17533742.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] EC 2.7.11.1 / PAK1 protein, human; EC 2.7.11.1 / p21-Activated Kinases
  •  go-up   go-down


44. Hakamada K, Miura T, Kimura A, Nara M, Toyoki Y, Narumi S, Sasak M: Anaplastic carcinoma associated with a mucinous cystic neoplasm of the pancreas during pregnancy: report of a case and a review of the literature. World J Gastroenterol; 2008 Jan 7;14(1):132-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic carcinoma associated with a mucinous cystic neoplasm of the pancreas during pregnancy: report of a case and a review of the literature.
  • We herein report an unusual case of anaplastic carcinoma occurring with a recurrent mucinous cystic neoplasm in a 38-year-old female.
  • A 10-cm retroperitoneal cystic mass was pointed out in the first pregnancy and a probable diagnosis of mucinous cystic neoplasm was made in October 2000.
  • During her second pregnancy in 2002, however, she presented hematemesis and underwent urgent distal pancreatectomy, splenectomy and partial resection of the gastric wall where the tumor perforated.
  • A diagnosis of borderline-type mucinous cystic neoplasm with ovarian-like stroma was made.
  • Nine months later, CT visualized a recurrent cystic tumor near the pancreatic stump, which was subsequently resected.
  • Pathology revealed that the tumor was composed of two different components of borderline-type mucinous cystic neoplasm and anaplastic carcinoma.
  • She survived four years after the second surgery without tumor recurrence.
  • Although the origin of anaplastic carcinoma has not been determined yet, it should be remembered that anaplastic carcinoma can occur in association with mucinous cystic neoplasm of more benign histology.
  • [MeSH-major] Carcinoma / pathology. Neoplasms, Cystic, Mucinous, and Serous / pathology. Pancreatic Neoplasms / pathology. Pregnancy Complications, Neoplastic / pathology

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] West J Med. 1982 Feb;136(2):157-62 [6278785.001]
  • [Cites] Cell. 1983 Aug;34(1):245-53 [6192933.001]
  • [Cites] Lab Invest. 1987 Oct;57(4):359-69 [3669613.001]
  • [Cites] Cancer. 1991 Jan 15;67(2):494-8 [1702351.001]
  • [Cites] Cancer. 1992 Dec 15;70(12):2792-6 [1333354.001]
  • [Cites] Histopathology. 1995 Mar;26(3):284-7 [7541017.001]
  • [Cites] Am J Clin Pathol. 1978 Jun;69(6):573-80 [665578.001]
  • [Cites] Arch Pathol Lab Med. 1997 May;121(5):533-5 [9167613.001]
  • [Cites] AMA Arch Pathol. 1954 Aug;58(2):101-11 [13170907.001]
  • [Cites] Am J Clin Pathol. 1946 Mar;16:219-24 [21027097.001]
  • [Cites] Mod Pathol. 2000 Jan;13(1):86-91 [10658914.001]
  • [Cites] Pancreas. 2004 Apr;28(3):219-30 [15084961.001]
  • [Cites] Am J Surg Pathol. 1997 Jan;21(1):70-80 [8990143.001]
  • (PMID = 18176976.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] China
  • [Number-of-references] 14
  • [Other-IDs] NLM/ PMC2673378
  •  go-up   go-down


45. Brustmann H: Immunohistochemical detection of human telomerase reverse transcriptase (hTERT) and c-kit in serous ovarian carcinoma: a clinicopathologic study. Gynecol Oncol; 2005 Sep;98(3):396-402
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical detection of human telomerase reverse transcriptase (hTERT) and c-kit in serous ovarian carcinoma: a clinicopathologic study.
  • OBJECTIVE: This study investigated the expression of human telomerase reverse transcriptase (hTERT) and c-kit in a cohort of serous ovarian carcinomas by immunohistochemistry with regard to outcome and clinicopathologic variables.
  • METHODS: Formalin-fixed, paraffin-embedded archival tissue sections of 10 benign serous cystadenomas, 10 serous neoplasms of low malignant potential (LMP), and 41 serous ovarian carcinomas were immunostained with antibodies to hTERT and c-kit.
  • RESULTS: hTERT expression was negative in serous cystadenomas; 70% of LMP showed strong nuclear immunoreactivity.
  • In serous carcinomas, nuclear and sometimes cytoplasmic immunoreactivity was observed; 14% of cases were scored as negative, 42% as moderate, and 44% as strong. hTERT immunoreactivity increased with grade (P < 0.0192) and mitotic activity (P = 0.0018), but not with FIGO stage (P = 0.2752), and was related with outcome (P = 0.0477).
  • No c-kit immunoreactivity was observed in serous cystadenomas and LMP; 27% of serous carcinomas were negative, 46% showed moderate, and 27% strong immunostaining. c-kit immunoreactivity was positively correlated with grade (P = 0.0008) and FIGO stage (P = 0.0247), but not with mitotic activity (P = 0.1433) and outcome (P = 0.1145); however, c-kit expression was positively related with poor outcome in FIGO II and III stages (P = 0.0105).
  • CONCLUSIONS: hTERT and c-kit are frequently up-regulated in serous ovarian carcinomas; c-kit immunoexpression may serve as a marker of aggressive behavior in high stage tumors.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Cystadenocarcinoma, Serous / enzymology. DNA-Binding Proteins / biosynthesis. Ovarian Neoplasms / enzymology. Proto-Oncogene Proteins c-kit / biosynthesis. Telomerase / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Growth Processes / physiology. Female. Humans. Immunohistochemistry. Middle Aged. Mitosis / physiology. Neoplasm Staging. Prognosis. Survival Rate

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16005054.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


46. Zhang WY, Pan Y, Zhu LR, Zhang JZ, Zhang M, Feng K, Zhou L, Yu L, Zhang XM, Ng SW: [Expression of topoisomerase III alpha in epithelial ovarian tumors of different types and relation between the expression of topoisomerase III alpha and the clinical pathology of tumor]. Zhonghua Yi Xue Za Zhi; 2005 Nov 9;85(42):2988-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of topoisomerase III alpha in epithelial ovarian tumors of different types and relation between the expression of topoisomerase III alpha and the clinical pathology of tumor].
  • OBJECTIVE: To investigate the expression status of topoisomerase IIIa in epithelial ovarian tumor and the relationship between the expression status of topoisomerase IIIa and pathological type and clinical stage of epithelial ovarian carcinoma.
  • METHODS: Immunohistochemistry was carried out in the samples of ovarian tumor obtained during operation from 169 patients, aged 28 approximately 59, 18 cases with serous cystadenoma, 30 cases with serous borderline cystadenoma, 37 serous cystadenocarcinoma, 10 cases with mucous cystadenoma, 20 mucous borderline cystadenoma, 26 mucous cystadenocarcinoma, 19 cases with endometrial carcinoma of ovary, and 9 cases with clear cell carcinoma.
  • RESULTS: The expression rate of topoisomerase IIIa was 17.9% in the benign ovarian tumors, 74.0% in the borderline cystadenoma, and 42.7% in the malignant tumors with statistical significance among them (chi(2) = 24.657, P < 0.001).
  • CONCLUSION: Topoisomerase IIIa is highly expressed in epithelial ovarian carcinoma, and its expression level is correlated with the character and type of tumor tissues.
  • [MeSH-major] DNA Topoisomerases, Type I / biosynthesis. Ovarian Neoplasms / enzymology
  • [MeSH-minor] Adult. Cystadenoma, Mucinous / enzymology. Cystadenoma, Mucinous / pathology. Cystadenoma, Serous / enzymology. Cystadenoma, Serous / pathology. Female. Humans. Immunohistochemistry. Isoenzymes / biosynthesis. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16324386.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Isoenzymes; EC 5.99.1.2 / DNA Topoisomerases, Type I; EC 5.99.1.2 / DNA topoisomerase III
  •  go-up   go-down


47. Bonome T, Lee JY, Park DC, Radonovich M, Pise-Masison C, Brady J, Gardner GJ, Hao K, Wong WH, Barrett JC, Lu KH, Sood AK, Gershenson DM, Mok SC, Birrer MJ: Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res; 2005 Nov 15;65(22):10602-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary.
  • Papillary serous low malignant potential (LMP) tumors are characterized by malignant features and metastatic potential yet display a benign clinical course.
  • The aim of this study is to determine the relationships among LMP tumors and invasive ovarian cancers and identify genes contributing to their phenotypes.
  • Affymetrix U133 Plus 2.0 microarrays (Santa Clara, CA) were used to interrogate 80 microdissected serous LMP tumors and invasive ovarian malignancies along with 10 ovarian surface epithelium (OSE) brushings.
  • Gene expression profiles for each tumor class were used to complete unsupervised hierarchical clustering analyses and identify differentially expressed genes contributing to these associations.
  • The expression profiles of LMP, low-grade, and high-grade papillary serous ovarian carcinomas suggest that LMP tumors are distinct from high-grade cancers; however, they are remarkably similar to low-grade cancers.
  • Prominent expression of p53 pathway members may play an important role in the LMP tumor phenotype.
  • [MeSH-major] Carcinoma, Papillary / genetics. Carcinoma, Papillary / pathology. Cystadenocarcinoma, Serous / genetics. Cystadenocarcinoma, Serous / pathology. Ovarian Neoplasms / genetics. Ovarian Neoplasms / pathology
  • [MeSH-minor] Cluster Analysis. Female. Gene Expression Profiling. Humans. Neoplasm Staging. Oligonucleotide Array Sequence Analysis / methods. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16288054.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50CA165009; United States / NCI NIH HHS / CA / R33CA103595
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


48. Moolthiya W, Yuenyao P: The risk of malignancy index (RMI) in diagnosis of ovarian malignancy. Asian Pac J Cancer Prev; 2009;10(5):865-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The risk of malignancy index (RMI) in diagnosis of ovarian malignancy.
  • OBJECTIVE: To evaluate the ability of two risk of malignancy indices (RMI) based on serum levels of CA 125, ultrasonographic score, and menopausal status to discriminate between benign and borderline or malignant ovarian tumor.
  • CONCLUSION: The RMI is able to discriminate between benign and borderline or malignant ovarian tumor.
  • [MeSH-major] Adenocarcinoma, Clear Cell / diagnosis. Adenocarcinoma, Mucinous / diagnosis. CA-125 Antigen / blood. Cystadenocarcinoma, Serous / diagnosis. Endometrial Neoplasms / diagnosis. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Adult. Biomarkers, Tumor / blood. Female. Humans. Middle Aged. Neoplasm Staging. Postmenopause. Radioimmunoassay. Retrospective Studies. Sensitivity and Specificity. Survival Rate. Treatment Outcome. Ultrasonography

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20162854.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen
  •  go-up   go-down


49. Abd El-Wahed MM: Expression and subcellular localization of maspin in human ovarian epithelial neoplasms: correlation with clinicopathologic features. J Egypt Natl Canc Inst; 2005 Sep;17(3):173-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and subcellular localization of maspin in human ovarian epithelial neoplasms: correlation with clinicopathologic features.
  • BACKGROUND AND PURPOSE: Maspin is an inhibitor of serine proteinases with tumor suppressor activity that is down-regulated in breast and prostate cancer, but overexpressed in pancreatic carcinoma.
  • However, there were very few published data regarding the role of maspin in ovarian carcinoma.
  • The aim of the present study was to evaluate maspin expression in ovarian epithelial neoplasms and correlate its expression with some clinicopathologic parameters.
  • MATERIAL AND METHODS: Seventy eight paraffin embedded ovarian specimens from patients with ovarian epithelial neoplasms comprised the material of this study.
  • They included 18 benign, 14 low malignant potential (LMP) and 46 malignant epithelial ovarian neoplasms, in addition to seven specimens from normal ovarian tissues as a control.
  • RESULTS: Immunohistochemical study of maspin expression using streptavidin biotin immunoperoxidase method revealed that, normal ovarian surface epithelium did not express maspin as well as benign serous and mucinous ovarian epithelial neoplasm.
  • However, all benign Brenner ovarian tumors were maspin positive.
  • On the other hand, 57.14% of LMP tumors showed weak maspin expression and 63% of malignant ovarian epithelial tumors showed maspin expression with 39.1% over expression.
  • CONCLUSION: Maspin was expressed in a substantial proportion of ovarian tumors with poor prognostic parameters.
  • These results may offer new insights regarding the role of maspin in ovarian cancer that may also impact diagnosis and treatment strategies.
  • Moreover, variation in maspin expression between Brenner tumor and other epithelial surface ovarian tumors may indicate that the different histological types probably represent distinct disease entities and involve different molecular pathways.
  • [MeSH-major] Neoplasms, Glandular and Epithelial / metabolism. Ovarian Neoplasms / metabolism. Serine Proteinase Inhibitors / metabolism
  • [MeSH-minor] Adolescent. Adult. Brenner Tumor / metabolism. Brenner Tumor / pathology. CA-125 Antigen / analysis. Carcinoembryonic Antigen / analysis. Epithelium / metabolism. Female. Genes, Tumor Suppressor. Humans. Immunohistochemistry. Middle Aged. Ovary / metabolism. Serpins

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16799655.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Chemical-registry-number] 0 / CA-125 Antigen; 0 / Carcinoembryonic Antigen; 0 / SERPIN-B5; 0 / Serine Proteinase Inhibitors; 0 / Serpins
  •  go-up   go-down


50. Wertel I, Polak G, Bednarek W, Barczyński B, Roliński J, Kotarski J: Dendritic cell subsets in the peritoneal fluid and peripheral blood of women suffering from ovarian cancer. Cytometry B Clin Cytom; 2008 Jul;74(4):251-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dendritic cell subsets in the peritoneal fluid and peripheral blood of women suffering from ovarian cancer.
  • BACKGROUND: Evaluation of immature myeloid and lymphoid dendritic cells (DCs) in the peritoneal fluid (PF) and peripheral blood (PB) mononuclears of women with ovarian carcinoma (n = 47) and benign ovarian tumors (n = 37).
  • RESULTS: The percentage of PF myeloid DC (MDC) in mononuclears was significantly lower in patients with ovarian cancer in comparison to the group of nonmalignant ovarian tumors (0.65% and 6.95%).
  • The percentage of PF lymphoid DCs (LDCs) was higher in patients with ovarian cancer than in the reference group (0.64% and 0.09%).
  • In women suffering from ovarian cancer the percentage of both MDCs and LDCs was higher in the PF than in the PB.
  • In women with ovarian cancer, PF MDCs/LDCs ratio was lower in comparison to patients with serous cystadenoma.
  • [MeSH-major] Ascitic Fluid / cytology. Dendritic Cells / metabolism. Ovarian Neoplasms
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cystadenoma, Serous / immunology. Cystadenoma, Serous / pathology. Disease Progression. Female. Flow Cytometry. Humans. Leukocytes, Mononuclear / immunology. Middle Aged. Neoplasm Metastasis

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18302193.001).
  • [ISSN] 1552-4957
  • [Journal-full-title] Cytometry. Part B, Clinical cytometry
  • [ISO-abbreviation] Cytometry B Clin Cytom
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Jeurnink SM, Vleggaar FP, Siersema PD: Overview of the clinical problem: facts and current issues of mucinous cystic neoplasms of the pancreas. Dig Liver Dis; 2008 Nov;40(11):837-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pancreatic cystic lesions are uncommon and consist of pseudocysts, congenital cysts and cystic neoplasms including mucinous cystic neoplasms, intraductal papillary mucinous neoplasms and serous cystic neoplasms.
  • Mucinous cystic neoplasms are large septated cysts without connection to the ductal system, characterised by the presence of thick-walled ovarian-type stroma and mucin.
  • Serous cystic neoplasms appear as multiple cysts lined with cubic flat epithelium containing glycogen-rich cells with clear cytoplasm.
  • They mainly occur in women in their 50s and are generally benign.
  • As both mucinous cystic neoplasm and intraductal papillary mucinous neoplasms have a high malignant potential, it is important to differentiate between the various pancreatic cystic lesions.
  • Nonetheless, definitive guidelines to differentiate between serous cystic neoplasms, mucinous cystic neoplasms and intraductal papillary mucinous neoplasms are still poorly defined.
  • A number of management issues regarding these neoplasms are still under debate, for example which imaging technique to use, differentiation between malignant or benign lesions and the preferred treatment modality for each pancreatic cystic neoplasm.
  • Further research may lead to a definitive guideline for the diagnosis and treatment of mucinous cystic neoplasms, intraductal papillary mucinous neoplasms and serous cystic neoplasms.
  • [MeSH-major] Carcinoembryonic Antigen / analysis. Cystadenocarcinoma / pathology. Cystadenoma, Mucinous / pathology. Cystadenoma, Serous / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Age Factors. Aged. Biomarkers, Tumor / analysis. Biopsy, Needle. Endosonography. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Pancreaticoduodenectomy / methods. Precancerous Conditions / pathology. Prognosis. Risk Assessment. Sex Factors. Survival Analysis. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18499541.001).
  • [ISSN] 1878-3562
  • [Journal-full-title] Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • [ISO-abbreviation] Dig Liver Dis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen
  • [Number-of-references] 46
  •  go-up   go-down


52. Kawamura K, Komohara Y, Takaishi K, Katabuchi H, Takeya M: Detection of M2 macrophages and colony-stimulating factor 1 expression in serous and mucinous ovarian epithelial tumors. Pathol Int; 2009 May;59(5):300-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of M2 macrophages and colony-stimulating factor 1 expression in serous and mucinous ovarian epithelial tumors.
  • Tumor-associated macrophages (TAM) are known to possess the immunosuppressive M2 macrophage phenotype.
  • They contribute to tumor growth, invasion, and metastasis by producing various mediators.
  • Macrophages, especially M2 polarized macrophages, preferentially express CD163 and CD204, but few studies have investigated macrophage phenotypes in human ovarian tumors.
  • The purpose of the present study was therefore to present results on macrophage differentiation in human ovarian serous and mucinous epithelial tumors.
  • The method focused on immunostaining of paraffin-embedded tumor samples.
  • Almost all macrophages infiltrating tumor tissues expressed CD163 and CD204, indicating the phenotypic shift toward M2 macrophage.
  • The numbers of CD68-positive macrophages as well as of CD163- and CD204-positive macrophages in borderline and malignant tumors were significantly higher than in benign tumors.
  • CSF-1 expression in malignant tumor cells was significantly higher than that in benign tumor cells and correlated with histological malignancy.
  • These results suggest that CSF-1 derived from tumor tissues induces macrophages to shift toward the M2 phenotype, which is considered to promote tumor growth.
  • [MeSH-major] Cystadenocarcinoma, Mucinous / immunology. Cystadenocarcinoma, Serous / immunology. Macrophage Colony-Stimulating Factor / biosynthesis. Macrophages / immunology. Ovarian Neoplasms / immunology
  • [MeSH-minor] Adult. Aged. Antigens, CD / immunology. Antigens, CD / metabolism. Antigens, Differentiation, Myelomonocytic / immunology. Antigens, Differentiation, Myelomonocytic / metabolism. Cell Differentiation / immunology. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Invasiveness / immunology. Phenotype. Receptors, Cell Surface / immunology. Receptors, Cell Surface / metabolism. Scavenger Receptors, Class A / immunology. Scavenger Receptors, Class A / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19432671.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD163 antigen; 0 / MSR1 protein, human; 0 / Receptors, Cell Surface; 0 / Scavenger Receptors, Class A; 81627-83-0 / Macrophage Colony-Stimulating Factor
  •  go-up   go-down


53. Rabban JT, Bell DA: Current issues in the pathology of ovarian cancer. J Reprod Med; 2005 Jun;50(6):467-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current issues in the pathology of ovarian cancer.
  • The majority of primary ovarian tumors are histologically classified as surface epithelial-stromal neoplasms.
  • The malignant potential of such neoplasms may be categorized, on the basis of the extent of epithelial proliferation and stromal invasion, as benign, borderline or malignant.
  • Recent efforts to further classify the malignant potential of such neoplasms have produced a new system for the histologic grading of ovarian carcinoma as well as new potential histologic predictors of behavior, including micropapillary morphology and stromal microinvasion in serous tumors.
  • Among mucinous ovarian neoplasms, new criteria have been proposed to distinguish primary ovarian from metastatic carcinomas; the distinction may be difficult but has great clinical significance.
  • The origin of ovarian mucinous tumors associated with pseudomyxoma peritonei has been reassessed.
  • Finally, recent pathologic findings from prophylactic salpingo-oophorectomy specimens in patients with hereditary risks for ovarian carcinoma have highlighted the additional risk for fallopian tube carcinoma and primary peritoneal carcinoma.
  • These current issues in the pathology of ovarian carcinoma and their clinical significance form the basis of this review.
  • [MeSH-major] Cystadenocarcinoma / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Cystadenocarcinoma, Mucinous / classification. Cystadenocarcinoma, Mucinous / pathology. Cystadenocarcinoma, Serous / classification. Cystadenocarcinoma, Serous / pathology. Female. Humans. Neoplasm Invasiveness. Neoplasm Staging. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16050571.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 57
  •  go-up   go-down


54. Taylor DD, Atay S, Metzinger DS, Gercel-Taylor C: Characterization of humoral responses of ovarian cancer patients: antibody subclasses and antigenic components. Gynecol Oncol; 2010 Feb;116(2):213-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of humoral responses of ovarian cancer patients: antibody subclasses and antigenic components.
  • OBJECTIVES: Current antigen-based diagnostic assays for ovarian cancers rely on intravasation of specific aberrantly expressed proteins and their achieving detectable steady-state concentrations, resulting in their inability to truly detect small early lesions.
  • In contrast, tumor antigen immunorecognition is observed following initial transformation events.
  • Our objective was to characterize humoral antitumor responses in terms of IgG subclasses generated and tumor antigens recognized.
  • METHODS: For patients with benign and malignant ovarian disease, tumor-reactive IgG subclasses were characterized by Western immunoblotting.
  • RESULTS: Sera from ovarian cancer patients exhibited significantly greater immunoreactivities than either controls or women with benign disease.
  • Two-dimensional electrophoresis revealed 32 stage-linked antigenic differences with 11 in early-stage and 21 in late-stage ovarian cancer.
  • CONCLUSIONS: Owing to the timing and stability of humoral responses, quantitation of IgG subclasses recognizing specific tumor antigens provides superior biomarkers for early cancer identification and allows for differentiation of benign versus malignant ovarian masses and early- and late-stage cancers.
  • [MeSH-major] Antibodies, Neoplasm / classification. Antigens, Neoplasm / classification. Ovarian Neoplasms / immunology
  • [MeSH-minor] Blotting, Western. Carcinoma, Papillary / immunology. Case-Control Studies. Cystadenocarcinoma, Serous / immunology. Electrophoresis, Gel, Two-Dimensional. Epitopes. Female. Humans. Immunity, Humoral. Immunoglobulin G / classification. Immunoglobulin G / immunology. Middle Aged. Neoplasm Staging. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Inc. All rights reserved.
  • (PMID = 19945743.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Neoplasm; 0 / Antigens, Neoplasm; 0 / Epitopes; 0 / Immunoglobulin G
  •  go-up   go-down


55. McCluggage WG: My approach to and thoughts on the typing of ovarian carcinomas. J Clin Pathol; 2008 Feb;61(2):152-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] My approach to and thoughts on the typing of ovarian carcinomas.
  • Ovarian carcinomas of epithelial type comprise a heterogeneous group of neoplasms, each with a different underlying pathogenesis and natural behaviour.
  • Accurate classification of ovarian carcinomas is important since each type may be associated with a different behaviour, natural history and outcome.
  • Previous studies have shown significant interobserver variation in the typing of ovarian carcinomas.
  • There are several areas where there are particular difficulties; these include the distinction between high-grade serous and endometrioid adenocarcinomas and the distinction between a true clear cell carcinoma and clear cell areas within other adenocarcinomas.
  • This review details my approach to the typing of ovarian carcinomas.
  • Morphological assessment, which remains the mainstay in diagnosis, can be supplemented by immunohistochemistry which, for example, is useful in the distinction between serous carcinomas (WT1 positive) and other carcinomas (generally WT1 negative).
  • In recent years, there has been emerging new information regarding the major underlying molecular events in several types of ovarian carcinoma.
  • This has resulted in the acceptance that there are two distinct types of ovarian serous carcinoma.
  • These are termed low-grade and high-grade serous carcinoma, but represent two distinct tumour types rather than low-grade and high-grade variants of the same neoplasm.
  • The integration of clinical, morphological and molecular data has resulted in a more precise classification of ovarian carcinomas and has resulted in the proposal for a broad dualistic pathway of ovarian epithelial carcinogenesis with, in general, low-grade type 1 tumours evolving from benign and borderline neoplasms through a well-defined adenoma-carcinoma sequence, and high-grade type 2 neoplasms arising from an, as yet, undefined precursor lesion.
  • [MeSH-major] Ovarian Neoplasms / classification
  • [MeSH-minor] Adenocarcinoma, Clear Cell / classification. Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Mucinous / classification. Adenocarcinoma, Mucinous / pathology. Carcinoma, Endometrioid / classification. Carcinoma, Endometrioid / pathology. Carcinoma, Transitional Cell / classification. Carcinoma, Transitional Cell / pathology. Cystadenocarcinoma, Serous / classification. Cystadenocarcinoma, Serous / pathology. Female. Humans

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17704261.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 89
  •  go-up   go-down


56. Do TV, Kubba LA, Du H, Sturgis CD, Woodruff TK: Transforming growth factor-beta1, transforming growth factor-beta2, and transforming growth factor-beta3 enhance ovarian cancer metastatic potential by inducing a Smad3-dependent epithelial-to-mesenchymal transition. Mol Cancer Res; 2008 May;6(5):695-705
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transforming growth factor-beta1, transforming growth factor-beta2, and transforming growth factor-beta3 enhance ovarian cancer metastatic potential by inducing a Smad3-dependent epithelial-to-mesenchymal transition.
  • Transforming growth factor-beta (TGF-beta) is thought to play a role in the pathobiological progression of ovarian cancer because this peptide hormone is overexpressed in cancer tissue, plasma, and peritoneal fluid.
  • In the current study, we investigated the role of the TGF-beta/Smad3 pathway in ovarian cancer metastasis by regulation of an epithelial-to-mesenchymal transition.
  • Analysis of Smad3 nuclear expression in microarrays of serous benign tumors, borderline tumors, and cystadenocarcinoma revealed that Smad3 expression could be used to distinguish benign and borderline tumors from carcinoma (P = 0.006).
  • Collectively, these results implicate an important role for the TGF-beta/Smad3 pathway in mediating ovarian oncogenesis by enhancing metastatic potential.


57. Daponte A, Kostopoulou E, Kollia P, Papamichali R, Vanakara P, Hadjichristodoulou C, Nakou M, Samara S, Koukoulis G, Messinis IE: L1 (CAM) (CD171) in ovarian serous neoplasms. Eur J Gynaecol Oncol; 2008;29(1):26-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] L1 (CAM) (CD171) in ovarian serous neoplasms.
  • PURPOSE OF THE INVESTIGATION: The evaluation of L1 (CAM) as a tumor progression marker and as a prognostic factor in serous ovarian tumors.
  • METHODS: L1 (CAM) protein expression was assessed by immunohistochemistry and Western blot in serous ovarian tumors [cystadenomas (n = 20), borderline tumors (n = 14) and carcinomas (n = 47)], and was correlated with stage,grade, progression-free survival time (PFS) and overall survival.
  • It increased from benign tumors to early carcinomas and to advanced stage carcinomas progressively and significantly.
  • CONCLUSION: L1 (CAM) expression represents a novel diagnostic marker in serous ovarian neoplasms that shows characteristics of tumor progression.
  • [MeSH-major] Biomarkers, Tumor. Disease-Free Survival. Neoplasms, Cystic, Mucinous, and Serous / metabolism. Neural Cell Adhesion Molecule L1 / metabolism. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Female. Follow-Up Studies. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18386459.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neural Cell Adhesion Molecule L1
  •  go-up   go-down


58. Hayashi M, Shibazaki M, Sohma R, Inaba N: Effects of histologic type on levels of macrophage colony-stimulating factor in liquid contents of benign ovarian tumors. Am J Med Sci; 2006 Oct;332(4):181-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of histologic type on levels of macrophage colony-stimulating factor in liquid contents of benign ovarian tumors.
  • BACKGROUND: Normal ovarian tissue is rich in cytokines.
  • Cytokines are important in the physiology of ovarian function.
  • Most of the same cytokines that are found in normal ovarian tissue are also found in association with benign and malignant tumors in contrast to their functions in normal tissues.
  • Thus, we measured macrophage colony-stimulating factor (M-CSF) levels in the liquid contents of benign ovarian tumors--serous cystadenoma, mucinous cystadenoma, and mature cystic teratoma--and investigated whether M-CSF levels were associated with the histologic type of the ovarian tumors.
  • METHODS: We enrolled 65 patients, 52 with benign ovarian tumor and 13 in the early postmenopausal period with symptoms of a menopausal disorder.
  • Among the 52 patients with benign ovarian tumor, 16 had serous cystadenoma, 21 had mucinous cystadenoma, and 15 had mature cystic teratoma.
  • Immediately after surgery, the liquid content was drawn from the ovarian tumor, then centrifuged, and the separated supernatant was stored at -30 degrees C.
  • RESULTS: The level of M-CSF was 12,513 U/mL (median) (range, 0-169,000 U/mL) in serous cystadenoma, 915 U/mL (0-82,500 U/mL) in mucinous cystadenoma, and 149 U/mL (0-6,230 U/mL) in mature cystic teratoma.
  • The M-CSF levels increased significantly from mature cystic teratoma to mucinous cystadenoma to serous cystadenoma.
  • The serum M-CSF levels were 308 to 499 U/mL in patients with benign ovarian tumor.
  • CONCLUSIONS: Elevation of levels of M-CSF varies according to histologic type in benign ovarian tumors.
  • This implies that the antitumor activities of M-CSF for serous cystadenoma, mucinous cystadenoma, and mature cystic teratoma differ by histologic type.
  • [MeSH-major] Extracellular Fluid / metabolism. Macrophage Colony-Stimulating Factor / metabolism. Neoplasm Proteins / metabolism. Neoplasms / metabolism. Neoplasms / pathology. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17031243.001).
  • [ISSN] 0002-9629
  • [Journal-full-title] The American journal of the medical sciences
  • [ISO-abbreviation] Am. J. Med. Sci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 81627-83-0 / Macrophage Colony-Stimulating Factor
  •  go-up   go-down


59. Worley MJ Jr, Landen CN, Slomovitz BM, Malpica A, Palla SL, Ramirez PT: Expression of the retinoblastoma-related gene Rb2/p130 in the pathogenesis of serous carcinoma of the ovary. Appl Immunohistochem Mol Morphol; 2010 Dec;18(6):509-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of the retinoblastoma-related gene Rb2/p130 in the pathogenesis of serous carcinoma of the ovary.
  • OBJECTIVE: The purpose of this study was to evaluate the immunohistochemical Rb2/p130 expression in a series of benign, borderline, and malignant ovarian tumors.
  • Frequencies and percents were calculated for variables by each of the 5 disease stage groups in increasing severity and again for the disease stage groups collapsed into benign (serous cystadenoma or endosalpingosis), low-grade [serous borderline tumors (SBT) or low-grade serous carcinoma (LGSC)] and high-grade serous carcinoma.
  • RESULTS: There was no loss of expression in benign serous cystadenomas (0/18).
  • CONCLUSIONS: Loss of Rb2/p130 expression is a rare event in benign cystadenoma.

  • Genetic Alliance. consumer health - Retinoblastoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20661130.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Lectins; 0 / Membrane Glycoproteins; 0 / Phytohemagglutinins; 0 / Retinoblastoma-Like Protein p130; 0 / erythroagglutinating phytohemagglutinin; EC 2.4.1.- / N-Acetylglucosaminyltransferases; V956696549 / Acetylglucosamine
  •  go-up   go-down


60. Huang Y, Hua K, Zhou X, Jin H, Chen X, Lu X, Yu Y, Zha X, Feng Y: Activation of the PI3K/AKT pathway mediates FSH-stimulated VEGF expression in ovarian serous cystadenocarcinoma. Cell Res; 2008 Jul;18(7):780-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activation of the PI3K/AKT pathway mediates FSH-stimulated VEGF expression in ovarian serous cystadenocarcinoma.
  • There is evidence to suggest that follicle-stimulating hormone (FSH) can facilitate the neovascularization of ovarian cancers by increasing vascular endothelial growth factor (VEGF) expression in cancer cells, although the underlying molecular mechanism of this process is not well known.
  • Therefore, we investigated the effect of FSH on VEGF expression in the ovarian cancer cell lines SKOV-3 and ES-2.
  • We further showed that ovarian serous cystadenocarcinoma samples had much higher incidence of positive AKT and phosphorylated AKT (pAKT) protein staining than did benign ovarian cystadenoma samples (p < 0.01).
  • The 5-year survival rate was only about 15% in patients with ovarian serous cystadenocarcinoma who had AKT and pAKT expression, whereas it was about 80% in those who did not have AKT or pAKT expression.
  • Understanding the role of the PI3K/AKT pathway in FSH-stimulated expression of survivin and VEGF will be beneficial for evaluating the prognosis for patients with ovarian serous cystadenocarcinoma and for pursuing effective treatment against this disease.
  • [MeSH-major] Cystadenocarcinoma, Serous / metabolism. Microtubule-Associated Proteins / metabolism. Neoplasm Proteins / metabolism. Ovarian Neoplasms / metabolism. Proto-Oncogene Proteins c-akt / metabolism. Signal Transduction. Vascular Endothelial Growth Factor A / genetics
  • [MeSH-minor] Adult. Cell Line, Tumor. Female. Follicle Stimulating Hormone / metabolism. Humans. Hypoxia-Inducible Factor 1, alpha Subunit / metabolism. Inhibitor of Apoptosis Proteins. Middle Aged. Phosphatidylinositol 3-Kinases / metabolism. Phosphorylation. RNA Interference

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. MENOTROPINS .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18574502.001).
  • [ISSN] 1748-7838
  • [Journal-full-title] Cell research
  • [ISO-abbreviation] Cell Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / Vascular Endothelial Growth Factor A; 9002-68-0 / Follicle Stimulating Hormone; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  •  go-up   go-down


61. Zhang LL, Shao SL, Wu Y: [Expressions of osteopontin and B7-H4 in epithelial ovarian neoplasm and their significance]. Chin J Cancer; 2010 Jan;29(1):25-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expressions of osteopontin and B7-H4 in epithelial ovarian neoplasm and their significance].
  • BACKGROUND AND OBJECTIVE: Epithelial ovarian cancer involves a number of factors.
  • Recent studies have shown that osteopontin (OPN) is related to the occurrence and development of a variety of tumors, but few studies are on ovarian cancer.
  • B7-H4 is a newly identified tumor marker in ovarian cancer.
  • This study explored the expression of OPN and B7-H4 and their clinical significance in epithelial ovarian tumors.
  • METHODS: The expression of OPN and B7-H4 in 15 cases of normal ovarian tissue, 20 of benign ovarian tumor tissue, 20 of borderline ovarian tumor tissue, and 40 of ovarian cancer tissue were detected by immunohistochemistry, and the relationship of OPN and B7-H4 expression to clinical and pathologic features of ovarian cancer was analyzed.
  • RESULTS: The expression of OPN and B7-H4 were significantly higher in ovarian cancer than in borderline and benign tumors (P<0.05).
  • The positive rates of OPN and B7-H4 were significantly higher in poorly differentiated ovarian cancer than in medium and highly differentiated ovarian cancer (P<0.05), and the levels of expression were significantly lower in tissue at stages I and III of ovarian cancer than in stages III and IV (P<0.05).
  • The positive rate of B7-H4 were significantly higher in ovarian serous carcinoma than in the mucinous carcinoma (P<0.05), but did not relate to age and lymph node metastasis.
  • CONCLUSION: The expression of OPN and B7-H4 increased in epithelial ovarian cancer, which could be referenced in the diagnosis of ovarian malignant tumors.
  • [MeSH-major] Cystadenocarcinoma, Serous / metabolism. Neoplasms, Glandular and Epithelial / metabolism. Osteopontin / metabolism. Ovarian Neoplasms / metabolism. V-Set Domain-Containing T-Cell Activation Inhibitor 1 / metabolism
  • [MeSH-minor] Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Adolescent. Adult. Aged. Female. Gene Expression Regulation, Neoplastic. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Ovary / metabolism. Young Adult

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20038306.001).
  • [ISSN] 1000-467X
  • [Journal-full-title] Chinese journal of cancer
  • [ISO-abbreviation] Chin J Cancer
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / SPP1 protein, human; 0 / V-Set Domain-Containing T-Cell Activation Inhibitor 1; 106441-73-0 / Osteopontin; Ovarian epithelial cancer
  •  go-up   go-down


62. Zaman S, Majid S, Hussain M, Chughtai O, Mahboob J, Chughtai S: A retrospective study of ovarian tumours and tumour-like lesions. J Ayub Med Coll Abbottabad; 2010 Jan-Mar;22(1):104-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A retrospective study of ovarian tumours and tumour-like lesions.
  • Objective of the study was to determine the nature of various ovarian lesions and to ascertain the frequency and distribution of the various non-neoplastic and neoplastic lesions.
  • METHODS: The study was a retrospective review of all cases of ovarian cancer, benign ovarian neoplasm and functional ovarian cysts received during Jan-Dec 2008 at Chughtai's Lahore Laboratory.
  • Among the neoplastic tumours 78.70% were benign and 21.29% were malignant.
  • Benign serous cysts were the commonest benign tumour followed by mature cystic teratoma and mucinous cyst.
  • Serous cystadenocarcinoma was the commonest malignant tumour followed closely by endometrioid carcinoma and granulosa cell tumour.
  • CONCLUSION: The morphologic diversity of ovarian masses poses many challenges.
  • [MeSH-major] Ovarian Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Middle Aged. Ovarian Cysts / epidemiology. Ovarian Cysts / pathology. Pakistan / epidemiology. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21409917.001).
  • [ISSN] 1025-9589
  • [Journal-full-title] Journal of Ayub Medical College, Abbottabad : JAMC
  • [ISO-abbreviation] J Ayub Med Coll Abbottabad
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


63. Cai Y, Shao SL, Wang QH, Yan LJ, Wang XY, Wang LX: [Expression and significance of GLUT-1 and DNA-PKcs in serous ovarian tumors]. Ai Zheng; 2007 Nov;26(11):1188-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression and significance of GLUT-1 and DNA-PKcs in serous ovarian tumors].
  • This study was to evaluate the expression and biologic significance of GLUT-1 and DNA-PKcs in serous ovarian tumors.
  • METHODS: The expression of GLUT-1 and DNA-PKcs in 20 specimens of normal ovarian tissues, 20 specimens of serous cystadenoma, 20 specimens of borderline serous cystadenoma, and 40 specimens of serous cystadenocarcinoma were detected by SP immunohistochemistry.
  • The correlation of GLUT-1 and DNA-Pkcs expression to clinicopathologic characteristics of serous ovarian tumors was analyzed by Chi-square test.
  • RESULTS: The positive rate of GLUT-1 was significantly higher in malignant and borderline serous ovarian carcinomas than in benign tumors and normal ovarian tissues (100% and 55% vs. 0% and 0%, P<0.01).
  • The differences in the positive rate of DNA-PKcs were significant among normal ovarian tissues, benign, borderline, and malignant serous ovarian tumors (100%, 95%, 90%, and 60%, P<0.01).
  • GLUT-1 expression in borderline and malignant serous ovarian tumors was related to intraperitoneal implants, ascites, lymph node metastasis, and FIGO stage, but DNA-PKcs was only related to FIGO stage and lymph node metastasis (P<0.05).
  • CONCLUSION: The expression of GLUT-1 and the loss of DNA-PKcs may be closely related to the malignant transformation of serous ovarian tumors.
  • [MeSH-major] Cystadenocarcinoma, Serous / metabolism. Cystadenoma, Serous / metabolism. DNA-Activated Protein Kinase / metabolism. Glucose Transporter Type 1 / metabolism. Nuclear Proteins / metabolism. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Chi-Square Distribution. Female. Humans. Immunohistochemistry. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Ovary / metabolism. Ovary / pathology. Young Adult

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17991316.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Glucose Transporter Type 1; 0 / Nuclear Proteins; EC 2.7.11.1 / DNA-Activated Protein Kinase; EC 2.7.11.1 / PRKDC protein, human
  •  go-up   go-down


64. Pylväs M, Puistola U, Kauppila S, Soini Y, Karihtala P: Oxidative stress-induced antioxidant enzyme expression is an early phenomenon in ovarian carcinogenesis. Eur J Cancer; 2010 Jun;46(9):1661-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oxidative stress-induced antioxidant enzyme expression is an early phenomenon in ovarian carcinogenesis.
  • However, there is only some information about their role in ovarian carcinogenesis or in ovarian carcinomas in vivo.
  • We studied immunohistochemical nuclear and/or cytoplasmic expression of oxidative stress markers 8-hydroxydeoxyguanosine (8-OHdG) and nitrotyrosine, as well as major antioxidative enzymes peroxiredoxins (PRDX) I-VI and thioredoxin (TXN) in ovarian tumours.
  • The material consisted of 20 benign (10 serous, 10 mucinous) and 51 borderline (33 serous, 18 mucinous) epithelial ovarian tumours.
  • The markers of oxidative stress, 8-OHdG and nitrotyrosine, were seen already in benign tumours (in 20% and 45% of the tumours, respectively) and their expression patterns were similar in benign and borderline tumours.
  • The levels of PRDX II, III, IV, V and VI were significantly higher in borderline than in benign tumours (p<0.02 for all).
  • Specifically for PRDX II (for both nuclear and cytoplasmic expression, p<0.00005) and PRDX VI (for cytoplasmic expression, p=0.0003 and for nuclear expression, p=0.0005) the difference between benign and borderline tumours was remarkable.
  • In general, serous benign and borderline tumours expressed higher antioxidant enzyme levels than mucinous ones.
  • Nuclear TXN was expressed more strongly in benign than in borderline tumours (p=0.003).
  • Oxidative stress occurs already in benign ovarian tumours and the levels are comparable to borderline tumours.
  • However, some of the antioxidant enzymes, especially PRDX II and VI, are more profoundly induced in borderline ovarian tumours, reflecting their possible role as cancer preventers.
  • This difference could also offer a potential tool for differential diagnosis between benign and borderline epithelial ovarian tumours.
  • [MeSH-major] Antioxidants / metabolism. Neoplasm Proteins / metabolism. Ovarian Neoplasms / enzymology. Oxidative Stress / physiology
  • [MeSH-minor] Adenocarcinoma, Mucinous / enzymology. Biomarkers, Tumor / metabolism. Deoxyguanosine / analogs & derivatives. Deoxyguanosine / metabolism. Female. Humans. Immunohistochemistry. Peroxiredoxins / metabolism. Reactive Oxygen Species / metabolism. Thioredoxins / metabolism. Tyrosine / analogs & derivatives. Tyrosine / metabolism

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. L-TYROSINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20206498.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / Reactive Oxygen Species; 3604-79-3 / 3-nitrotyrosine; 42HK56048U / Tyrosine; 52500-60-4 / Thioredoxins; 88847-89-6 / 8-oxo-7-hydrodeoxyguanosine; EC 1.11.1.15 / Peroxiredoxins; G9481N71RO / Deoxyguanosine
  •  go-up   go-down


65. Kumar SR, Masood R, Spannuth WA, Singh J, Scehnet J, Kleiber G, Jennings N, Deavers M, Krasnoperov V, Dubeau L, Weaver FA, Sood AK, Gill PS: The receptor tyrosine kinase EphB4 is overexpressed in ovarian cancer, provides survival signals and predicts poor outcome. Br J Cancer; 2007 Apr 10;96(7):1083-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The receptor tyrosine kinase EphB4 is overexpressed in ovarian cancer, provides survival signals and predicts poor outcome.
  • We wanted to determine the biological role of EphB4 in ovarian cancer.
  • We studied the expression of EphB4 in seven normal ovarian specimens and 85 invasive ovarian carcinomas by immunohistochemistry.
  • EphB4 expression was largely absent in normal ovarian surface epithelium, but was expressed in 86% of ovarian cancers.
  • We also studied the biological significance of EphB4 expression in ovarian tumour cells lines in vitro and in vivo.
  • All five malignant ovarian tumour cell lines tested expressed higher levels of EphB4 compared with the two benign cell lines.
  • Treatment of malignant, but not benign, ovarian tumour cell lines with progesterone, but not oestrogen, led to a 90% reduction in EphB4 levels that was associated with 50% reduction in cell survival.
  • Furthermore, EphB4 antisense significantly inhibited growth of ovarian tumour xenografts and tumour microvasculature in vivo.
  • Inhibition of EphB4 may hence have prognostic and therapeutic utility in ovarian carcinoma.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PROGESTERONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dev Biol. 2001 Feb 15;230(2):139-50 [11161568.001]
  • [Cites] Br J Cancer. 2007 Jan 15;96(1):151-6 [17179984.001]
  • [Cites] Ann Oncol. 2003 Feb;14(2):220-6 [12562648.001]
  • [Cites] Int J Cancer. 2003 May 1;104(5):603-10 [12594815.001]
  • [Cites] Pathol Oncol Res. 2004;10(1):26-33 [15029258.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 13;101(15):5583-8 [15067119.001]
  • [Cites] Cell. 1998 May 29;93(5):741-53 [9630219.001]
  • [Cites] Virchows Arch. 1998 Aug;433(2):103-11 [9737787.001]
  • [Cites] Mol Cell. 1999 Sep;4(3):403-14 [10518221.001]
  • [Cites] Cancer Res. 2005 Jun 1;65(11):4623-32 [15930280.001]
  • [Cites] BMC Cancer. 2005;5:119 [16171530.001]
  • [Cites] Oncogene. 2006 Feb 2;25(5):769-80 [16205642.001]
  • [Cites] Panminerva Med. 2006 Mar;48(1):13-7 [16633327.001]
  • [Cites] Gynecol Oncol. 2006 Jul;102(1):15-21 [16499955.001]
  • [Cites] Am J Pathol. 2006 Jul;169(1):279-93 [16816380.001]
  • [Cites] Int J Cancer. 2006 Sep 15;119(6):1236-48 [16615113.001]
  • [Cites] J Cell Sci. 2002 Jan 1;115(Pt 1):25-37 [11801721.001]
  • (PMID = 17353927.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA083639; United States / NCI NIH HHS / CA / R01 CA079218; United States / NCI NIH HHS / CA / R01CA79218
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Progestins; 0 / RNA, Small Interfering; 4G7DS2Q64Y / Progesterone; EC 2.7.10.1 / Receptor, EphB4; EC 3.4.22.- / Caspases
  • [Other-IDs] NLM/ PMC2360128
  •  go-up   go-down


66. Leiserowitz GS: Managing ovarian masses during pregnancy. Obstet Gynecol Surv; 2006 Jul;61(7):463-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Managing ovarian masses during pregnancy.
  • The etiologies of ovarian masses are reflective of the patient's age; and, therefore, benign entities such as functional ovarian cysts, benign cystic teratomas, and serous cystadenomas predominate.
  • In the unusual cases when cancer is present, they are typically germ cell and borderline ovarian tumors, and are commonly low stage and low grade.
  • Ultrasound is the primary modality used to detect ovarian masses and to assess the risk of malignancy.
  • Morphologic criteria more accurately identify benign cysts compared with malignant tumors.
  • Tumor markers are used primarily to monitor disease status after treatment rather than establish the ovarian tumor diagnosis as a result of lack of specificity, because several markers can be elevated inherent to the pregnancy itself (eg, CA-125, beta-hCG).
  • Expectant management is recommended for most pregnant patients with asymptomatic, nonsuspicious cystic ovarian masses.
  • The extent of surgery depends on the intraoperative diagnosis of a benign versus a malignant tumor.
  • Conservative surgery is appropriate for benign masses and borderline ovarian tumors.
  • More aggressive surgery is indicated for ovarian malignancies, including surgical staging.
  • Although rarely necessary, chemotherapy has been used during pregnancy with minimal fetal toxicity in patients with advanced-stage ovarian cancer in which the risk of maternal mortality outweighs the fetal consequences.
  • [MeSH-major] Ovarian Cysts / complications. Ovarian Neoplasms / complications. Pregnancy Complications, Neoplastic
  • [MeSH-minor] Female. Humans. Laparoscopy / methods. Neoplasm Staging. Pregnancy. Pregnancy Outcome. Prognosis. Risk Factors. Sensitivity and Specificity


67. Lee CH, Xue H, Sutcliffe M, Gout PW, Huntsman DG, Miller DM, Gilks CB, Wang YZ: Establishment of subrenal capsule xenografts of primary human ovarian tumors in SCID mice: potential models. Gynecol Oncol; 2005 Jan;96(1):48-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Establishment of subrenal capsule xenografts of primary human ovarian tumors in SCID mice: potential models.
  • OBJECTIVE: To evaluate subrenal capsule xenografting of primary ovarian tumor tissues in mice for development of new ovarian cancer models.
  • METHODS: Pieces (1 x 3 x 3 mm) of ovarian tumor specimens from patients were meticulously grafted under renal capsules of female NOD/SCID mice within 2 h of surgical removal.
  • Tumor types included papillary serous adenocarcinomas, borderline and benign mucinous cystadenomas, granulosa cell tumors, a serous borderline tumor and a grade 3 mixed surface epithelial tumor of transitional and undifferentiated types.
  • RESULTS: Tumor tissue engraftment rate was > 95%.
  • CONCLUSIONS: Subrenal capsule xenografts of primary human ovarian tumors in SCID mice can retain major histopathological and immunohistochemical characteristics of the original tissues.
  • The achievable, consistently high engraftment rate allows use of such xenografts as tools for studying a wide range of ovarian tumors, including granulosa cell tumors and benign, borderline, and malignant surface epithelial neoplasms.
  • Potential applications include preclinical testing of patients' tumor responses to various chemotherapeutic regimens, evaluation of novel therapeutic agents, analysis of tumor progression at cellular and molecular levels, and identification of new therapeutic targets.
  • [MeSH-major] Disease Models, Animal. Ovarian Neoplasms / pathology. Subrenal Capsule Assay
  • [MeSH-minor] Animals. Female. Humans. Immunophenotyping. Mice. Mice, Inbred NOD. Mice, SCID. Neoplasm Transplantation. Transplantation, Heterologous

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15589579.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


68. Castellvi J, Garcia A, Rojo F, Ruiz-Marcellan C, Gil A, Baselga J, Ramon y Cajal S: Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer. Cancer; 2006 Oct 15;107(8):1801-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer.
  • BACKGROUND: Growth factor receptors and cell signaling factors play a crucial role in human carcinomas and have been studied in ovarian tumors with varying results.
  • The objectives of this study were to analyze the real role that these pathways play in ovarian cancer, to correlate them with clinicopathologic characteristics, and to identify the factors that transmit individual proliferation signals and are associated with pathologic grade and prognosis, regardless specific oncogenic alterations upstream.
  • METHODS: One hundred twenty-nine ovarian epithelial tumors were studied, including 20 serous cystadenomas, 7 mucinous cystadenomas, 11 serous borderline tumors, 16 mucinous borderline tumors, 29 serous carcinomas, 16 endometrioid carcinomas, 15 clear cell carcinomas, and 15 mucinous carcinomas.
  • RESULTS: Among 129 ovarian neoplasms, 17.8% were positive for c-erb-B2, 9.3% were positive for EGFR, 47.3% were positive for phosphorylated AKT (p-AKT), 58.9% were positive for p-ERK, 41.1% were positive for p-4EBP1, 26.4% were positive for p70S6K, and 15.5% were positive for p-S6.
  • Although EGFR, p-AKT, and p-ERK expression did not differ between benign, borderline, or malignant tumors, c-erb-B2, p-4EBP1, p-p70S6K, and p-S6 were expressed significantly more often in malignant tumors.
  • CONCLUSIONS: In patients with ovarian carcinoma, significant expression of p-4EBP1 was associated with high-grade tumors and a poor prognosis, regardless other oncogenic alterations upstream.
  • This finding supports the study of this factor as a hallmark or pivotal factor in cell signaling in ovarian carcinoma that may crucial in the transmission of the proliferation cell signal and may reflect the real oncogenic role of this pathway in ovarian tumors.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / physiology. Ovarian Neoplasms / metabolism. Phosphoproteins / physiology. Signal Transduction
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Middle Aged. Neoplasm Recurrence, Local. Oncogene Protein v-akt / metabolism. Phosphorylation. Prognosis. Receptor, Epidermal Growth Factor / metabolism. Receptor, ErbB-2 / metabolism. Survival Analysis


69. Mayr D, Hirschmann A, Löhrs U, Diebold J: KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants. Gynecol Oncol; 2006 Dec;103(3):883-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.
  • OBJECTIVE: Mutations of BRAF, a downstream mediator of K-RAS, have been described in serous borderline tumors of the ovary.
  • Data concerning other types of ovarian tumors are scarce.
  • Therefore, we assessed KRAS and BRAF mutation in a series of more than 100 different ovarian tumors.
  • METHODS: Paraffin-embedded material, including invasive carcinomas, borderline tumors, benign lesions and implants, was used.
  • RESULTS: 92 cases (92%), including all serous carcinomas (100%), did not show a mutation of BRAF.
  • Eight cases (8.0%), including five serous borderline tumors (31.25%), contained a mutation.
  • In all serous borderline tumors, codon 600 was affected.
  • The 11 positive borderline tumors (10.7%) were of serous (22.2%) and of mucinous type (46.6%).
  • There was a KRAS mutation in a serous and a mucinous invasive carcinoma each.
  • CONCLUSION: Mutation of either K-RAS or BRAF is frequent in borderline tumors but is not found in invasive serous carcinomas and is very rare in other invasive subtypes.
  • [MeSH-major] Genes, ras / genetics. Ovarian Neoplasms / genetics. Proto-Oncogene Proteins B-raf / genetics
  • [MeSH-minor] Adenocarcinoma, Clear Cell / genetics. Adenocarcinoma, Clear Cell / pathology. Adult. Aged. Aged, 80 and over. Carcinoma, Endometrioid / genetics. Carcinoma, Endometrioid / pathology. Cystadenocarcinoma, Mucinous / genetics. Cystadenocarcinoma, Mucinous / pathology. Cystadenocarcinoma, Serous / genetics. Cystadenocarcinoma, Serous / pathology. DNA, Neoplasm / analysis. Female. Humans. Middle Aged. Mutation. Neoplasm Invasiveness. Neoplasm Metastasis. Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16806438.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  •  go-up   go-down


70. Litkouhi B, Litkouhi B, Fleming E, Welch WR, Berkowitz RS, Birrer MJ, Mok SC: Overexpression of CEACAM6 in borderline and invasive mucinous ovarian neoplasms. Gynecol Oncol; 2008 May;109(2):234-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of CEACAM6 in borderline and invasive mucinous ovarian neoplasms.
  • OBJECTIVE: Identifying markers specific for mucinous ovarian neoplasms (MON) is important for cancer diagnosis and surveillance, and will help improve our general understanding of the pathobiology of these tumors.
  • METHODS: Western blot compared CEACAM6 expression in normal human ovarian surface epithelium (HOSE) and ovarian cancer cell lines.
  • Quantitative RT-PCR (qRT-PCR) was performed on 75 laser-microdissected HOSE and ovarian cancer tissue samples.
  • Expression was absent in all 2 HOSE, 7 serous cancer, and 2 clear cell cancer cell lines.
  • 100-fold CEACAM6 overexpression (qRT-PCR) was demonstrated in 13/16 (81%) borderline, low-grade, and high-grade invasive MON's, compared to 5/50 (10%) serous and 1/5 (20%) benign mucinous samples.
  • CEACAM6 expression was not different between borderline and invasive MON's (p=0.55) or across tumor stage (p=0.76).
  • None of the serous or benign mucinous tumors exhibited CEACAM6 staining.
  • [MeSH-major] Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Antigens, CD / metabolism. Cell Adhesion Molecules / metabolism. Neoplasm Invasiveness. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / metabolism. Blotting, Western. Cell Line, Tumor. Cystadenocarcinoma, Serous / metabolism. Epithelium / metabolism. Female. GPI-Linked Proteins. Humans. Immunohistochemistry / methods. Ovary / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Staining and Labeling. Up-Regulation

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18331757.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50CA165009; United States / NCI NIH HHS / CA / R33CA103595; United States / Intramural NIH HHS / /
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / CEACAM6 protein, human; 0 / Cell Adhesion Molecules; 0 / GPI-Linked Proteins
  •  go-up   go-down


71. Zhang J, Chen AP, Wang B, Zhao SP, Liu LZ, Dai SZ: [Correlations of EGFR and LRP to chemotherapy resistance and prognosis of ovarian cancer]. Ai Zheng; 2008 Dec;27(12):1331-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Correlations of EGFR and LRP to chemotherapy resistance and prognosis of ovarian cancer].
  • BACKGROUND & OBJECTIVE: Abnormal expression and activation of epidermal growth factor receptor (EGFR), which is closely related to the recurrence and poor prognosis of ovarian cancer, can promote chemotherapy resistance of tumor cells.
  • Lung resistance protein (LRP), a multidrug resistance protein causing platinum-resistance, is an independent factor in predicting chemotherapy sensitivity to ovarian cancer.
  • This study was to explore the correlations of EGFR and LRP to chemotherapy resistance and prognosis of ovarian cancer.
  • METHODS: Expressions of EGFR and LRP in 76 specimens of ovarian malignant tumor, nine borderline tumor, 17 benign tumor and 15 normal ovary were studied using immunohistochemistry.
  • Patients with ovarian cancer were followed up.
  • Correlations of EGFR and LRP to chemotherapy efficacy and survival time of patients with ovarian cancer after operation were analyzed.
  • RESULTS: The positive rates of EGFR and LRP in malignant specimens (73.68% and 71.79%) were significantly higher than those in normal and benign ones (P <0.01).
  • EGFR was highly expressed in ovarian cancer patients at late stage (III-IV), with poor differentiation and ascites (P <0.05).
  • The short-term efficacy rates of ovarian cancer were lower in patients with positive expressions of EGFR and LRP (57.14% and 53.70%) than in those with negative expressions (P<0.05).
  • The three-year survival rate of ovarian cancer patients was 53.00%.
  • CONCLUSION: The expression of EGFR and LRP could be used to predict chemotherapy resistance and prognosis of ovarian cancer.
  • [MeSH-major] Cystadenocarcinoma, Serous / metabolism. Drug Resistance, Neoplasm. Ovarian Neoplasms / metabolism. Receptor, Epidermal Growth Factor / metabolism. Vault Ribonucleoprotein Particles / metabolism
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Cisplatin / pharmacology. Cystadenocarcinoma, Mucinous / drug therapy. Cystadenocarcinoma, Mucinous / metabolism. Cystadenocarcinoma, Mucinous / pathology. Cystadenoma, Mucinous / drug therapy. Cystadenoma, Mucinous / metabolism. Cystadenoma, Mucinous / pathology. Cystadenoma, Serous / drug therapy. Cystadenoma, Serous / metabolism. Cystadenoma, Serous / pathology. Female. Follow-Up Studies. Humans. Middle Aged. Neoplasm Staging. Survival Rate


72. Wan T, Liu JH, Zheng LM, Cai MY, Ding T: [Prognostic significance of tumor-associated macrophage infiltration in advanced epithelial ovarian carcinoma]. Ai Zheng; 2009 Mar;28(3):323-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic significance of tumor-associated macrophage infiltration in advanced epithelial ovarian carcinoma].
  • BACKGROUND AND OBJECTIVE: Tumor-associated macrophage (TAM) infiltration promotes the progression of various malignancies.
  • This study was to investigate the influence of TAM infiltration on the survival and prognosis of patients with ovarian cancer.
  • METHODS: The expression of CD68, a TAM-specific marker, in 67 specimens of ovarian cancer and 22 specimens of benign ovarian lesion was detected by SP immunohistochemistry to investigate the density of TAM.
  • The correlation of TAM density to the prognosis of ovarian cancer was analyzed.
  • Cox multivariate proportional hazard model was used to analyze prognostic factors of ovarian cancer.
  • RESULTS: Observing under x 400 lens, the mean density of TAM was significantly higher in ovarian cancer than in benign ovarian lesions (57.7 vs. 25.3 per vision field, p<0.01).
  • The 5-year survival rate was significantly higher in low-density TAM group than in high-density TAM group of ovarian cancer patients (73.3% vs. 41.2%, p=0.01).
  • Univariate analysis found that TAM infiltration was more obvious in serous carcinoma, moderately and poorly differentiated carcinoma and in patients aged >or=40 than in the counterparts.
  • CONCLUSION: TAM infiltration is obvious in advanced ovarian cancer, which indicates poor prognosis.
  • [MeSH-major] Antigens, CD / metabolism. Antigens, Differentiation, Myelomonocytic / metabolism. Cystadenocarcinoma, Serous / pathology. Macrophages / pathology
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adult. Age Factors. Aged. Cystadenocarcinoma, Mucinous / metabolism. Cystadenocarcinoma, Mucinous / pathology. Cystadenocarcinoma, Mucinous / surgery. Female. Follow-Up Studies. Humans. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Neoplasms, Glandular and Epithelial / metabolism. Neoplasms, Glandular and Epithelial / pathology. Neoplasms, Glandular and Epithelial / surgery. Ovarian Cysts / metabolism. Ovarian Cysts / pathology. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology. Ovarian Neoplasms / surgery. Proportional Hazards Models. Survival Rate

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19619451.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD68 antigen, human; Ovarian epithelial cancer
  •  go-up   go-down


73. Hu CJ, Zhang F, Chen YJ, Sun XM, Zheng JF: [Correlation of hK6 expression with clinicopathological features and prognosis in epithelial ovarian cancer]. Zhonghua Zhong Liu Za Zhi; 2009 Jul;31(7):520-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Correlation of hK6 expression with clinicopathological features and prognosis in epithelial ovarian cancer].
  • OBJECTIVE: To approach the relationship between the expression of hK6 in ovarian neoplasm and clinicopathological variables and prognosis in ovarian cancer patients for finding a new tumor marker of the ovarian cancer.
  • METHODS: The expression of hK6 was detected by immunohistochemistry in 19 cases of benign, 11 cases of borderline and 45 cases of malignant ovarian neoplasms and statistically analyzed whether its expression correlate with clinicopathological variables and prognosis in patients with ovarian cancer.
  • RESULTS: The expression of hK6 in ovarian cancer tissues (60.0%) was significantly higher than that in the benign (15.8%) and borderline (27.3%) ovarian neoplasm tissues (P < 0.01).
  • The expression of hK6 in higher-grade ovarian cancer tissues (68.4% ) was higher than that in low-grade ones (14.3%, P < 0.05).
  • CONCLUSION: The expression of hK6 in ovarian cancer was higher than that in benign and borderline ovarian neoplasms.
  • The expression of hK6 is higher in the ovarian cancer of late stage, higher-grade, with lymph node metastasis and is associated with a poorer prognosis. hK6 may become a new markers in prediction of prognosis of the patients with ovarian tumors.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Cystadenocarcinoma, Mucinous / metabolism. Cystadenocarcinoma, Serous / metabolism. Kallikreins / metabolism. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Carcinoma, Endometrioid / metabolism. Carcinoma, Endometrioid / pathology. Cystadenoma, Mucinous / metabolism. Cystadenoma, Mucinous / pathology. Cystadenoma, Serous / metabolism. Cystadenoma, Serous / pathology. Female. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. Young Adult

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19950700.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.21.- / KLK6 protein, human; EC 3.4.21.- / Kallikreins
  •  go-up   go-down


74. Klasa-Mazurkiewicz D, Narkiewicz J, Milczek T, Lipińska B, Emerich J: Maspin overexpression correlates with positive response to primary chemotherapy in ovarian cancer patients. Gynecol Oncol; 2009 Apr;113(1):91-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Maspin overexpression correlates with positive response to primary chemotherapy in ovarian cancer patients.
  • Experimental studies revealed that maspin suppresses tumor growth, angiogenesis, invasion and metastasis.
  • We examined maspin expression in human ovarian tumors and relation between maspin expression and clinicopathological features as well as the role of maspin in predicting clinical outcome in patients with ovarian cancer.
  • METHODS: Tissue samples consisted of 42 benign tumors, 10 borderline (LMP) tumors, 76 ovarian carcinomas, 8 Krukenberg tumors and 32 normal tissues.
  • RESULTS: Relative maspin level was significantly higher in patients with LMP tumors (median 0.74) and early stages ovarian cancers (median 0.46) when compared with healthy tissues (median 0.03), those with benign (median 0.23) and metastatic tumors (median 0.22).
  • Overexpression of maspin was found to correlate with the early stage of the disease (p=0.001), non-serous subtype of ovarian cancer (p=0.03) and positive response to chemotherapy (p=0.02).
  • CONCLUSIONS: Maspin is upregulated in borderline tumors and the early stages of ovarian carcinoma and then significantly downregulated with malignant transformation.
  • High expression may paradoxically promote the invasion and metastasis of ovarian carcinomas.
  • Our study revealed that maspin expression could play an important role in predicting the results of treatment of ovarian cancer patients.
  • [MeSH-major] Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / metabolism. Serpins / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Blotting, Western. Female. Humans. Krukenberg Tumor / drug therapy. Krukenberg Tumor / metabolism. Krukenberg Tumor / pathology. Middle Aged. Neoplasm Staging. Prognosis. Young Adult

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19193429.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / SERPIN-B5; 0 / Serpins
  •  go-up   go-down


75. Schultz KA, Sencer SF, Messinger Y, Neglia JP, Steiner ME: Pediatric ovarian tumors: a review of 67 cases. Pediatr Blood Cancer; 2005 Feb;44(2):167-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric ovarian tumors: a review of 67 cases.
  • BACKGROUND: Ovarian tumors are uncommon but important childhood neoplasms.
  • RESULTS: Thirty patients had benign tumors.
  • Thirty-seven patients had malignant tumors: 11 immature teratomas, seven malignant mixed germ cell tumors, seven juvenile granulosa cell tumors, five dysgerminomas, two endodermal sinus tumors, two serous papillary cystadenocarcinomas, one small cell carcinoma, one anaplastic sex-cord tumor, and one undifferentiated sarcoma.
  • Torsion was seen more often in patients with benign tumors (23 vs. 8%); two patients had both torsion and acute appendicitis.
  • The neoplasm was an incidental finding in 12 patients.
  • CONCLUSIONS: Fifty-five percent of the 67 ovarian tumors presenting to our centers were malignant.
  • Ovarian tumors must be considered in the differential diagnosis of young girls with abdominal pain, mass, or other non-specific symptoms.
  • [MeSH-major] Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Biomarkers, Tumor / blood. Child. Child, Preschool. Chromosome Aberrations. Female. Humans. Infant. Infant, Newborn. Neoplasm Metastasis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15490488.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


76. Zhang S, Zhou X, Yu H, Yu Y: Expression of tumor-specific antigen MAGE, GAGE and BAGE in ovarian cancer tissues and cell lines. BMC Cancer; 2010;10:163
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of tumor-specific antigen MAGE, GAGE and BAGE in ovarian cancer tissues and cell lines.
  • BACKGROUND: To observe mRNA expression of tumor-specific antigen MAGE, BAGE and GAGE in epithelial ovarian cancer tissues and cell lines, to explore the relationship between gene expression and diagnosis, treatment and prognosis of ovarian cancer, and to evaluate the feasibility of their gene products as markers, and an immunotherapy target for ovarian cancer.
  • METHODS: mRNA expression of MAGE-1, MAGE-3, GAGE-1/2 and BAGE were determined by reverse transcription polymerase chain reaction (RT-PCR) in 14 cases of normal ovarian tissue, 20 cases of ovarian benign tumor specimens, 41 cases of ovarian cancer specimens, and ovarian cancer cell lines SKOV3, A2780, and COC1.
  • RESULTS: MAGE, GAGE and BAGE genes were not expressed in normal ovarian tissue.
  • In benign tumors, only the MAGE gene was expressed; the expression rate of this gene in benign tumors was 15% (3/20).
  • In ovarian cancer tissues, MAGE-1 and MAGE-3 was highly expressed, with expression rates of 53.7% (22/41) and 36.6% (15/41), while GAGE-1/2 and BAGE had relatively low expression, with rates of 26.8% (11/41) and 14.6% (6/41).
  • In metastatic lesions of ovarian cancer, only MAGE-1 and BAGE were expressed, with expression rates of 28.6% (2/7) and 14.3% (1/7).
  • The positive expression rates of MAGE-1 and MAGE-3 in serous cystadenocarcinoma were significantly higher than that in other types of ovarian cancer (P < 0.05).
  • Positive expression of MAGE-1 and MAGE-3 was positively correlated with tumor differentiation and the clinical stage of the ovarian cancer.
  • In addition, the positive expression rate of BAGE was significantly higher in ovarian cancer patients with ascites (P < 0.05).
  • The mRNA expression profiles of MAGE, GAGE and BAGE in ovarian carcinoma cell lines SKOV3, A2780 and COC1 varied, but there was at least one gene expressed in each cell line.
  • CONCLUSION: Tumor-specific antigen MAGE, BAGE and GAGE may play a role in the occurrence and development of ovarian cancer.
  • These genes can be used as one of the important indicators for early diagnosis, efficacy evaluation and prognostic determination of ovarian cancer.
  • [MeSH-major] Antigens, Neoplasm / genetics. Biomarkers, Tumor / genetics. Cystadenocarcinoma, Serous / genetics. Neoplasm Proteins / genetics. Ovarian Neoplasms / genetics
  • [MeSH-minor] Cell Line, Tumor. Feasibility Studies. Female. Gene Expression Regulation, Neoplastic. Humans. Melanoma-Specific Antigens. Neoplasm Staging. Prognosis. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Tissue Antigens. 2000 Aug;56(2):166-9 [11019919.001]
  • [Cites] Cancer. 2002 Jun 25;96(3):187-93 [12115308.001]
  • [Cites] Hematol Oncol Clin North Am. 2003 Aug;17(4):1051-73 [12959191.001]
  • [Cites] Int J Cancer. 1996 Jul 29;67(3):457-60 [8707425.001]
  • [Cites] Cancer Res. 2008 May 15;68(10):3931-40 [18483279.001]
  • [Cites] Nat Rev Cancer. 2005 Aug;5(8):615-25 [16034368.001]
  • [Cites] J Clin Oncol. 2005 Dec 10;23(35):9008-21 [16061912.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Feb 5;105(5):1650-5 [18216244.001]
  • [Cites] J Immunol. 2008 Mar 1;180(5):3585-93 [18292586.001]
  • [Cites] Br J Cancer. 1998 Sep;78(6):816-21 [9743307.001]
  • (PMID = 20423514.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / BAGE protein, human; 0 / Biomarkers, Tumor; 0 / GAGE1 protein, human; 0 / GAGE2A protein, human; 0 / MAGEA1 protein, human; 0 / MAGEA3 protein, human; 0 / Melanoma-Specific Antigens; 0 / Neoplasm Proteins; 0 / RNA, Messenger
  • [Other-IDs] NLM/ PMC2868811
  •  go-up   go-down


77. Nolen B, Marrangoni A, Velikokhatnaya L, Prosser D, Winans M, Gorelik E, Lokshin A: A serum based analysis of ovarian epithelial tumorigenesis. Gynecol Oncol; 2009 Jan;112(1):47-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A serum based analysis of ovarian epithelial tumorigenesis.
  • OBJECTIVES: Ovarian epithelial carcinoma can be subdivided into separate histological subtypes including clear cell, endometrioid, mucinous, and serous.
  • This distinction could potentially be reflected in the levels of tumor produced factors that enter into the circulation and serve as biomarkers of malignant growth.
  • Here, we analyze levels of circulating biomarkers from a diverse set of patients diagnosed with ovarian carcinoma to identify biomarker trends and relationships associated with distinct carcinoma histotypes and divergent tumorigenic pathways.
  • METHODS: We utilize multiplexed bead-based immunoassays to measure serum levels of a diverse array of fifty-eight biomarkers from the sera of patients diagnosed with various histological subtypes of ovarian carcinoma and benign lesions.
  • Levels of each biomarker are compared statistically across carcinoma subtypes as well as with benign cases.
  • RESULTS: A total of 21 serum biomarkers differ significantly between patients diagnosed with ovarian carcinomas and benign cases.
  • Nine of these biomarkers are specific for carcinomas identified as clear cell, endometrioid, or mucinous in histology, while two biomarkers are specific for the serous histology.
  • Identified biomarkers include traditional and emerging tumor markers, cytokines and receptors, hormones, and adhesion- and metastasis-related proteins.
  • CONCLUSIONS: We demonstrate here that the divergent histology-based tumorigenic pathways proposed for ovarian epithelial carcinomas are associated with distinct profiles of circulating biomarkers.
  • Continued investigation into the relationships between these factors should reveal new insights into the complex mechanisms underlying ovarian epithelial tumorigenesis.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Leukoc Biol. 2005 May;77(5):598-625 [15689384.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):981-7 [15824174.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):10794-800 [16322225.001]
  • [Cites] Immunobiology. 2005;210(9):661-71 [16323703.001]
  • [Cites] Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2117-24 [16609024.001]
  • [Cites] Mutagenesis. 2006 Jul;21(4):225-36 [16870698.001]
  • [Cites] Gynecol Oncol. 2006 Dec;103(3):883-7 [16806438.001]
  • [Cites] J Clin Pathol. 2007 Apr;60(4):355-60 [17018684.001]
  • [Cites] Clin Cancer Res. 2007 Apr 15;13(8):2385-91 [17438097.001]
  • [Cites] Endocr Rev. 2007 Jun;28(4):440-61 [17463396.001]
  • [Cites] Cancer Res. 2007 Aug 1;67(15):7194-202 [17671187.001]
  • [Cites] Gynecol Oncol. 2008 Feb;108(2):402-8 [18061248.001]
  • [Cites] J Clin Oncol. 2008 Feb 20;26(6):995-1005 [18195328.001]
  • [Cites] Am J Obstet Gynecol. 2008 Apr;198(4):351-6 [18395030.001]
  • [Cites] Am J Pathol. 2000 Feb;156(2):409-17 [10666369.001]
  • [Cites] Endocr Relat Cancer. 1999 Mar;6(1):93-107 [10732792.001]
  • [Cites] Hum Reprod Update. 2000 Sep-Oct;6(5):495-504 [11045880.001]
  • [Cites] Endocr Rev. 2001 Apr;22(2):255-88 [11294827.001]
  • [Cites] Semin Diagn Pathol. 2001 Aug;18(3):161-235 [11554665.001]
  • [Cites] Biol Cell. 2001 Sep;93(1-2):53-62 [11730323.001]
  • [Cites] Am J Pathol. 2002 Apr;160(4):1223-8 [11943707.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Feb;12(2):103-13 [12582019.001]
  • [Cites] J Natl Cancer Inst. 2003 Mar 19;95(6):484-6 [12644542.001]
  • [Cites] Med Electron Microsc. 2003 Mar;36(1):9-17 [12658347.001]
  • [Cites] Am J Surg Pathol. 2003 Jun;27(6):725-36 [12766576.001]
  • [Cites] Clin Cancer Res. 2003 Oct 1;9(12):4460-4 [14555519.001]
  • [Cites] Int J Gynecol Pathol. 2004 Jan;23(1):41-4 [14668549.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1511-8 [15111296.001]
  • [Cites] Int J Gynecol Pathol. 2004 Jul;23(3):200-5 [15213595.001]
  • [Cites] Cancer Res. 1990 Nov 1;50(21):6959-65 [2208162.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Oct 1;89(19):9267-71 [1409633.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jun 1;90(11):4961-5 [8506342.001]
  • [Cites] J Natl Cancer Inst. 1993 Sep 15;85(18):1513-9 [8360934.001]
  • [Cites] J Cancer Res Clin Oncol. 1994;120(3):137-42 [7505272.001]
  • [Cites] Cancer. 1994 Apr 1;73(7):1859-64 [8137211.001]
  • [Cites] Int J Cancer. 1995 Aug 22;64(4):280-5 [7657393.001]
  • [Cites] Br J Cancer. 1996 Feb;73(3):301-6 [8562334.001]
  • [Cites] Int J Cancer. 1996 Aug 22;69(4):329-34 [8797878.001]
  • [Cites] Am J Surg Pathol. 1996 Nov;20(11):1331-45 [8898837.001]
  • [Cites] Biochem Pharmacol. 1997 Sep 1;54(5):541-4 [9337069.001]
  • [Cites] Cancer Res. 1998 Apr 1;58(7):1344-7 [9537226.001]
  • [Cites] Cancer Res. 1998 May 15;58(10):2095-7 [9605750.001]
  • [Cites] Int J Gynecol Pathol. 1999 Jan;18(1):29-41 [9891239.001]
  • [Cites] Gene. 1999 Mar 18;229(1-2):101-8 [10095109.001]
  • [Cites] Cancer Res. 2005 Jan 1;65(1):331-7 [15665311.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2162-9 [15781627.001]
  • [Cites] Gynecol Oncol. 2008 Aug;110(2):196-201 [18495222.001]
  • [Cites] Cancer Res. 2008 Jul 15;68(14):5849-58 [18632639.001]
  • [Cites] Am J Surg Pathol. 2005 Aug;29(8):1034-41 [16006797.001]
  • (PMID = 19007974.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA117452-04S1; United States / NCI NIH HHS / CA / CA117452-03; United States / NCI NIH HHS / CA / R01 CA098642-03; United States / NCI NIH HHS / CA / R01 CA098642; United States / NCI NIH HHS / CA / R01 CA108990; United States / NCI NIH HHS / CA / U01 CA117452; United States / NCI NIH HHS / CA / R01 CA098642-02; United States / NCI NIH HHS / CA / U01 CA117452-04S1; United States / NCI NIH HHS / CA / R03 CA136019-01; United States / NCI NIH HHS / CA / R03 CA136019; United States / NCI NIH HHS / CA / U01 CA117452-03; United States / NCI NIH HHS / CA / U01 CA117452-01; United States / NCI NIH HHS / CA / CA117452-04; United States / NCI NIH HHS / CA / R01 CA098642-01A1; United States / NCI NIH HHS / CA / R01 CA108990-02; United States / NCI NIH HHS / CA / CA117452-02; United States / NCI NIH HHS / CA / U01 CA117452-02; United States / NCI NIH HHS / CA / U01 CA117452-04; United States / NCI NIH HHS / CA / R01 CA108990-04; United States / NCI NIH HHS / CA / R01 CA098642-04; United States / NCI NIH HHS / CA / CA136019-01; United States / NCI NIH HHS / CA / R01 CA108990-01A1; United States / NCI NIH HHS / CA / R01 CA108990-03; United States / NCI NIH HHS / CA / CA117452-01
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ NIHMS92465; NLM/ PMC2657848
  •  go-up   go-down


78. Brustmann H: DNA fragmentation factor (DFF45): expression and prognostic value in serous ovarian cancer. Pathol Res Pract; 2006;202(10):713-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DNA fragmentation factor (DFF45): expression and prognostic value in serous ovarian cancer.
  • This study investigated the expression of DNA fragmentation factor (DFF45), MIB-1, and p53 in formalin-fixed, paraffin-embedded archival tissues of 50 ovarian serous carcinomas.
  • In addition, 10 benign serous cystadenomas and 10 serous neoplasms of low malignant potential (LMP) were included in this DFF45 immunostudy.
  • For p53, at least 10% of tumor cells had to display nuclear staining to consider a case positive.
  • Low DFF45 expression was identified in all serous cystadenomas and in LMPs, as well as in 18 (36%) ovarian serous carcinomas.
  • This study indicates that DFF45 expression is frequently upregulated in ovarian serous carcinomas and may serve as a marker of aggressive behavior with prognostic value.
  • [MeSH-major] Apoptosis Regulatory Proteins / metabolism. Cystadenocarcinoma, Serous / metabolism. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Apoptosis. Biomarkers, Tumor / metabolism. Cell Count. Cell Nucleus / metabolism. Cell Nucleus / pathology. Cell Proliferation. Cystadenoma, Serous / metabolism. Cystadenoma, Serous / pathology. Disease-Free Survival. Female. Fluorescent Antibody Technique, Direct. Humans. Immunoenzyme Techniques. Middle Aged. Neoplasm Staging. Survival Rate

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16962250.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / Biomarkers, Tumor; 0 / caspase-activated DNase inhibitor
  •  go-up   go-down


79. Chen AP, Zhang J, Liu H, Zhao SP, Dai SZ, Sun XL: [Association of EGFR expression with angiogenesis and chemoresistance in ovarian carcinoma]. Zhonghua Zhong Liu Za Zhi; 2009 Jan;31(1):48-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Association of EGFR expression with angiogenesis and chemoresistance in ovarian carcinoma].
  • OBJECTIVE: To clarify the association of EGFR expression with angiogenesis and chemoresistance in ovarian cancer.
  • METHODS: Immunohistochemical PV-6000 staining was used to detect the expression of EGFR, LRP protein and MVD in 102 ovarian tumor specimens.
  • RESULTS: EGFR, LRP positive rates and MVD in borderline and malignant ovarian specimens were significantly higher than those in the normal and benign ones (P < 0.01).
  • MVD was related to histological grade, residual tumor and ascites, LRP positive expression had no correlation with the clinicopathologic parameters (P > 0.05).
  • CONCLUSION: The expression of EGFR in ovarian cancer is related to angiogenesis and chemoresistance.
  • EGFR and LRP-positive expression are related to chemoresistance, and detection of the two proteins may be helpful in guiding chemotherapy choice for ovarian cancer.
  • [MeSH-major] Drug Resistance, Neoplasm. Neovascularization, Pathologic / pathology. Ovarian Neoplasms / blood supply. Receptor, Epidermal Growth Factor / metabolism. Vault Ribonucleoprotein Particles / metabolism
  • [MeSH-minor] Antigens, CD34 / metabolism. Ascites / pathology. Cystadenocarcinoma, Mucinous / blood supply. Cystadenocarcinoma, Mucinous / drug therapy. Cystadenocarcinoma, Mucinous / metabolism. Cystadenocarcinoma, Mucinous / pathology. Cystadenocarcinoma, Serous / blood supply. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / pathology. Cystadenoma, Mucinous / blood supply. Cystadenoma, Mucinous / drug therapy. Cystadenoma, Mucinous / metabolism. Cystadenoma, Mucinous / pathology. Cystadenoma, Serous / blood supply. Cystadenoma, Serous / drug therapy. Cystadenoma, Serous / metabolism. Cystadenoma, Serous / pathology. Drug Resistance, Multiple. Female. Follow-Up Studies. Gene Expression Regulation, Neoplastic. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Survival Rate

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19538870.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Vault Ribonucleoprotein Particles; 0 / major vault protein; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


80. Ye S, Hao X, Zhou T, Wu M, Wei J, Wang Y, Zhou L, Jiang X, Ji L, Chen Y, You L, Zhang Y, Xu G, Zhou J, Ma D, Wang S: Plexin-B1 silencing inhibits ovarian cancer cell migration and invasion. BMC Cancer; 2010;10:611
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plexin-B1 silencing inhibits ovarian cancer cell migration and invasion.
  • However, whether or not Plexin-B1 expression is involved in human ovarian tumors remains unclear.
  • In the present study, Plexin-B1 expression was explored in benign and malignant human ovarian tumor tissues.
  • In addition, the impact of Plexin-B1 expression on ovarian cancer cell proliferation, migration and invasion were investigated in vitro.
  • METHODS: Plexin-B1 expression was analyzed in normal and benign ovarian tissues and serous ovarian tumors (both borderline and malignant) by immunohistochemical staining, as well as in four human ovarian cancer cell lines (A2780, C13*, SKOV3, and OV2008) by RT-PCR and western blot analyses.
  • RESULTS: Expression levels of Plexin-B1 protein were significantly higher in serous ovarian carcinomas than in normal ovaries or benign ovarian neoplasms, and in the former, Plexin-B1 expression was positively correlated with lymphatic metastasis, and the membrane and cytoplasm of cancer cells stained positively.
  • SKOV3 cells displayed the highest Plexin-B1 expression at both the mRNA and protein levels among the four tested human ovarian cancer cell lines and was selected as a cell model for further in vitro experiments.
  • CONCLUSION: Plexin-B1 expression correlates with malignant phenotypes of serous ovarian tumors, probably via phosphorylation of AKT at Ser473, suggesting that Plexin-B1 might be a useful biomarker and/or a novel therapeutic target.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Gene Silencing. Nerve Tissue Proteins / genetics. Ovarian Neoplasms / genetics. Receptors, Cell Surface / genetics
  • [MeSH-minor] Adult. Aged. Cell Line, Tumor. Cell Movement. Cell Proliferation. Female. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Invasiveness. Proto-Oncogene Proteins c-akt / metabolism

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2000 Nov 7;97(23):12457-62 [11035813.001]
  • [Cites] Mol Cancer. 2009;8:26 [19386116.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3498-504 [11369643.001]
  • [Cites] Trends Immunol. 2001 Dec;22(12):670-6 [11738997.001]
  • [Cites] Sci STKE. 2002 Apr 16;2002(128):re4 [11972358.001]
  • [Cites] Nat Cell Biol. 2002 Sep;4(9):720-4 [12198496.001]
  • [Cites] Ann Hematol. 2002;81 Suppl 2:S74 [12611086.001]
  • [Cites] J Biol Chem. 2004 Jan 16;279(3):1885-91 [14559914.001]
  • [Cites] Dev Cell. 2004 Jul;7(1):107-16 [15239958.001]
  • [Cites] Mol Endocrinol. 2004 Oct;18(10):2570-82 [15243131.001]
  • [Cites] Neuron. 1995 Jun;14(6):1189-99 [7605632.001]
  • [Cites] Nature. 1996 Oct 10;383(6600):525-8 [8849723.001]
  • [Cites] Cell Oncol. 2009;31(6):423-36 [19940359.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11780-5 [8876214.001]
  • [Cites] Cancer Res. 1998 Mar 15;58(6):1238-44 [9515811.001]
  • [Cites] J Cell Biol. 1999 Mar 22;144(6):1235-44 [10087266.001]
  • [Cites] Curr Opin Immunol. 1999 Aug;11(4):387-91 [10448143.001]
  • [Cites] Cell. 1999 Oct 1;99(1):71-80 [10520995.001]
  • [Cites] Blood. 2005 Jun 1;105(11):4321-9 [15632204.001]
  • [Cites] Cell Mol Life Sci. 2005 Jun;62(12):1363-71 [15818466.001]
  • [Cites] Cytokine Growth Factor Rev. 2005 Aug-Oct;16(4-5):535-48 [15979925.001]
  • [Cites] Mol Cell Biol. 2005 Aug;25(16):6889-98 [16055703.001]
  • [Cites] Cancer. 2000 Mar 15;88(6):1378-83 [10717620.001]
  • [Cites] Mech Dev. 2000 Oct;97(1-2):35-45 [11025205.001]
  • [Cites] Biochem J. 2005 Aug 15;390(Pt 1):125-36 [15839837.001]
  • [Cites] Dev Dyn. 2005 Oct;234(2):393-403 [16145665.001]
  • [Cites] Fertil Steril. 2005 Oct;84 Suppl 2:1210-9 [16210013.001]
  • [Cites] Biochem J. 2006 Mar 1;394(Pt 2):459-64 [16187944.001]
  • [Cites] Endothelium. 2006 Mar-Apr;13(2):81-91 [16728327.001]
  • [Cites] Nat Cell Biol. 2006 Jun;8(6):615-22 [16715077.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9017-22 [16754882.001]
  • [Cites] EMBO Rep. 2006 Jul;7(7):704-9 [16799460.001]
  • [Cites] Clin Cancer Res. 2007 Feb 15;13(4):1115-22 [17317819.001]
  • [Cites] OMICS. 2007 Spring;11(1):41-57 [17411395.001]
  • [Cites] Annu Rev Cell Dev Biol. 2007;23:263-92 [17539753.001]
  • [Cites] J Biol Chem. 2007 Nov 30;282(48):34888-95 [17855350.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Nov 27;104(48):19040-5 [18024597.001]
  • [Cites] J Biol Chem. 2008 Jan 25;283(4):1893-901 [18025083.001]
  • [Cites] Oncology. 2007;72(3-4):172-80 [18097168.001]
  • [Cites] Transl Res. 2008 Mar;151(3):134-40 [18279812.001]
  • [Cites] Protein Sci. 2008 Jun;17(6):1003-14 [18411422.001]
  • [Cites] Am J Pathol. 2008 Aug;173(2):545-60 [18599607.001]
  • [Cites] Mol Biol Cell. 2009 Mar;20(6):1728-36 [19158377.001]
  • [Cites] PLoS One. 2009;4(4):e5052 [19337377.001]
  • [Cites] Curr Biol. 2001 Mar 6;11(5):339-44 [11267870.001]
  • (PMID = 21059203.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Nerve Tissue Proteins; 0 / PLXNB1 protein, human; 0 / Receptors, Cell Surface; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  • [Other-IDs] NLM/ PMC2991310
  •  go-up   go-down


81. Chen EY, Mehra K, Mehrad M, Ning G, Miron A, Mutter GL, Monte N, Quade BJ, McKeon FD, Yassin Y, Xian W, Crum CP: Secretory cell outgrowth, PAX2 and serous carcinogenesis in the Fallopian tube. J Pathol; 2010 Sep;222(1):110-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secretory cell outgrowth, PAX2 and serous carcinogenesis in the Fallopian tube.
  • The 'p53 signature' is a benign secretory cell outgrowth in the distal Fallopian tube that shares properties with ovarian serous cancer-including p53 mutations-and is a putative serous cancer precursor.
  • We expanded the precursor definition to all secretory cell outgrowths (SCOUTs) of 30 or more cells and scored normal (N) and altered (A) expression of both p53 and PAX2, a gene down-regulated in ovarian and endometrial cancer.
  • SCOUTs were identified by BCL2/p73 staining in tubes from women with serous carcinoma, inherited mutations in BRCA1 or BRCA2 and controls.
  • SCOUTs were prevalent in both proximal and distal tube and significantly associated with serous carcinoma versus the others (p < 0.001); 89% were PAX2 (A) and 26% were PAX2 (A)/p53 (A) (p53 signatures).
  • SCOUTs are discretely localized alterations commonly containing altered expression of multiple genes within histologically benign tubal epithelium.
  • This study reveals, for the first time, an entity (SCOUT) that is associated with serous cancer, expands the topography of altered PAX2 expression in the female genital tract mucosa and highlights another potential pathway disturbance involved in early serous carcinogenesis in the Fallopian tube.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2008 Nov;111(2):226-32 [18718648.001]
  • [Cites] Lancet Oncol. 2008 Dec;9(12):1191-7 [19038766.001]
  • [Cites] Int J Gynecol Cancer. 2009 Jan;19(1):58-64 [19258943.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] Mod Pathol. 2009 Sep;22(9):1243-50 [19525924.001]
  • [Cites] Mod Pathol. 2009 Sep;22(9):1133-8 [19543244.001]
  • [Cites] Int J Gynecol Pathol. 2009 Nov;28(6):570-8 [19851209.001]
  • [Cites] Oncogene. 2010 Feb 25;29(8):1103-13 [19935705.001]
  • [Cites] Mod Pathol. 2010 Oct;23(10):1316-24 [20562848.001]
  • [Cites] Mod Pathol. 2011 Jan;24(1):152-6 [20871594.001]
  • [Cites] J Natl Cancer Inst. 2000 Jun 7;92(11):924-30 [10841828.001]
  • [Cites] J Pathol. 2001 Nov;195(4):451-6 [11745677.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):20-30 [12538447.001]
  • [Cites] Int J Gynecol Pathol. 2003 Apr;22(2):109-20 [12649664.001]
  • [Cites] Science. 1983 Nov 18;222(4625):771-8 [6356358.001]
  • [Cites] N Engl J Med. 1993 Nov 18;329(21):1550-9 [8155119.001]
  • [Cites] Med Pediatr Oncol. 1996 Nov;27(5):440-4 [8827071.001]
  • [Cites] Hum Reprod. 1998 Nov;13(11):3114-20 [9853867.001]
  • [Cites] Mol Cell. 2005 Jun 10;18(6):617-22 [15949437.001]
  • [Cites] Obstet Gynecol. 2005 Dec;106(6):1327-34 [16319259.001]
  • [Cites] Gynecol Oncol. 2006 Jan;100(1):58-64 [16137750.001]
  • [Cites] J Pathol. 2007 Jan;211(1):26-35 [17117391.001]
  • [Cites] Am J Surg Pathol. 2007 Feb;31(2):161-9 [17255760.001]
  • [Cites] J Clin Oncol. 2007 Sep 1;25(25):3985-90 [17761984.001]
  • [Cites] Int J Gynecol Pathol. 2008 Jan;27(1):1-9 [18156967.001]
  • [Cites] J Clin Oncol. 2008 Sep 1;26(25):4160-5 [18757330.001]
  • [Cites] J Clin Oncol. 2008 Nov 10;26(32):5284-93 [18854563.001]
  • (PMID = 20597068.001).
  • [ISSN] 1096-9896
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R21 CA124688-02S1; United States / NCI NIH HHS / CA / P50 CA105009; United States / NIGMS NIH HHS / GM / R01 GM083348; United States / NCI NIH HHS / CA / R21 CA124688; United States / NCI NIH HHS / CA / 1R21CA124688-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / PAX2 Transcription Factor; 0 / PAX2 protein, human; 0 / Tumor Suppressor Protein p53
  • [Other-IDs] NLM/ NIHMS207936; NLM/ PMC2914810
  •  go-up   go-down


82. Zhang XL, Peng CJ, Peng J, Jiang LY, Ning XM, Zheng JH: Prognostic role of Wnt7a expression in ovarian carcinoma patients. Neoplasma; 2010;57(6):545-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic role of Wnt7a expression in ovarian carcinoma patients.
  • The aim of this study was to investigate the expression and prognostic significance of Wnt7a in ovarian carcinoma.
  • Wnt7a expression was immunohistochemically examined in normal ovaries (n=15), benign tumors (n=50) and ovarian carcinomas (n=78).
  • Wnt7a expression was higher in ovarian carcinomas compared to normal ovaries and benign tumors (p<0.001 and p=0.001, respectively).
  • Wnt7a positive expression was significantly correlated with serous subtype (p<0.001), elder age (p=0.017), advanced stage (p<0.001), high grade (p=0.001), a high degree of ascitic fluid volume (p=0.015) and high CA125 expression (p=0.025).
  • High Wnt7a expression in ovarian cancer may be associated with poor prognosis.
  • [MeSH-major] Ovarian Neoplasms / mortality. Wnt Proteins / analysis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Prognosis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20845993.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0 / WNT7A protein, human; 0 / Wnt Proteins
  •  go-up   go-down


83. Grisaru-Granovsky S, Salah Z, Maoz M, Pruss D, Beller U, Bar-Shavit R: Differential expression of protease activated receptor 1 (Par1) and pY397FAK in benign and malignant human ovarian tissue samples. Int J Cancer; 2005 Jan 20;113(3):372-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of protease activated receptor 1 (Par1) and pY397FAK in benign and malignant human ovarian tissue samples.
  • Although proteases in general have been implicated in the remodeling of the extracellular tumor microenvironment, the role of cell surface receptors activated by proteolysis is now emerging.
  • In our present study we investigated the expression pattern of protease activated receptor 1 hPar1 in ovarian carcinoma tissue samples.
  • In contrast, no hPar1 expression was detected on the cell surface of normal ovarian epithelium.
  • In early stages of ovarian carcinoma (Ia), the contra lateral normal ovary showed strong PAR1 expression as opposed to the lack of expression in the ovarian epithelium obtained from normal individuals.
  • Phosphorylated FAK was seen in invasive ovarian carcinoma, but not in the normal ovarian epithelium.
  • The abundant hPar1 levels in pathological malignant ovarian carcinoma is likely to transmit signals leading to the phosphorylation of FAK and thereby alterations in the integrin functional state.
  • Altogether our data suggest that hPar1 and FAK cooperate to promote ovarian cancer malignancy.
  • [MeSH-major] Ovarian Neoplasms / metabolism. Receptor, PAR-1 / metabolism
  • [MeSH-minor] Adenocarcinoma, Clear Cell / genetics. Adenocarcinoma, Clear Cell / metabolism. Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Carcinoma, Endometrioid / genetics. Carcinoma, Endometrioid / metabolism. Carcinoma, Endometrioid / pathology. Cystadenocarcinoma, Serous / genetics. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / pathology. Epithelium / metabolism. Epithelium / pathology. Female. Focal Adhesion Kinase 1. Focal Adhesion Protein-Tyrosine Kinases. Gene Expression Regulation, Neoplastic. Humans. Immunoenzyme Techniques. In Situ Hybridization. Integrins / genetics. Integrins / metabolism. Neoplasm Invasiveness / pathology. Ovary / metabolism. Ovary / pathology. Phosphorylation. Protein-Tyrosine Kinases / genetics. Protein-Tyrosine Kinases / metabolism. RNA, Messenger / genetics. RNA, Messenger / metabolism. Receptors, Vitronectin / genetics. Receptors, Vitronectin / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15455382.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Integrins; 0 / RNA, Messenger; 0 / Receptor, PAR-1; 0 / Receptors, Vitronectin; 0 / integrin alphaVbeta5; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / Focal Adhesion Kinase 1; EC 2.7.10.2 / Focal Adhesion Protein-Tyrosine Kinases; EC 2.7.10.2 / PTK2 protein, human
  •  go-up   go-down


84. Poli Neto OB, Candido Dos Reis FJ, Zambelli Ramalho LN, Nogueira AA, de Andrade JM: p63 expression in epithelial ovarian tumors. Int J Gynecol Cancer; 2006 Jan-Feb;16(1):152-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p63 expression in epithelial ovarian tumors.
  • Ovarian cancer is a highly lethal disease and its underlying biology is poorly understood.
  • The p63 is a homologue gene of the tumor suppressor p53. p63 appears to be important for the development and differentiation of reproductive epithelium and interacts with p53 in human tumorigenesis.
  • This study presents the immunoexpression of the p63 in benign and malignant epithelial ovarian tumors.
  • We evaluated the p63 immunoexpression in 91 ovarian benign cystadenomas (29 mucinous and 62 serous) and in 29 ovarian malignant tumors (3 mucinous borderline, 3 serous borderline, 17 serous carcinomas, 2 endometrioid, 2 undifferentiated, 1 mucinous, and 1 clear-cell carcinoma) using a monoclonal antibody clone 4A4 (1:200), which recognizes all p63 variants.
  • We observed 85.7% of positivity in benign tumors, 50% in borderline tumors, and 8.7% in invasive ovarian cancer (P < .0001).
  • The benign serous cystadenomas were positive in 91.9% of cases and benign mucinous cystadenomas in 72.4% (P= .02).
  • These data suggests an important role of p63 in the control of ovarian epithelium behavior.
  • The p63 may be involved in the development of benign and malignant epithelial ovarian tumors.
  • [MeSH-major] Carcinoma / genetics. Carcinoma / pathology. Cystadenoma / pathology. Ovarian Neoplasms / genetics. Ovarian Neoplasms / pathology. Phosphoproteins / metabolism. Trans-Activators / metabolism
  • [MeSH-minor] Adult. Age Factors. Biomarkers, Tumor / analysis. Biopsy, Needle. Cohort Studies. DNA-Binding Proteins. Female. Gene Expression Regulation, Neoplastic. Genes, Tumor Suppressor. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Probability. Prognosis. Risk Assessment. Sensitivity and Specificity. Tissue Culture Techniques. Transcription Factors. Tumor Suppressor Proteins

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16445626.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Phosphoproteins; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


85. Bar JK, Słomska I, Rabczyńki J, Noga L, Gryboś M: Expression of p53 protein phosphorylated at serine 20 and serine 392 in malignant and benign ovarian neoplasms: correlation with clinicopathological parameters of tumors. Int J Gynecol Cancer; 2009 Nov;19(8):1322-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of p53 protein phosphorylated at serine 20 and serine 392 in malignant and benign ovarian neoplasms: correlation with clinicopathological parameters of tumors.
  • The study investigated the expression of p53 protein phosphorylated at serine 20 (Ser20) and Ser392 and the association between clinicopathological parameters of ovarian neoplasms with respect to p53 protein overexpression.
  • METHODS: p53 protein expression was evaluated on tissues from malignant and benign ovarian tumors.
  • RESULTS: The correlation between p53 protein overexpression and p53-Ser392 phosphorylation was found in ovarian carcinomas (P = 0.001, r = +0.27).
  • In the total group of ovarian carcinomas, significant differences were observed in p53 protein overexpression between well (G1) and poor (G3) tumor grades (P = 0.005) and between serous and endometrioid types of tumor (P = 0.04), whereas p53-Ser20 phosphorylation was associated with advanced International Federation of Gynecology and Obstetrics stage (P = 0.004) and high tumor grade (P = 0.02).
  • In p53-positive ovarian carcinomas, p53-Ser392 phosphorylation was associated with advanced tumor stage (P = 0.02) and high tumor grade (P = 0.049).
  • p53-Ser20 phosphorylation was associated with low tumor grade of p53-positive ovarian carcinomas (P = 0.02) and with high tumor grade of p53-negative ovarian carcinomas (P = 0.02).
  • CONCLUSIONS: These results revealed that p53 phosphorylation at Ser20 and Ser392 is an early event in ovarian tumor development.
  • The authors suggest that the expression of p53 protein phosphorylated at Ser20 and Ser392 in ovarian carcinomas determines their individual clinical features depending on p53 protein status and may be useful biological biomarkers characterizing their behavior.
  • [MeSH-major] Adenocarcinoma, Mucinous / metabolism. Cystadenocarcinoma, Serous / metabolism. Endometrial Neoplasms / metabolism. Neoplasms / metabolism. Ovarian Neoplasms / metabolism. Serine / metabolism. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Adult. Aged. Female. Humans. Immunoenzyme Techniques. Middle Aged. Neoplasm Staging. Phosphorylation. Prognosis. Young Adult


86. Shih IeM, Chen L, Wang CC, Gu J, Davidson B, Cope L, Kurman RJ, Xuan J, Wang TL: Distinct DNA methylation profiles in ovarian serous neoplasms and their implications in ovarian carcinogenesis. Am J Obstet Gynecol; 2010 Dec;203(6):584.e1-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinct DNA methylation profiles in ovarian serous neoplasms and their implications in ovarian carcinogenesis.
  • OBJECTIVE: The purpose of this study was to analyze DNA methylation profiles among different types of ovarian serous neoplasm, which is a task that has not been performed.
  • STUDY DESIGN: The Illumina beads array (Illumina Inc, San Diego, CA) was used to profile DNA methylation in enriched tumor cells that had been isolated from 75 benign and malignant serous tumor tissues and 6 tumor-associated stromal cell cultures.
  • RESULTS: We found significantly fewer hypermethylated genes in high-grade serous carcinomas than in low-grade serous carcinoma and borderline tumors, which in turn had fewer hypermethylated genes than serous cystadenoma.
  • Unsupervised analysis identified that serous cystadenoma, serous borderline tumor, and low-grade serous carcinomas tightly clustered together and were clearly different from high-grade serous carcinomas.
  • CONCLUSION: The findings support the view that low-grade and high-grade serous carcinomas are distinctly different with low-grade, but not high-grade, serous carcinomas that are related to serous borderline tumor and cystadenoma.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Mosby, Inc. All rights reserved.
  • [Cites] Am J Pathol. 2002 Apr;160(4):1223-8 [11943707.001]
  • [Cites] Clin Cancer Res. 2010 Apr 1;16(7):1997-2008 [20233889.001]
  • [Cites] J Natl Cancer Inst. 2003 Mar 19;95(6):484-6 [12644542.001]
  • [Cites] J Biochem. 2003 Mar;133(3):303-8 [12761165.001]
  • [Cites] Nat Genet. 2003 Jul;34(3):337-43 [12819783.001]
  • [Cites] N Engl J Med. 2003 Nov 20;349(21):2042-54 [14627790.001]
  • [Cites] Ann Oncol. 2004 Feb;15(2):252-6 [14760118.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1511-8 [15111296.001]
  • [Cites] Cancer Res. 2004 Sep 15;64(18):6476-81 [15374957.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):6915-8 [15466181.001]
  • [Cites] Curr Opin Oncol. 2005 Jan;17(1):33-8 [15608510.001]
  • [Cites] Cancer Res. 2005 Jun 1;65(11):4963-8 [15930319.001]
  • [Cites] Oncogene. 2005 Jun 2;24(24):3875-85 [15735666.001]
  • [Cites] Cancer. 2005 Nov 1;104(9):1924-30 [16134181.001]
  • [Cites] Clin Cancer Res. 2005 Oct 15;11(20):7273-9 [16243797.001]
  • [Cites] Nat Rev Cancer. 2006 Feb;6(2):107-16 [16491070.001]
  • [Cites] Virchows Arch. 2006 Mar;448(3):331-6 [16315018.001]
  • [Cites] Cancer. 2006 Jul 15;107(2):299-308 [16773633.001]
  • [Cites] Am J Surg Pathol. 2007 Jul;31(7):1007-12 [17592266.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21 [11309499.001]
  • [Cites] J Urol. 2008 Feb;179(2):743-7 [18082200.001]
  • [Cites] Int J Gynecol Pathol. 2008 Apr;27(2):151-60 [18317228.001]
  • [Cites] Gynecol Oncol. 2008 Apr;109(1):129-39 [18234305.001]
  • [Cites] Int J Cancer. 2008 Aug 1;123(3):725-9 [18478570.001]
  • [Cites] Gynecol Oncol. 2008 Nov;111(2):320-9 [18757082.001]
  • [Cites] Am J Obstet Gynecol. 2009 Feb;200(2):177.e1-9 [19110234.001]
  • [Cites] Annu Rev Pathol. 2009;4:287-313 [18842102.001]
  • [Cites] Cancer Res. 2009 May 1;69(9):4036-42 [19383911.001]
  • [Cites] Cancer Res. 2009 Nov 1;69(21):8482-90 [19826047.001]
  • [Cites] J Clin Oncol. 2009 Dec 10;27(35):5874-80 [19901110.001]
  • [Cites] PLoS One. 2010;5(2):e9359 [20179752.001]
  • [Cites] Lab Invest. 2010 Mar;90(3):414-25 [20065949.001]
  • [Cites] Clin Cancer Res. 2002 Jul;8(7):2246-52 [12114427.001]
  • (PMID = 20965493.001).
  • [ISSN] 1097-6868
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA103937; United States / NCI NIH HHS / CA / CA103937-07; United States / NCI NIH HHS / CA / R01 CA129080-04; United States / NCI NIH HHS / CA / CA129080; United States / NCI NIH HHS / CA / R01 CA129080; United States / NCI NIH HHS / CA / CA129080-04; United States / NCI NIH HHS / CA / R01 CA103937-07; United States / NCI NIH HHS / CA / R01 CA103937
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS230506; NLM/ PMC2993872
  •  go-up   go-down


87. Sciallis AP, Aubry MC, Bell DA: Ciliated adenocarcinoma of the ovary with evidence of serous differentiation: report of a case. Int J Gynecol Pathol; 2009 Sep;28(5):447-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ciliated adenocarcinoma of the ovary with evidence of serous differentiation: report of a case.
  • A patient with bilateral ovarian adenocarcinomas composed predominantly of ciliated cells incidentally found at autopsy is reported.
  • In one of the masses, the neoplastic cells seemed to arise from a serous adenofibroma.
  • The tumor was confined to the ovaries without evidence of metastatic spread.
  • Although morphologically resembling an endometrioid-type neoplasm, immunohistochemical and molecular studies were more consistent with a serous phenotype, especially in light of its apparent origination from a serous adenofibroma.
  • We agree with previous observations suggesting that although the neoplasm seems morphologically worrisome, it may actually portend a more benign clinical course.
  • [MeSH-major] Adenocarcinoma / pathology. Cilia / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19696614.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Manolis T, Lee YC, Temkin S, Hellman M, Nacharaju VL, Abulafia O: NAD dependent 11beta-hydroxysteroid dehydrogenase activity in human endometrium and endometrial tumors. Gynecol Obstet Invest; 2006;62(2):103-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The isoforms of 11beta-hydroxysteroid dehydrogenase (11beta-HSD) types 1 and 2, regulated by ovarian steroids, catalyze the interconversion of glucocorticoids and their 11-keto metabolites.
  • METHODS: NAD dependent 11beta-HSD activity was determined in endometrial tissue obtained from patients undergoing hysterectomy for benign or malignant disease (endometroid, serous and carcinosarcomas).
  • The activities were 0.61+/- 0.27 in normal (n = 9), 0.43 +/- 0.29 in endometrioid endometrial carcinoma (n = 14), 0.50 +/- 0.26 in uterine serous carcinoma (n = 6) and 0.25 +/- 0.37 in carcinosarcomas (n = 9).
  • [MeSH-minor] Female. Humans. Hysterectomy. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16645302.001).
  • [ISSN] 0378-7346
  • [Journal-full-title] Gynecologic and obstetric investigation
  • [ISO-abbreviation] Gynecol. Obstet. Invest.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] EC 1.1.1.146 / 11-beta-Hydroxysteroid Dehydrogenase Type 2
  •  go-up   go-down


89. Ma L, Liu FR, Zhang SL: [Detection of circulating hypermethylated tumor-specific RASSF1A DNA in ovarian cancer patients]. Zhonghua Bing Li Xue Za Zhi; 2005 Dec;34(12):785-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Detection of circulating hypermethylated tumor-specific RASSF1A DNA in ovarian cancer patients].
  • OBJECTIVE: To detect hypermethylated tumor-specific RASSF1A DNA in the circulation and its significance in ovarian cancers patients.
  • METHODS: Methylation-specific polymerase chain reaction (MSP) was used to study the hypermethylation of RASSF1A in preoperative serum samples from 51 ovarian cancer patients.
  • RESULTS: The RASSF1A gene was not methylated in peripheral blood samples from 51 normal patients and 51 patients with benign ovarian tumors.
  • Hypermethylation of RASSF1A gene was found in circulating tumor-specific DNA in 43.1% of patients (22 out of 51 cases) with ovarian cancers (P < 0.05).
  • There was no difference in hypermethylation of RASSF1A gene amongst various ovarian cancer subtypes (P < 0.05).
  • CONCLUSIONS: There is a higher frequency of RASSF1A hypermethylation in circulating tumor-specific DNA of ovarian cancer patients.
  • RASSF1A has been postulated to play an important role as tumor suppressor gene and can be silenced by promoter hypermethylation.
  • Such observation may carry diagnostic and prognostic implications when assessing ovarian tumors.
  • [MeSH-major] DNA Methylation. Ovarian Neoplasms / blood. Tumor Suppressor Proteins / blood
  • [MeSH-minor] Carcinoma, Endometrioid / blood. Carcinoma, Endometrioid / pathology. Cystadenocarcinoma, Mucinous / blood. Cystadenocarcinoma, Mucinous / pathology. Cystadenocarcinoma, Serous / blood. Cystadenocarcinoma, Serous / pathology. Female. Humans. Neoplasm Staging

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16545186.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / RASSF1 protein, human; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


90. O'Neill CJ, Deavers MT, Malpica A, Foster H, McCluggage WG: An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms. Am J Surg Pathol; 2005 Aug;29(8):1034-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms.
  • Ovarian serous carcinoma (OSC) is the most common ovarian epithelial malignancy.
  • Recently, a dualistic pathway of ovarian serous carcinogenesis has been proposed based on morphologic observations and molecular genetic analysis.
  • In this scheme, low-grade OSC arises in a stepwise fashion from a benign serous cystadenoma through a usual serous borderline tumor through a micropapillary variant of serous borderline tumor.
  • In contrast, the more common high-grade OSC arises de novo from the ovarian surface epithelium or the epithelium of cortical inclusion cysts with an as yet unrecognized precursor lesion.
  • [MeSH-major] Biomarkers, Tumor / analysis. Cystadenoma, Serous / chemistry. Cystadenoma, Serous / pathology. Ki-67 Antigen / analysis. Ovarian Neoplasms / chemistry. Ovarian Neoplasms / pathology. Peptide Fragments / analysis. Proto-Oncogene Proteins c-bcl-2 / analysis. Proto-Oncogene Proteins c-kit / analysis. Receptor, ErbB-2 / analysis. Tumor Suppressor Protein p53 / analysis
  • [MeSH-minor] Female. Humans. Inhibitor of Apoptosis Proteins. Microtubule-Associated Proteins / analysis. Neoplasm Proteins / analysis. Osteopontin. Sialoglycoproteins / analysis. WT1 Proteins / analysis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16006797.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Biomarkers, Tumor; 0 / HER2-neu-derived peptide (654-662); 0 / Inhibitor of Apoptosis Proteins; 0 / Ki-67 Antigen; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / Peptide Fragments; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / SPP1 protein, human; 0 / Sialoglycoproteins; 0 / Tumor Suppressor Protein p53; 0 / WT1 Proteins; 106441-73-0 / Osteopontin; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


91. Mülayim B, Gürakan H, Dagli V, Mülayim S, Aydin O, Akkaya H: Unaware of a giant serous cyst adenoma: a case report. Arch Gynecol Obstet; 2006 Mar;273(6):381-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unaware of a giant serous cyst adenoma: a case report.
  • A case of 36-year-old nonmarried virgin woman presenting a giant ovarian serous cyst adenoma weighing 9.5 kg is reported here.
  • Ovarian neoplasms may be divided by origin cell type into three main groups: epithelial, stromal and germ cell.
  • The single most common benign ovarian neoplasm is the benign cystic teratoma; however, according to some studies it is serous cyst adenoma.
  • Her pathology report disclosed a 35 x 20 x 16 cm(3) serous cyst adenoma weighing 9.5 kg.
  • This is the largest ovarian cyst that ever reported from our hospital and one of the largest among the reported cases in the literature.
  • [MeSH-major] Cystadenoma, Serous / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16249904.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


92. Maeda D, Ota S, Takazawa Y, Aburatani H, Nakagawa S, Yano T, Taketani Y, Kodama T, Fukayama M: Glypican-3 expression in clear cell adenocarcinoma of the ovary. Mod Pathol; 2009 Jun;22(6):824-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Glypican-3 is a heparan sulfate proteoglycan that is overexpressed in various neoplasms such as hepatocellular carcinoma, malignant melanoma, and testicular yolk sac tumor.
  • Glypican-3 is currently regarded as a tumor marker and potential target for immunotherapy.
  • To clarify the significance of glypican-3 expression in ovarian clear cell adenocarcinoma, we evaluated glypican-3 expression by immunohistochemistry in nonneoplastic and neoplastic ovaries, and other Müllerian duct derivatives including endometrium in different menstrual phases.
  • Among the benign lesions examined, glypican-3 expression was identified exclusively in the endometrial epithelium in the gestational period.
  • A total of 213 cases of ovarian adenocarcinoma, including 94 clear cell adenocarcinomas, were studied.
  • Glypican-3 expression was observed in 44% of clear cell adenocarcinomas, whereas it was rarely observed in other histological subtypes: mucinous (4%), endometrioid (5%), and serous (11%; P<0.0001).
  • All six ovarian yolk sac tumors showed diffuse immunoreactivity for glypican-3.
  • In cases of clear cell adenocarcinoma, no correlations were found between glypican-3 expression and clinicopathological factors, such as tumor stage, lymph node metastasis, peritoneal dissemination, and death rate.
  • Our results suggest that overexpression of glypican-3 may be related to the development and aggressive behavior of ovarian clear cell adenocarcinoma.
  • [MeSH-major] Adenocarcinoma, Clear Cell / metabolism. Biomarkers, Tumor / analysis. Glypicans / biosynthesis. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19329941.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glypicans
  •  go-up   go-down


93. Denkert C, Dietel M: Borderline tumors of the ovary and peritoneal implants. Verh Dtsch Ges Pathol; 2005;89:84-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The new WHO series on Pathology and Genetics of Tumours of the Breast and Female Genital Organs (33) defined to name the group of epithelial ovarian tumors with a dignity between benign and malignant exclusively as Borderline Tumors of the Ovary (BOT) and to skip the term "... of low malignant potential".
  • The group of borderline ovarian tumors is heterogeneous.
  • 80 to 90% of the cases have a very favourable prognosis while 10-20% exhibit a recurrent clinical course with peritoneal implants and very rarely death from the tumor within 10 years.
  • The morphological criteria and supporting methods for recognizing unfavorable BOT and for distinguishing them from highly differentiated ovarian carcinomas are summarized.
  • The concept of micropapillary serous carcinomas (MPSC) and its implications on the diagnostic work of pathologists will be discussed.
  • The presented data focus on serous tumors since this is by far the most common variant.
  • [MeSH-major] Ovarian Neoplasms / pathology. Peritoneal Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Disease-Free Survival. Female. Humans. Meta-Analysis as Topic. Neoplasm Invasiveness. Neoplasm Staging. Survival Analysis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18035677.001).
  • [ISSN] 0070-4113
  • [Journal-full-title] Verhandlungen der Deutschen Gesellschaft für Pathologie
  • [ISO-abbreviation] Verh Dtsch Ges Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


94. Liguang Z, Peishu L, Hongluan M, Hong J, Rong W, Wachtel MS, Frezza EE: Survivin expression in ovarian cancer. Exp Oncol; 2007 Jun;29(2):121-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survivin expression in ovarian cancer.
  • AIM: To examine the expression of survivin in benign ovarian tumors, ovarian carcinomas of different stages.
  • METHODS: We screened the expression of survivin mRNA by reverse transcription polymerase chain reaction in 114 ovarian tissue samples.
  • RESULTS: No survivin mRNA was expressed in all normal ovarian specimens, while it appeared in 73% of ovarian carcinomas, 47% of borderline ovarian carcinomas and 19% of benign ovarian tumors.
  • There was notably statistically significant difference in the survivin mRNA expression rate dependent on different histological types (serous, mucinous, endometrioid, P = 0.008), but not - dependent on lymph node metastasis (P = 0.921) and ascites (P = 0.87).
  • In tissues with positive expression of survivin, we also found that mean survivin mRNA expression levels were higher in ovarian carcinomas than that in benign ovarian tumors and borderline ovarian carcinoma tissues (P < 0.001).
  • Among ovarian carcinomas, the high survivin mRNA expression levels correlated with the clinical stages, differentiation grade, lymph node metastasis, but not - with ascites and histological type.
  • CONCLUSION: Our study suggest that survivin is associated with progression of ovarian carcinoma.
  • [MeSH-major] Cystadenoma, Mucinous / metabolism. Cystadenoma, Serous / metabolism. Neoplasm Proteins / biosynthesis. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Carcinoma / metabolism. Carcinoma / pathology. Disease Progression. Female. Humans. Middle Aged. Neoplasm Staging. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Retrospective Studies. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17704744.001).
  • [ISSN] 1812-9269
  • [Journal-full-title] Experimental oncology
  • [ISO-abbreviation] Exp. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ukraine
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / RNA, Messenger
  •  go-up   go-down


95. Han S, Xuan Y, Liu S, Zhang M, Jin D, Jin R, Lin Z: Clinicopathological significance of DEK overexpression in serous ovarian tumors. Pathol Int; 2009 Jul;59(7):443-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological significance of DEK overexpression in serous ovarian tumors.
  • To investigate the significance of DEK protein expression in ovarian lesions, a total of 113 ovarian serous tumors, including 62 serous cystadenocarcinomas and 19 serous borderline tumors, were studied on immunohistochemistry.
  • For comparison, 32 benign serous tumors, including 12 serous papillary cystadenomas, 10 serous cystadenomas, and 10 serous surface papillomas, were also included.
  • DEK was positive in 93.5% of serous cystadenocarcinomas (58/62), 63.2% of serous borderline tumors (12/19), and weakly positive in 15.6% of benign serous tumors (5/32).
  • The strong positive signal was detected only in serous adenocarcinomas (80.6%, 50/62) and borderline tumors (21.1%, 4/19), but no serous benign tumors were strongly positive (0%, 0/32).
  • Meanwhile, the strong positivity rate of DEK protein was significantly higher in grade 2 and grade 3 than in grade 1 ovarian cancers (P < 0.05), but there was no significant association between DEK protein expression level and International Federation of Gynecology and Obstetrics (FIGO) stage of serous ovarian adenocarcinoma (P > 0.05).
  • In summary, DEK plays an important role in the progression of ovarian serous cancers.
  • The detection of DEK protein expression should be useful for the diagnosis and prognosis of ovarian serous cancers, and DEK might be a useful molecular target for ovarian cancer therapy.
  • [MeSH-major] Biomarkers, Tumor / analysis. Chromosomal Proteins, Non-Histone / biosynthesis. Cystadenocarcinoma, Serous / pathology. Cystadenoma, Serous / pathology. Oncogene Proteins / biosynthesis. Ovarian Neoplasms / pathology
  • [MeSH-minor] Aged, 80 and over. Female. Humans. Immunohistochemistry. Neoplasm Staging. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19563407.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chromosomal Proteins, Non-Histone; 0 / Dek protein, human; 0 / Oncogene Proteins
  •  go-up   go-down


96. Tongsong T, Wanapirak C, Sukpan K, Khunamornpong S, Pathumbal A: Subjective sonographic assessment for differentiation between malignant and benign adnexal masses. Asian Pac J Cancer Prev; 2007 Jan-Mar;8(1):124-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subjective sonographic assessment for differentiation between malignant and benign adnexal masses.
  • OBJECTIVE: To determine the accuracy of subjective sonographic assessment in distinguishing between benign and malignant adnexal masses.
  • All patients were sonographically examined within 72 hours of surgery were subjectively evaluated by the experienced sonographer, who had no any information of the patients, to differentiate between benign and malignant adnexal masses based on sonographic morphology.
  • RESULTS: One hundred and fifty-eight patients with 174 adnexal masses, (benign; 108 and malignant;.
  • CONCLUSIONS: Subjective evaluation of sonographic morphology has high accuracy in differentiating between benign and malignant adnexal masses.
  • [MeSH-major] Ovarian Neoplasms / diagnostic imaging. Ultrasonography, Doppler
  • [MeSH-minor] Adenocarcinoma, Mucinous / ultrastructure. Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Endometrioid / ultrastructure. Cross-Sectional Studies. Cystadenoma, Serous / ultrastructure. Diagnosis, Differential. Female. Humans. Incidence. Middle Aged. Neoplasm Staging. Predictive Value of Tests. ROC Curve. Risk Factors. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17477786.001).
  • [ISSN] 1513-7368
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Thailand
  •  go-up   go-down


97. Yoshida A, Sarian LO, Andrade LA, Pignataro F, Pinto GA, Derchain SF: Cell proliferation activity unrelated to COX-2 expression in ovarian tumors. Int J Gynecol Cancer; 2007 May-Jun;17(3):607-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell proliferation activity unrelated to COX-2 expression in ovarian tumors.
  • The objective of this study was to assess the expression of Cyclooxygenase-2 (COX-2) and cell proliferation activity (Ki67 expression) in benign, borderline, and malignant serous and mucinous ovarian tumors.
  • Expression of COX-2 and Ki67 proteins were evaluated by immunohistochemistry, in paraffin-embedded sections of ovarian epithelial tumors.
  • The study included 113 serous (67 benign, 15 borderline, and 31 malignant) and 85 mucinous (48 benign, 28 borderline, and 9 malignant) tumors, removed from women who underwent laparotomy between January 1997 and December 2003.
  • From benign to malignant tumors, there was a progressive positive trend in COX-2 expression in both serous and mucinous tumors, more evident in mucinous ones (P < 0.001).
  • Comparing histologic types, COX-2 expression was more prominent in serous than in mucinous benign tumors (P < 0.01), but this difference was not significant in the borderline (P= 0.11) or malignant categories (P= 0.71).
  • There was a progressive Ki67 positivity in line with the tumor histologic gradient for both serous (P < 0.01) and mucinous lesions (P < 0.01), but this increasing expression did not correlate with COX-2 expression in the present series (P= 0.78).
  • There was a higher COX-2 expression in serous ovarian adenomas than in mucinous ones.
  • COX-2 positivity increases in line with the morphologic gradient, from benign to malignant in both histologic types, but it was more prominent in mucinous lesions, pointing to different oncogenic pathways related to different histologic types.
  • A correlation between the expression of COX-2 and Ki67 was not found, suggesting that COX-2 may be required for carcinogenesis, but this pathway is not responsible for cell proliferation in ovarian tumors.
  • [MeSH-major] Adenocarcinoma, Mucinous / metabolism. Cell Proliferation. Cyclooxygenase 2 / metabolism. Cystadenocarcinoma, Serous / metabolism. Membrane Proteins / metabolism. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Adult. Female. Humans. Ki-67 Antigen / metabolism. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17504375.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Membrane Proteins; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human
  •  go-up   go-down


98. McIntosh MW, Liu Y, Drescher C, Urban N, Diamandis EP: Validation and characterization of human kallikrein 11 as a serum marker for diagnosis of ovarian carcinoma. Clin Cancer Res; 2007 Aug 01;13(15 Pt 1):4422-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Validation and characterization of human kallikrein 11 as a serum marker for diagnosis of ovarian carcinoma.
  • PURPOSE: The serum tumor marker CA 125 is elevated in most clinically advanced ovarian carcinomas, and currently, one of the most promising early detection strategies for ovarian cancer uses CA 125 level in conjunction with imaging.
  • However, CA 125 is elevated in only 50% of early-stage ovarian cancer and is often elevated in women with benign ovarian tumors and other gynecologic diseases.
  • The human kallikrein 11 (hK11) marker has been reported to have favorable predictive value for ovarian cancer, although, by itself, it may be inferior to CA 125.
  • CA 125, hK11, and the composite marker were evaluated for their performance in identifying ovarian cancer and for temporal stability.
  • RESULTS: hK11 significantly distinguished ovarian cancer cases from healthy controls and is less sensitive to benign ovarian disease than is CA 125.
  • CONCLUSION: We conclude that hK11 is a valuable new biomarker for ovarian cancer and its temporal stability implies that it may do even better when used in a longitudinal screening program for early detection.
  • [MeSH-major] Biomarkers, Tumor / blood. Ovarian Neoplasms / blood. Serine Endopeptidases / blood
  • [MeSH-minor] Adenocarcinoma / blood. Adenocarcinoma / diagnosis. Adenocarcinoma, Mucinous / blood. Adenocarcinoma, Mucinous / diagnosis. CA-125 Antigen / metabolism. Carcinoma, Endometrioid / blood. Carcinoma, Endometrioid / diagnosis. Case-Control Studies. Cystadenocarcinoma, Serous / blood. Cystadenocarcinoma, Serous / diagnosis. Disease Progression. Enzyme-Linked Immunosorbent Assay. Female. Gene Expression Regulation, Neoplastic. Humans. Neoplasm Staging. Prognosis. Survival Rate. Up-Regulation

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17671125.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA083636; United States / NCI NIH HHS / CA / P50 CA83636; United States / NCI NIH HHS / CA / R21CA093568
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / trypsin-like serine protease; EC 3.4.21.- / Serine Endopeptidases
  •  go-up   go-down


99. Ota K, Ito K, Akahira J, Sato N, Onogawa T, Moriya T, Unno M, Abe T, Niikura H, Takano T, Yaegashi N: Expression of organic cation transporter SLC22A16 in human epithelial ovarian cancer: a possible role of the adriamycin importer. Int J Gynecol Pathol; 2007 Jul;26(3):334-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of organic cation transporter SLC22A16 in human epithelial ovarian cancer: a possible role of the adriamycin importer.
  • Adriamycin is considered to be an active agent for ovarian cancer.
  • Recently, the benefit of adding adriamycin to the current standard regimen, paclitaxel and platinum, is evaluated to improve the outcome of patients with ovarian cancer.
  • Therefore, we examined the expression of SLC22A16 in ovarian cancers.
  • Twelve ovarian carcinoma cell lines were used for immunoblotting and reverse transcription-polymerase chain reaction to confirm the expression of SLC22A16 mRNA and protein.
  • Five normal ovaries, 12 ovarian adenomas, and 94 ovarian cancer cases were obtained from patients after surgical therapy.
  • The SLC22A16 immunoreactivity was detected in 15 (16%) of 94 epithelial ovarian cancer, 1 (8.3%) of 12 benign adenomas, but 0 (0%) of 5 normal ovary cases.
  • In ovarian cancer tissues, SLC22A16 immunoreactivity was detected in 2 (5%) of 38 serous adenocarcinoma, 1 (6.7%) of 15 endometrioid adenocarcinoma, 0 (0%) of 14 mucinous adenocarcinoma, and 12 (46.2%) of 26 clear-cell adenocarcinoma (P < 0.0001, clear-cell vs other histologies).
  • [MeSH-major] Adenocarcinoma, Clear Cell / metabolism. Antibiotics, Antineoplastic / pharmacokinetics. Doxorubicin / pharmacokinetics. Organic Cation Transport Proteins / biosynthesis. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Blotting, Western. Cell Line, Tumor. Female. Humans. Immunohistochemistry. RNA, Neoplasm / chemistry. RNA, Neoplasm / genetics. Retrospective Studies. Reverse Transcriptase Polymerase Chain Reaction


100. Wanapirak C, Srisupundit K, Tongsong T: Sonographic morphology scores (SMS) for differentiation between benign and malignant adnexal masses. Asian Pac J Cancer Prev; 2006 Jul-Sep;7(3):407-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sonographic morphology scores (SMS) for differentiation between benign and malignant adnexal masses.
  • OBJECTIVE: To determine the sensitivity and specificity of a scoring system for distinguishing between benign and malignant adnexal masses and to detect threshold scores for prediction of malignant ovarian tumors.
  • SUBJECTS: A total 158 patients scheduled for elective surgery due to ovarian tumors at Maharaj Nakorn Chiang Mai Hospital between June 16, 2002 and August 8, 2004 were recruited into the study.
  • CONCLUSION: Sonographic morphology scores are useful in distinguishing adnexal malignancies from benign lesions in some selected cases.
  • [MeSH-major] Adnexal Diseases / diagnostic imaging. Ovarian Neoplasms / diagnostic imaging. Ultrasonography, Doppler
  • [MeSH-minor] Adenocarcinoma, Clear Cell / ultrastructure. Adenocarcinoma, Mucinous / ultrastructure. Adolescent. Adult. Aged. Carcinoma, Endometrioid / ultrastructure. Cross-Sectional Studies. Cystadenoma, Serous / ultrastructure. Diagnosis, Differential. Female. Humans. Incidence. Middle Aged. Neoplasm Staging. Predictive Value of Tests. ROC Curve. Risk Factors. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17059332.001).
  • [ISSN] 1513-7368
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down






Advertisement